<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005576.pub3" GROUP_ID="ANAESTH" ID="553804102616142792" MERGED_FROM="" MODIFIED="2016-05-13 08:24:03 +0100" MODIFIED_BY="Jane Cracknell" REVIEW_NO="110" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2016-05-13 08:23:52 +0100" MODIFIED_BY="Jane Cracknell">
<TITLE MODIFIED="2015-06-17 15:36:07 +0100" MODIFIED_BY="[Empty name]">Hypertonic salt solution for peri-operative fluid management</TITLE>
<CONTACT MODIFIED="2016-05-13 08:23:52 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="95D3358382E26AA201C330AAE1864BA7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vivian</FIRST_NAME><LAST_NAME>McAlister</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>vmcalist@uwo.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><ADDRESS_1>C4-212, University Hospital</ADDRESS_1><CITY>London</CITY><ZIP>N6A 5A5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 663 2920</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-05-13 08:23:52 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="z1411191223371088890582534250940" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Brad</FIRST_NAME><LAST_NAME>Shrum</LAST_NAME><POSITION>Laboratory Manager</POSITION><EMAIL_1>mcalisterclinic@lhsc.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>General Surgery Experimental Laboratory</DEPARTMENT><ORGANISATION>University Hospital London Health Sciences Centre</ORGANISATION><ADDRESS_1>Department of Surgery</ADDRESS_1><ADDRESS_2>339 Windermere Road</ADDRESS_2><CITY>London</CITY><ZIP>N6A 5A5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="27794338678498601203090729133757" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Brian</FIRST_NAME><LAST_NAME>Church</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Anesthetist</POSITION><EMAIL_1>brian.church@lhsc.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>1 Canadian Field Hospital, Canadian Forces Medical Service</DEPARTMENT><ORGANISATION>Department of Anesthesia, University of Western Ontario</ORGANISATION><ADDRESS_1>D2-315 Victoria Hospital</ADDRESS_1><CITY>London</CITY><ZIP>N6A 5A5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>519 6858500 (58525)</PHONE_1></ADDRESS></PERSON><PERSON ID="78431597879360474119120516105233" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Eric</FIRST_NAME><LAST_NAME>McArthur</LAST_NAME><EMAIL_1>emcarth2@uwo.ca</EMAIL_1><ADDRESS><DEPARTMENT>ELL-218</DEPARTMENT><ORGANISATION>Victoria Hospital</ORGANISATION><ADDRESS_1>800 Commissioners Rd E</ADDRESS_1><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>519-317-1372</PHONE_1></ADDRESS></PERSON><PERSON ID="12162" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Karen</FIRST_NAME><MIDDLE_INITIALS>EA</MIDDLE_INITIALS><LAST_NAME>Burns</LAST_NAME><SUFFIX>MD, FRCPC, MSc (Epid)</SUFFIX><POSITION>Assistant Professor, Clinician Scientist</POSITION><EMAIL_1>BurnsK@smh.ca</EMAIL_1><EMAIL_2>burnske2@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Interdepartmental Division of Critical Care</DEPARTMENT><ORGANISATION>Keenan Research Centre/Li Ka Shing Knowledge Institute, University of Toronto</ORGANISATION><ADDRESS_1>30 Bond Street, Rm 4-045 Queen Wing</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5B 1WB</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416-864-6060 X3567</PHONE_1><FAX_1>+1 416-864-6013</FAX_1></ADDRESS></PERSON><PERSON ID="4AAA496382E26AA2005CED83B3880004" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tammy</FIRST_NAME><LAST_NAME>Znajda</LAST_NAME><POSITION>Clinical Fellow ICU</POSITION><EMAIL_1>t_znajda@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Departments of General Surgery and Intensive Care Medicine</DEPARTMENT><ORGANISATION>Lakeshore General Hospital</ORGANISATION><ADDRESS_1>160 Stillview Ave</ADDRESS_1><CITY>Pointe-Claire</CITY><ZIP>H9R 2Y2</ZIP><REGION>QC</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="95D3358382E26AA201C330AAE1864BA7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vivian</FIRST_NAME><LAST_NAME>McAlister</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>vmcalist@uwo.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><ADDRESS_1>C4-212, University Hospital</ADDRESS_1><CITY>London</CITY><ZIP>N6A 5A5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 663 2920</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-04-12 17:20:02 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="8" MONTH="4" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="4" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="9" MONTH="4" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-05-05 15:32:36 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-05-05 15:32:36 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>In this update, we searched CENTRAL, Pubmed, EMBASE, LILACS, and CINAHL, and reviewed the results up to April 08, 2016. We identified and screened 42 additional studies. We excluded 39 of those studies, added no studies to the 'Awaiting classification' section, or to 'Ongoing studies'. We include three new studies (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>A new author has been added to the review team (Brad Shrum). We added three new studies which did not change the conclusions of the review. We updated the methods for the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-04-12 11:14:26 +0100" MODIFIED_BY="Jane Cracknell"/>
<SOURCES_OF_SUPPORT MODIFIED="2012-11-01 20:34:57 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-11-01 20:34:57 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-11-01 20:33:09 +0000" MODIFIED_BY="[Empty name]">
<NAME>Lawson Health Research Institute</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P> LHRF F9738 (V McAlister Research Fund)</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-11-01 20:34:57 +0000" MODIFIED_BY="[Empty name]">
<NAME>University of Western Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P>Division of General Surgery Research Fund</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-11-01 20:33:44 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-11-01 20:33:44 +0000" MODIFIED_BY="[Empty name]">
<NAME>No external funds sought or received</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-05-10 19:16:07 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-05-05 16:00:08 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-06-10 17:35:49 +0100" MODIFIED_BY="[Empty name]">Increased salt in solution to maintain fluid during surgery</TITLE>
<SUMMARY_BODY MODIFIED="2016-05-05 16:00:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>Are solutions containing more salt than is normally used safe during surgery?</P>
<P>
<B>Background</B>
</P>
<P>People usually require fluids during surgery. Sometimes large volumes of fluid are given in order to maintain adequate blood volume, but these volumes may leave people with too much fluid. The fluids normally used during surgery have a salt balance similar to that found in blood, and are called isotonic. Hypertonic salt solutions (HS) have a higher sodium concentration than isotonic salt solutions (IS). HS might benefit people undergoing surgery by reducing the total volume of fluid required.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is up to date to April 8th, 2016.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We included 18 trials that compared HS to IS in people undergoing surgery. The trials included 1087 participants. Five hundred and forty-five (545) participants received HS and 542 received IS during their operations. The participants were randomly assigned to their groups. The studies took place in 11 countries. Study participants were over the age of 18. All studies excluded people with serious health risks from participating. All studies monitored fluid levels during the operation and up to three days after.</P>
<P>
<B>Key results</B>
</P>
<P>There were seven deaths in total, three (less than 1%) from the IS group and four (less than 1%) from the HS group. The risk of death was very low in these studies. The studies did not report the occurrence of serious adverse events.</P>
<P>Thirteen studies reported the amount of fluid given. The IS group received a mean of 2.4 L and the HS group received 0.91 L less (1.49 L). The highest amount of sodium in the blood over the course of the study was reported by 16 studies. The IS group had a median of 139 meq/L and the HS group was 7.73 meq/L higher. The normal acceptable range is 136 to 146 meq/L.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>For deaths and adverse events the trials lacked sufficient size and duration to adequately assess differences. We assessed the quality of evidence for deaths to be very low, and future studies are likely to change the result reported here.</P>
<P>The reporting of the highest amount of sodium is of moderate quality. The measuring of blood sodium during an operation is a common measurement that is unlikely to be misrepresented.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-05-05 15:34:13 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Fluid excess may place people undergoing surgery at risk for various complications. Hypertonic salt solution (HS) maintains intravascular volume with less intravenous fluid than isotonic salt (IS) solutions, but may increase serum sodium. This review was published in 2010 and updated in 2016.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the benefits and harms of HS versus IS solutions administered for fluid resuscitation to people undergoing surgery.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-05-05 15:34:13 +0100" MODIFIED_BY="[Empty name]">
<P>In this updated review we have searched the Cochrane Central Register of Controlled Trials (CENTRAL; Issue 4, 2016); MEDLINE (January 1966 to April 2016); EMBASE (January 1980 to April 2016); LILACS (January 1982 to April 2016) and CINAHL (January 1982 to April 2016) without language restrictions. We conducted the original search on April 30th, 2007, and reran it on April 8th, 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>We have included randomized clinical trials (RCTs) comparing HS to IS in people undergoing surgery, irrespective of blinding, language, and publication status.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Two independent review authors read studies that met our selection criteria. We collected study information and data using a data collection sheet with predefined parameters. We have assessed the impact of HS administration on mortality, organ failure, fluid balance, serum sodium, serum osmolarity, diuresis and physiologic measures of cardiovascular function. We have pooled the data using the mean difference (MD) for continuous outcomes. We evaluated heterogeneity between studies by I² percentage. We consider studies with an I² of 0% to 30% to have no or little heterogeneity, 30% to 60% as having moderate heterogeneity, and more than 60% as having high heterogeneity. In studies with low heterogeneity we have used a fixed-effect model, and a random-effects model for studies with moderate to high heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>We have included 18 studies with 1087 participants of whom 545 received HS compared to 542 who received IS. All participants were over 18 years of age and all trials excluded high-risk patients (ASA IV). All trials assessed haematological parameters peri-operatively and up to three days post-operatively.</P>
<P>There were three (&lt; 1%) deaths reported in the IS group and four (&lt; 1%) in the HS group, as assessed at 90 days in one study. There were no reports of serious adverse events. Most participants were in a positive fluid balance postoperatively (4.4 L IS and 2.5 L HS), with the excess significantly less in HS participants (MD -1.92 L, 95% confidence interval (CI) -2.61 to -1.22 L; P &lt; 0.00001). IS participants received a mean volume of 2.4 L and HS participants received 1.49 L, significantly less fluid than IS-treated participants (MD -0.91 L, 95% CI -1.24 to -0.59 L; P &lt; 0.00001). The maximum average serum sodium ranged between 138.5 and 159 in HS groups compared to between 136 and 143 meq/L in the IS groups. The maximum serum sodium was significantly higher in HS participants (MD 7.73, 95% CI 5.84 to 9.62; P &lt; 0.00001), although the level remained within normal limits (136 to 146 meq/L).</P>
<P>A high degree of heterogeneity appeared to be related to considerable differences in the dose of HS between studies. The quality of the evidence for the outcomes reported ranged from high to very low. The risk of bias for many of the studies could not be determined for performance and detection bias, criteria that we assess as likely to impact the study outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>HS reduces the volume of intravenous fluid required to maintain people undergoing surgery but transiently increases serum sodium. It is not known if HS affects survival and morbidity, but this should be examined in randomized controlled trials that are designed and powered to test these outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-05-10 19:16:07 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-05-05 15:41:14 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-05-05 15:41:14 +0100" MODIFIED_BY="[Empty name]">
<P>Low-volume resuscitation with hypertonic crystalloid solutions has been investigated for over 20 years (<LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>). More recently, alterations in cellular immune function with hypertonic salt solution (HS) administration have been demonstrated in experimental and clinical studies (<LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="REF-Rizoli-2006" TYPE="REFERENCE">Rizoli 2006</LINK>). Several randomized controlled trials (RCTs) of HS resuscitation in critically ill participants have been performed. A systematic review of HS compared to isotonic salt solution (IS) in resuscitation following burns or trauma was unable to reach a conclusion regarding benefit or harm in the presence of wide confidence intervals (<LINK REF="REF-Bunn-2004" TYPE="REFERENCE">Bunn 2004</LINK>). Trials of HS alone, or in combination with colloids, have also been performed in the trauma population. A meta-analysis comparing 250 mL of HS (with or without dextran) with administration of 250 mL of isotonic crystalloid for the treatment of hypotension either in the field or at admission to the emergency department in 1233 trauma patients failed to demonstrate that HS with dextran confers a survival benefit (<LINK REF="REF-Wade-1997" TYPE="REFERENCE">Wade 1997</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Standard peri-operative care includes IS administration to counter conditions which may cause transient intraoperative hypovolaemia including: fluid deprivation during preoperative fasting; vasodilatation due to epidural or general anaesthesia; third space sequestration of intravascular fluid; insensible fluid loss and intraoperative fluid or blood loss. These conditions are often reversed at the end of an operation. In fact, IS has been shown to increase the weight of people undergoing elective major surgery by an average of three to six kilograms (kg) (<LINK REF="REF-Grocott-2005" TYPE="REFERENCE">Grocott 2005</LINK>). While most people tolerate the additional fluid well, postoperative improvement or reversal of the conditions outlined above may place those with compromised cardiovascular or renal function at increased risk for development of pulmonary oedema. People without cardiovascular or renal risk factors may also be adversely affected by peri-operative fluid gain. A recent RCT demonstrated that peri-operative fluid restriction resulted in fewer major or minor postoperative complications compared to traditional care in 172 adult participants undergoing elective colorectal surgery (<LINK REF="REF-Brandstrup-2003" TYPE="REFERENCE">Brandstrup 2003</LINK>). Another study demonstrated that fluid overload delayed return of gastrointestinal function (<LINK REF="REF-Lobo-2002" TYPE="REFERENCE">Lobo 2002</LINK>). Conversely, failure to maintain intravascular volume during surgery may place people at risk for cardiac or cerebral ischaemia. Indeed, supplemental peri-operative fluid administration has been shown to improve tissue oxygenation (<LINK REF="REF-Arkili_x00e7_-2003" TYPE="REFERENCE">Arkiliç 2003</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>HS has the potential to reduce the total volume of fluid administered during operative procedures by allowing people to draw fluid from the interstitium (and other body compartments) to counter peri-operative hypotensive effects, and thereby provide Intravascular support without excess fluid administration. In situations where large volume resuscitation may be harmful, such as in brain trauma, a role for HS is emerging (<LINK REF="REF-Ogden-2005" TYPE="REFERENCE">Ogden 2005</LINK>). Notwithstanding, several risks have been associated with HS, including potential hypernatraemia, metabolic acidosis and vasodilatation.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-06-22 18:03:45 +0100" MODIFIED_BY="[Empty name]">
<P>Several RCTs of prophylactic HS administration in the peri-operative period have been published. In contrast to other trials where HS has been combined with colloid solutions to treat hypotension, these RCTs may provide a clinical picture of the effect of HS on peri-operative fluid management.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the benefits and harms of HS versus IS solutions administered for fluid resuscitation to people undergoing surgery.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-05-05 15:51:53 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-05-05 15:46:44 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-05-05 15:44:42 +0100" MODIFIED_BY="[Empty name]">
<P>We included RCTs comparing the administration of HS versus IS solution during non-emergency operative procedures, regardless of language or publication status. RCTs are the gold standard for comparing the effect of one treatment versus another.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>We included all participants undergoing any surgical procedures.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-06-17 18:10:19 +0100" MODIFIED_BY="[Empty name]">
<P>We have included peri-operative administration of either HS or IS solutions. We permitted concomitant measures so long as they applied to both arms of the study. We excluded studies that compared HS and a colloidal solution to IS alone. Additionally, we excluded studies that compared HS and IS solutions administered by inhalation or absorption from the nasal mucosa and involving non-surgical patient populations (burns, trauma and head injury).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-05-05 15:46:44 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Mortality</HEADING>
<P>Defined as any deaths occurring during the study period. Where all participants are included in the results for other outcomes we have extrapolated that as indicating no deaths.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Serious adverse events</HEADING>
<P>We collected other adverse outcomes as defined by each trial, or if any of the following occurred: any organ failure, any requirement for dialysis (renal failure) or prolonged ventilation (pulmonary failure); use of medical therapy for either pulmonary oedema or circulatory support (cardiac failure) or for confusion (cerebral failure).</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-05-05 15:46:44 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">3. Fluid balance over the study period</HEADING>
<P>We used authors' definitions where provided. For studies not clearly specifying the study period, we defined it to include the immediate preoperative (induction of anaesthesia), intraoperative and postoperative periods (up to 24 hours after surgery). Studies can report the fluid balance by reporting the difference in fluid given minus fluid excreted or by the change in weight of the participant. For studies that only reported weight change, we applied a conversion factor, wherein 1 kg = 1 L (litre), to calculate fluid balance. Fluid balance is expressed in litres.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Total volume of intravenous fluid delivered</HEADING>
<P>A report of the volume of resuscitating fluid given to the participant intravenously during the peri-operative and recovery period as reported by the studies. Fluid delivered is expressed in litres.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Peri-operative diuresis</HEADING>
<P>A measure of the urine output from the participant during the operative period. Diuresis is reported as litres.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Maximum serum sodium concentration</HEADING>
<P>As measured from the participant's blood during the study and reported as milliequivalents per litre (meq/L).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Final serum sodium concentration</HEADING>
<P>As measured in the participant's blood at the end of follow-up, and reported as milliequivalents per litre (meq/L).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Duration of endotracheal intubation after operation</HEADING>
<P>As reported by each study and converted to hours (h).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Duration of stay in intensive care after operation</HEADING>
<P>As reported by each study and converted to hours (h).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10. Duration of stay in hospital after operation</HEADING>
<P>As reported by each study and converted to days (d).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11. Other outcomes</HEADING>
<P>We collected data regarding serum osmolarity, expressed as milliosmoles per kilogram of water (mOsm/kg H2O) and peri-operative haemodynamic parameters: pulmonary artery wedge pressure, measured by mm of mercury (mm Hg); and cardiac index (CI), derived from cardiac output (CO = Heart rate/stroke volume/1000) and body surface area (BSA), CI = CO/BSA; it is a measure of the volume of blood passing through one square meter each minute (L/min/M²).</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>For this updated review we have searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 4, 2016); MEDLINE (January 1966 to April 2016); EMBASE (January 1980 to April 2016); LILACS (January 1982 to April 2016) and CINAHL (January 1982 to April 2016). We limited the publication types to clinical trials, controlled clinical trials, RCTs, multicentre studies and meta-analyses, without language restrictions.</P>
<P>We originally used the search strategy described in the appendices (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> MEDLINE; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> EMBASE; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> CINAHL; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> LILACS; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> CENTRAL) to search until August 2009. We have updated the search terms since the original search (see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>). In addition, we searched trial registries including <A HREF="http://clinicaltrials.gov/">clinicaltrials.gov/</A>, <A HREF="http://www.controlled-trials.com/">www.controlled-trials.com/</A> and <A HREF="http://www.ifpma.org/clinicaltrials.html">www.ifpma.org/clinicaltrials.html</A> for ongoing trials. We sought letter or email contact with principal investigators to inform them of the meta-analysis and to ask for additional information.</P>
<P>The search was last run on April 8th, 2016.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>We handsearched the bibliographies of retrieved articles and the abstracts of conference proceedings published in <I>Anaesthesia and Intensive Care</I>; <I>Anaesthesia and Analgesia;</I> <I>British Journal of Surgery;</I> <I>Critical Care Medicine</I>; <I>Journal of Vascular Surgery and Trauma;</I> <I>Injury; </I>and<I> Infection</I> <I>and Critical Care</I> for the years 2000 to 2006.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-05-05 15:51:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Vivian McAlister (VM) with Brad Shrum (BS) scanned titles and abstracts identified by the initial search to exclude overlapped and irrelevant studies. Three authors (Tammy Znajda (TZ), Karen Burns (KB) and BS) identified trials that met our inclusion criteria. Brian Church (BC) resolved differences in data recorded and we resolved all differences of opinion through discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-05-05 15:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>At least two of the review authors abstracted data independently from the studies, using standardized forms developed for this review. We wrote to primary study authors for information regarding missing data or data that were not clearly stated. We resolved differences of opinion through discussion. We abstracted data pertaining to the included participants, interventions applied and outcomes reported for each trial. Where translation was needed we sought the help of native speakers of the language who had scientific training. The translator collected relevant information on the data collection forms provided.</P>
<P>We abstracted the following details from each of the included studies:</P>
<OL>
<LI>Participants (inclusion and exclusion criteria; mean age; proportion of men; aetiology of disease; weight before and after surgery; serum electrolytes before, during and after surgery);</LI>
<LI>Interventions (type of surgery; concentration and volume of hypertonic saline given; total volume of fluid administered and concomitant therapy);</LI>
<LI>Trials (setting; methodological quality; publication status; duration of follow-up and all outcomes).</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>We based our assessment of 'Risk of bias' on the recommendations provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The assessments were based on the allocation sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other potential biases (<LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<P>Low risk of bias: sequence generation was achieved using computer random-number generation or a random-number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial.</P>
<P>Uncertain risk of bias: the method of sequence generation was not specified.</P>
<P>High risk of bias: the sequence generation method was not random.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomization unit. The allocation sequence was unknown to the investigators (for example, if the allocation sequence was hidden in sequentially-numbered, opaque, and sealed envelopes).</P>
<P>Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</P>
<P>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants, personnel, and outcome assessors</HEADING>
<P>Low risk of bias: blinding was performed adequately. Additionally, we defined lack of blinding (detection and performance bias) as not likely to affect the assessment of the outcome mortality.</P>
<P>Uncertain risk of bias: there was insufficient information to assess whether blinding was likely to introduce bias in the results.</P>
<P>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes were likely to be influenced by lack of blinding (all other outcomes than mortality and non-subjective laboratory measures).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<P>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data.</P>
<P>Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to introduce bias in the results</P>
<P>High risk of bias: the results were likely to be biased due to missing data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<P>Low risk of bias: the trial reported clinically relevant outcomes, which we defined as mortality, hepatic encephalopathy, and serious adverse events. If we had access to the original trial protocol, the outcomes should be those specified in that protocol. If we obtained the protocol from a trial registry such as <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>, we only used the information if the investigators registered the trial before inclusion of the first participant.</P>
<P>Unclear risk of bias: not all predefined criteria were reported fully, or it was unclear whether data on these outcomes were recorded or not.</P>
<P>High risk of bias: one or more predefined outcomes were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<P>Low risk of bias: the trial appeared to be free of other bias domains, including: medicinal dosing problems or follow-up (as defined below).</P>
<P>Uncertain risk of bias: the trial may or may not have been free of other domains that could put it at risk of bias.</P>
<P>High risk of bias: there were other factors in the trial that could put it at risk of bias, such as the administration of inappropriate treatments being given to the controls (e.g. an inappropriate dose) or follow-up (e.g. the trial included different follow-up schedules for participants in the allocation groups being compared).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Evidence Quality</HEADING>
<P>The control of bias in the included trials was part of the overall assessment of the quality of the body of evidence, which we classified as &#8216;High&#8217;, &#8216;Moderate&#8217;, &#8216;Low&#8217;, or &#8216;Very Low&#8217;. We based the assessment on the specific evidence grading system developed by the GRADE collaboration (<LINK REF="REF-GRADE-2004" TYPE="REFERENCE">GRADE 2004</LINK>).</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>We performed the analyses in Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used the result value and number of participants in all intervention arms to calculate the mean difference (MD) for continuous outcomes, with 95% confidence intervals (CIs).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>If the standard error of the mean was recorded in a study, we converted it to standard deviation following the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> chapter 7.7.3.2. Briefly, SD = SE x Sqrt(n).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>We used the last observed response carried forward (LOCF) for participants with missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity visually through the use of funnel plots and further assessed it using the I² value. We explored sources of heterogeneity through sensitivity, subgroup, and meta-regression analyses. The analyses included the extracted participant, intervention, and trial characteristics listed above as explanatory variables.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>We used funnel plot asymmetry to detect reporting biases where there were more than nine studies, to avoid false detections (<LINK REF="REF-Sterne-2001a" TYPE="REFERENCE">Sterne 2001a</LINK>; <LINK REF="REF-Sterne-2001b" TYPE="REFERENCE">Sterne 2001b</LINK>). Where funnel plots appeared to have asymmetry, we deployed the test by Matthias Egger (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) as described by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): linear regression of intervention effect estimate against its standard error, weighted by the inverse of the variance of the intervention effect estimate. We considered reporting biases to be evident where P &lt; 0.05.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-05-05 15:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>We combined data in fixed-effect meta-analysis if the group I² was less than 30%. Where I² was 30% or greater, we used random-effects meta-analyses. We conducted intention-to-treat (ITT) analyses including all participants irrespective of compliance or follow-up. In studies that had more than two treatment arms, we incorporated only two arms of the trial into the meta-analysis: the arm using IS and the treatment arm evaluating HS solution. If there were two HS arms, we selected the one most different in concentration from IS for analysis. Where meta-analysis was not possible due to a lack of events we used the Clopper-Pearson method to estimate treatment group CIs (<LINK REF="REF-Clopper-1934" TYPE="REFERENCE">Clopper 1934</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings table</HEADING>
<P>We summarize the compiled data for this meta-analysis in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. Each outcome is shown with its anticipated incidence per 1000 people for each treatment group. The MD is shown with 95% CIs for continuous outcomes. The overall quality of the evidence for each outcome has been determined using the Guideline Development Tool from the GRADE working group criteria and that of Cochrane (<LINK REF="REF-GRADE-2004" TYPE="REFERENCE">GRADE 2004</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We rated the quality of the evidence as high, moderate, low, or very low, and have shown it visually and textually. Where studies have been downgraded from high quality, we have used footnotes to indicate the reason. Notes are included for each outcome to briefly describe it, and if appropriate the method of measurement.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-05-05 15:51:24 +0100" MODIFIED_BY="[Empty name]">
<P>When appropriate after consideration of statistical and clinical heterogeneity, we performed subgroup analyses based on the following a priori criteria:</P>
<OL>
<LI>Type of surgery</LI>
<LI>Dose of HS: trials were stratified into three comparisons according to the dose of HS, calculated as the volume of 3% HS required to give the same amount of sodium: 7 mL/kg or less (comparison 01); 7.1 to 10 mL/kg (comparison 02); &gt; 10 mL/kg (comparison 03). We specified these dose stratifications before the review was conducted on the basis of an anticipated range of HS doses</LI>
<LI>Volume of crystalloid given to the control group: trials were stratified into three comparisons according to the total volume of fluid transfusion received by IS participants: &lt; 2 L (comparison 01); 2 L to 5 L (comparison 02); &gt; 5 L (comparison 03). We specified these volume stratifications in advance of the review on the basis of an anticipated range of peri-operative fluid administration</LI>
</OL>
<P>We interpreted a lack of overlap between two CIs in the subgroup analyses as representing a statistically significant difference.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-05-05 15:51:53 +0100" MODIFIED_BY="[Empty name]">
<P>Where the data permitted we performed a sensitivity analysis using the following <I>a priori</I> criteria<I>. </I>We removed studies that were deemed to have a moderate or higher risk of bias based on the aforementioned criteria (see <LINK TAG="BIAS_ASSESSMENT" TYPE="SECTION">Assessment of reporting biases</LINK>). Where potential for bias was uncertain the review authors considered the potential impact of each domain on the results. For the purposes of sensitivity analysis, unknown sequence randomization or allocation concealment did not increase the risk of bias in a study, but unknown or high risk in any other domains did increased the risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-05-10 19:16:07 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-05-05 15:53:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>From 284 reports identified by the search strategy, 25 reports met the criteria for further assessment (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Of these 25 references, we excluded seven studies after detailed review because they were not randomized (<LINK REF="STD-Auler-1987" TYPE="STUDY">Auler 1987</LINK>; <LINK REF="STD-Shao-2005" TYPE="STUDY">Shao 2005</LINK>), did not compare to an IS group (<LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>; <LINK REF="STD-Li-2015" TYPE="STUDY">Li 2015</LINK>), or did not report our desired primary or secondary outcomes (<LINK REF="STD-Auler-1992" TYPE="STUDY">Auler 1992</LINK>; <LINK REF="STD-Yang-Z-2014" TYPE="STUDY">Yang Z 2014</LINK>; <LINK REF="STD-Yousefshahi-F-2013" TYPE="STUDY">Yousefshahi F 2013</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). We found no recently completed studies in registries of clinical trials including <A HREF="http://clinicaltrials.gov/">clinicaltrials.gov/</A>; <A HREF="http://www.controlled-trials.com/">www.controlled-trials.com/</A>; and <A HREF="http://www.ifpma.org/clinicaltrials.html">www.ifpma.org/clinicaltrials.html</A>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-05-05 15:53:37 +0100" MODIFIED_BY="[Empty name]">
<P>Eighteen studies with 1087 participants were included (<LINK REF="STD-Baraka-1994" TYPE="STUDY">Baraka 1994</LINK>; <LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>; <LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>; <LINK REF="STD-Veroli-1992" TYPE="STUDY">Veroli 1992</LINK>; <LINK REF="STD-Wang-1997" TYPE="STUDY">Wang 1997</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The included trials were performed in a wide variety of surgical situations: aortic surgery (four trials) (<LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>); lower limb surgery (three trials) (<LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Veroli-1992" TYPE="STUDY">Veroli 1992</LINK>); transurethral prostate resection (three trials) (<LINK REF="STD-Baraka-1994" TYPE="STUDY">Baraka 1994</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>); coronary artery bypass grafting (three trials) (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>); hysterectomy (one trial) (<LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>); hernia repair (one trial) (<LINK REF="STD-Wang-1997" TYPE="STUDY">Wang 1997</LINK>); general surgery (one trial) (<LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>); pancreaticoduodenectomy (one trial) (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>); and neurological surgery (one trial) (<LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>). Anaesthetic techniques included: general anaesthesia (ten trials) (<LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>) and spinal anaesthesia (seven trials) (<LINK REF="STD-Baraka-1994" TYPE="STUDY">Baraka 1994</LINK>; <LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>; <LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>; <LINK REF="STD-Veroli-1992" TYPE="STUDY">Veroli 1992</LINK>; <LINK REF="STD-Wang-1997" TYPE="STUDY">Wang 1997</LINK>).</P>
<P>Studies were performed in 11 countries, which include Brazil, China, Denmark, Finland, France, Germany, Indonesia, Japan, Lebanon, Niger, and USA. Four publications were written in languages other than English, including Japanese (two trials) (<LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>); French (one trial) (<LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>); Portuguese (one trial) (<LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>). The majority of included studies had small sample sizes, enrolling between 20 and 72 participants. The largest study enrolled 259 participants (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>). The interval between the first and last study was approximately 30 years (1983 to 2014). Only one of the studies was designed to determine differences in short-term mortality (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>), with the remaining studies focusing on fluid and haemodynamic measurement during the peri-operative period. Follow-up extended into the postoperative period in 10 trials (<LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>), with durations ranging from the stay in the recovery unit to 90 days postoperative, while the other trials confined their observations to the period of anaesthesia. Two studies reported results with standard error which we converted to standard deviation by multiplication with the square root of the number in the group (<LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>).</P>
<P>Two authors of included studies whom we contacted for further information responded. Dr. Lavu kindly provided mean and standard deviation values that were not available in the publication (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>), and Dr. Jarvela provided additional methodological details regarding random sequence generation and allocation concealment for two studies (<LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>). Dr. Shao was contacted regarding methodology but did not respond (<LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Seven studies were found but ultimately excluded from analysis; two due to a lack of randomization (<LINK REF="STD-Auler-1987" TYPE="STUDY">Auler 1987</LINK>; <LINK REF="STD-Shao-2005" TYPE="STUDY">Shao 2005</LINK>), two because there was no isotonic saline control group (<LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>; <LINK REF="STD-Li-2015" TYPE="STUDY">Li 2015</LINK>), and three due to an absence of primary or secondary outcomes (<LINK REF="STD-Auler-1992" TYPE="STUDY">Auler 1992</LINK>; <LINK REF="STD-Yang-Z-2014" TYPE="STUDY">Yang Z 2014</LINK>; <LINK REF="STD-Yousefshahi-F-2013" TYPE="STUDY">Yousefshahi F 2013</LINK>). Dr. Yousefshahi was contacted for further information but did not respond (<LINK REF="STD-Yousefshahi-F-2013" TYPE="STUDY">Yousefshahi F 2013</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-05-05 15:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>The overall risk of bias in the included studies is undetermined due to a large number of studies (72%) not fully reporting methodology (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The domains with the largest potential for bias are for performance and detection bias. For performance and detection bias, eight studies did not provide sufficient information to determine the potential for bias (<LINK REF="STD-Baraka-1994" TYPE="STUDY">Baraka 1994</LINK>; <LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Wang-1997" TYPE="STUDY">Wang 1997</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>) and five studies did not protect their studies from performance or detection bias (<LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>). Despite there being limited or unknown protection from performance bias it is unlikely that participants were informed of the fluid given to them for resuscitation. However, care givers and outcome assessors were either not blinded or insufficient information was given to determine the risk of bias, although this is unlikely to impact the majority of our measured outcomes, including mortality (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), serious adverse events (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), peak and final serum sodium (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>), and maximum intraoperative serum osmolarity (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), pulmonary artery wedge pressure (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), and cardiac index (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). Performance and detection bias could impact the results of fluid measurements, leaving the outcomes of fluid balance (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), total volume of crystalloid administered (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), and diuresis during study period (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>), at a greater risk of this source of bias and overall bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Four trials described adequate random sequence generation (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>), using a table of random numbers or computer-generated random numbers. The remaining 14 studies alluded to randomization but did not describe the method used (<LINK REF="STD-Baraka-1994" TYPE="STUDY">Baraka 1994</LINK>; <LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>; <LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>; <LINK REF="STD-Veroli-1992" TYPE="STUDY">Veroli 1992</LINK>; <LINK REF="STD-Wang-1997" TYPE="STUDY">Wang 1997</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>).</P>
<P>Adequate allocation concealment was reported in six trials, four in the publication (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>) and two through correspondence with the author (<LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>).</P>
<P>From our assessment, four trials had a low risk of selection bias (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>) (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Five studies reported adequate concealment of treatment from participants, personnel, and outcome assessors (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Veroli-1992" TYPE="STUDY">Veroli 1992</LINK>); we have rated them as having a low risk of performance and detection bias (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-05-05 15:56:38 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed 16 trials at a low risk of attrition bias (<LINK REF="STD-Baraka-1994" TYPE="STUDY">Baraka 1994</LINK>; <LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>;<LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>; <LINK REF="STD-Veroli-1992" TYPE="STUDY">Veroli 1992</LINK>; <LINK REF="STD-Wang-1997" TYPE="STUDY">Wang 1997</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>). Each of the 16 studies provided clear information about all participants including those with missing outcome data (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>Of the 1121 enrolled participants, 1087 completed the protocol. Four participants in the HS group failed to complete the study, one because of consent withdrawal (<LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>); one for an anaphylactic reaction to another medication (<LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>); one because of operative complication which met <I>a priori</I> exclusion criteria (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>); and one without a reason specified (<LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>). Seven participants in the IS group failed to complete the protocol, four because of operative complications which met a priori exclusion criteria (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>), one because of an urgent return to the operating room for control of haemorrhage (<LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>); one because of a transfer to another hospital (<LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>) and one without a reason specified (<LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>). Twenty-three participants failed to complete the protocol and were withdrawn from the studies without further information (<LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>). One participant was withdrawn from <LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>, while the other study had 22 people removed from the analysis due to major protocol violation or incomplete data collection, although they were still included in the safety profile (<LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-05-05 15:57:49 +0100" MODIFIED_BY="[Empty name]">
<P>Seventeen of the studies reported all of the clinically relevant outcomes that were appropriate for their trial design (<LINK REF="STD-Baraka-1994" TYPE="STUDY">Baraka 1994</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>; <LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>; <LINK REF="STD-Veroli-1992" TYPE="STUDY">Veroli 1992</LINK>; <LINK REF="STD-Wang-1997" TYPE="STUDY">Wang 1997</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). However, only one of the studies explicitly reported mortality (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>). The remaining studies imply there were no deaths through their other outcome data and we have assessed them to be at an unclear risk of reporting bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Additionally, the study by <LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK> reported a disproportionately low number of female participants and we have assessed this as an unclear risk of bias because it was not explained.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-05-05 15:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Baseline parameters were reported in each study and appeared to be similar in both study groups in all trials. We found no evidence for other sources of bias in any of the studies (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-05-10 19:16:07 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Mortality</HEADING>
<P>One trial reported occurrences of deaths (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>), four in the HS group and three in the IS group. From all of the studies there were 545 participants in the HS group and 542 in the IS group. Because only one study reported events an analysis to compare treatment groups could not be performed. Assessment of the HS group using the Clopper-Person estimation shows that the upper bound for occurrences of events using a 95% CI is 0.019 (19/1000). Due to the paucity of events, neither a sensitivity nor subgroup analysis was feasible. We determine the quality of the evidence is very low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Serious adverse events</HEADING>
<P>There were no reports of serious adverse events such as organ failure, myocardial infarction, cerebrovascular accident or central pontine myelinolysis reported in the trials. The outcome was not explicitly measured and we have extrapolated the data. There were 1087 participants, 542 in the IS group and 545 in the HS group. Although an analysis comparing the treatment groups cannot be performed, assessment of the HS group utilizing the Clopper-Pearson estimation shows that the upper bound for occurrences of events using a 95% CI is 0.007 (7/1000). We have graded the quality of the evidence for this outcome as very low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Fluid balance</HEADING>
<P>Peri-operative fluid balance was calculated in eight trials with 737 participants (51.1% HS, 48.9% IS) (<LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>;<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>). Overall, the fluid balance was positive in both groups (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), the mean volume for the IS group being 4.4 L and 1.9 L lower for the HS group (MD -1.92, 95% CI -2.61 to -1.22; I² = 91%; P &lt; 0.00001; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). We rate the quality of this evidence as low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>We conducted a sensitivity analysis using only studies deemed to have a low risk of bias (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>). The fluid balance was again found to be statistically significantly lower for the HS group (MD -1.47, 95% CI -2.84 to -0.09; participants = 279; P = 0.04; I² = 60%; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>Subgroup analysis suggested no significant effect of the type of surgery (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), dose of HS given (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>), or the total volume of fluid transfused (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). There were too few studies to adequately investigate the high levels of heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Total volume of crystalloid administered</HEADING>
<P>The volume of intravenous fluid administered to participants was reported in 13 trials with 871 participants (51.3% HS, 48.7% IS) (<LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>; <LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>). IS participants received a mean volume of 2.4 L (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Participants in the HS group received 1.49 L, considerably less fluid intravenously than those in the IS group (MD -0.91, 95% CI -1.24 to -0.59; I² = 99%; P &lt; 0.00001; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). We rate the quality of the evidence for this outcome as moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>We conducted a sensitivity analysis to include only studies deemed to be at low risk of bias (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>). We found that the amount of fluid used in the HS group was still statistically significantly less than in the IS group (MD -1.08, 95% CI -1.92 to -0.24; I² = 75%; P = 0.01; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>A subgroup analysis according to type of surgery (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) and the dose of HS (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>) did not reveal differences between the subgroups. The high degree of heterogeneity for this outcome was not explained by subgroup analysis according to type of surgery (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) or the dose of HS (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). Funnel plot analysis showed this outcome to cluster symmetrically (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), except for three outliers from studies that used considerably more HS than other trials (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>). However, exclusion of these three trials from the analysis did not eliminate heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Diuresis during study period</HEADING>
<P>Urine output during the trial was reported in nine trials including 777 participants (51.1% HS, 48.9% IS) (<LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>). There was no difference in peri-operative urine output (L) between the two groups (MD 0.11, 95% CI -0.09 to 0.31; I² = 69%; P = 0.28; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). We rate the quality of the evidence to be low for risk of bias (downgraded one level because the majority of the studies have not confirmed blinding of outcome assessors, and bias could seriously impact this result) and imprecision (downgraded one level: the volume of crystalloid solution delivered has a large range between studies).</P>
<P>A sensitivity analysis limited to studies with a low risk of bias (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>) did not change the findings of the outcome (MD 1.25, 95% CI -1.17 to 3.67; studies = 2; I² = 33%; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>Stratification by type of surgery (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>), dose of HS (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>), or the total volume of crystalloid use in the IS group (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>) did not alter the outcome or the degree of heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Peak serum sodium</HEADING>
<P>The maximum serum sodium was measured in all but two trials (<LINK REF="STD-Durasnel-1999" TYPE="STUDY">Durasnel 1999</LINK>; <LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>), and included 780 participants (50.6% HS, 49.4% IS) from 16 trials. Maximum serum sodium was higher in the HS group than the IS group, 147.4 versus 139.1 meq/L (MD 7.73, 95% CI 5.84 to 9.62; I² = 97%; P &lt; 0.00001; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The maximum average serum sodium ranged between 138.5 and 159 in HS groups compared to between 136 and 143 meq/L in the IS groups. We rate the quality of the evidence as moderate for this outcome (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Sensitivity analysis restricted to studies with a low risk of bias did not change the outcome or the heterogeneity of the studies (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>Subgroup analysis by type of surgery (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>), the dose of crystalloid administered (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>), or by volume of HS (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>) did not alter the outcome or the heterogeneity between trials. Funnel plot analysis which showed peak serum sodium of each study clusters symmetrically around a positive MD. There is substantial overlap of MD from each study, regardless of the dose of HS given (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Final serum sodium</HEADING>
<P>Twelve studies with 640 participants (51.4% HS, 48.6% IS) reported final serum sodium (<LINK REF="STD-Bruegger-2005" TYPE="STUDY">Bruegger 2005</LINK>; <LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>; <LINK REF="STD-Wang-1997" TYPE="STUDY">Wang 1997</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>). By the end of the study period the serum sodium mean difference between the groups was considerably reduced from those reported at peak (MD 3.45, 95% CI 2.46 to 4.44; I² = 88%, P &lt; 0.00001; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) and the range for final average serum sodium was within normal limits: 136 to 146 meq/L and 136 to 140 meq/L in the HS and IS groups respectively. We assess the quality of this evidence as moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>A sensitivity analysis restricted to studies with a low risk of bias did not change the outcome or heterogeneity (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
<P>Neither the result nor heterogeneity were altered in subgroup analysis by surgery type (<LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>), dose of HS (<LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>) or volume of crystalloid (<LINK REF="CMP-003.14" TYPE="ANALYSIS">Analysis 3.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8 - 10. Duration of endotracheal intubation, intensive care stay and hospital stay</HEADING>
<P>None of the trials reported the duration of mechanical ventilation and the length of stay in hospital. Only one trial (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>) reported the length of stay in intensive care, with mean stays (standard deviation) of 2.3 (0.2) versus 2.4 (0.6) days in the HS and IS groups respectively (P = 0.63).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11. Other outcomes of interest</HEADING>
<P>Ten trials with 369 participants (50.9% HS, 49.1% IS) (<LINK REF="STD-Ishikawa-1996" TYPE="STUDY">Ishikawa 1996</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Kato-1996" TYPE="STUDY">Kato 1996</LINK>; <LINK REF="STD-Kimura-1994" TYPE="STUDY">Kimura 1994</LINK>; <LINK REF="STD-K_x00f8_lsen_x002d_Petersen-2004" TYPE="STUDY">Kølsen-Petersen 2004</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>; <LINK REF="STD-Shao-2013" TYPE="STUDY">Shao 2013</LINK>; <LINK REF="STD-Younes-1988" TYPE="STUDY">Younes 1988</LINK>) reported maximum serum osmolarity (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). We found that there was a statistically significant increase in serum osmolarity with HS, increased 5.3% from the median level of 289 mOsm/kg H20 in the IS group (MD 15.29 mOsm/kg H2O higher with HS, 95% CI 12.27 to 18.31; I² = 86%, P &lt; 0.00001). We assess the quality of the evidence to be moderate. We downgraded the study quality because of a high degree of heterogeneity that probably derives from the wide range of crystalloid fluid given across the studies. Future high-quality studies are likely to change this result.</P>
<P>Intraoperative pulmonary artery wedge pressure (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) was reported in three studies with 150 participants (50.7% HS, 49.3% IS) (<LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>). There was no difference between the treatment groups (MD 0.16, 95% CI -1.69 to 2.02; I² = 0%; P = 0.86).</P>
<P>Maximum intraoperative cardiac index was reported in six studies with 418 participants (51.7% HS, 48.3% IS) (<LINK REF="STD-Cross-1989" TYPE="STUDY">Cross 1989</LINK>; <LINK REF="STD-Jarvela-2000" TYPE="STUDY">Jarvela 2000</LINK>; <LINK REF="STD-Jarvela-2001" TYPE="STUDY">Jarvela 2001</LINK>; <LINK REF="STD-Leverve-2008" TYPE="STUDY">Leverve 2008</LINK>; <LINK REF="STD-Shackford-1983" TYPE="STUDY">Shackford 1983</LINK>; <LINK REF="STD-Shackford-1987" TYPE="STUDY">Shackford 1987</LINK>). We found that the maximum intraoperative cardiac index was elevated 11.7% in the HS group over the median level of 2.9 L/min/m² in the IS group (MD 0.34, 95% CI 0.19 to 0.49; I² = 40%; P = 0.0001; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). We rate the quality of these data to be high (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Although only one of the trials (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>) specifically reported adverse events, they have not met our criteria to be considered <I>serious</I> adverse events. Adverse events were reported over a 90-day follow-up period and the study found no difference between the HS and IS groups.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>It was not possible to determine differences with respect to mortality or major morbidity between the treatment arms of this meta-analysis. A preliminary survey carried out before designing the meta-analysis suggested that trials of peri-operative HS were usually designed to measure fluid volumes, haemodynamics and biochemistry rather than measure important clinical outcomes. Despite this, we chose mortality as the primary outcome for this review and we collected serious adverse event data because of their clinical importance.</P>
<P>Peri-operative diuresis was similar in the HS and IS participants, suggesting that adequate intravascular volumes were maintained throughout surgery despite the fact that HS participants received significantly less intravenous fluid than IS participants (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). All of the participant groups completed surgery with a positive fluid balance (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). In some trials, the positive fluid balance was almost 10 L by the end of surgery. Pulmonary oedema was not recorded in the trials but it is reasonable to be concerned that excess fluid of this magnitude would result in pulmonary oedema in a population at risk of this complication. Use of HS significantly reduced the positive fluid balance experienced by all participants undergoing surgery. HS increased serum sodium and osmolarity (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The doses of HS varied considerably between trials, but even in those who received very high doses of HS no adverse events related to hypernatraemia were encountered. Serum sodium returned to normal limits by the end of the study.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analysis of the outcomes measured by the trials provides a reasonably complete picture of the immediate impact of HS on peri-operative fluid management. HS significantly reduces the positive fluid balance experienced by people undergoing surgery while maintaining a stable haemodynamic state. This observation was independent of the type of surgery or whether peri-operative fluid protocol was restricted or unrestricted by volume. HS conserved fluid at lower doses as much as at higher doses. However the trials were not designed to look at the impact of the interventions on mortality or longer-term morbidity.</P>
<P>To date, we have only found one trial where mortality and adverse events were explicitly measured over a period that extended beyond the original hospital stay (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>). Mortality at 90 days did not differ between treatment groups of participants undergoing pancreaticoduodenectomy, but there is no evidence to suggest that this result would remain true at different centres or for different procedures. Until there are more, high-power studies examining mortality in different surgical procedures at multiple centres, we cannot say with certainty that there is no effect of HS on mortality. This same study also measured postoperative complications (non-serious adverse events). Although the result was not statistically significant, there were over 10% more postoperative complications in the IS group. Future trials will be necessary to test this finding.</P>
<P>This review showed that people receiving HS had a transient increase in serum sodium (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Hypernatraemia has the potential to harm but this was not seen in the included studies. In hyponatraemic people, the risk of central pontine myelinolysis is thought to be related to underlying conditions more than the rate of electrolyte repletion, but increases in serum sodium of more than 10 meq/L per day should be avoided if possible (<LINK REF="REF-Kumar-2006" TYPE="REFERENCE">Kumar 2006</LINK>). It is not known if people with normal serum sodium are at a similar risk of hyperosmotically induced demyelination. No episodes of central pontine myelinolysis were reported in these studies where the participants had normal serum sodium levels at baseline, and we did not find any case reports in the literature of central pontine myelinolysis in people who received HS.</P>
<P>Is there a potential therapeutic window for HS in people undergoing surgery, where peri-operative weight gain can be minimized without a risk of significant hypernatraemia? Hypernatraemia is transient after administration of HS. However, it would seem prudent to avoid large increases in serum sodium. This is possible, with these studies suggesting that up to 10 ml/kg of 3% HS will reduce the positive fluid balance peri-operatively by up to 1.5 L in the average adult without increasing serum sodium inappropriately. There is insufficient evidence to determine if such a reduction in peri-operative fluid excess would improve clinically relevant outcomes but it provides the basis for an RCT.</P>
<P>The evidence is strong for a reduction in the volume of peri-operative fluid required to maintain homeostasis with HS. There is no direct evidence that this results in better survival or quality of life. The principal barrier to meta-analysis of some outcomes is a high degree of heterogeneity between the trials. Heterogeneity appears to be due to differences in the magnitude of the effect observed rather than differences in the effect itself. Subgroup analysis identified sources of heterogeneity in some instances. For example, there was considerable heterogeneity in peri-operative diuresis even though there was no significant difference in diuresis between the test group, HS, and the control.</P>
<P>Overall there is a strong need for well-controlled, high-quality studies with adequate design to measure both short- and long-term variables. The results of this systematic review and future studies could prove to be very important to patient care, particularly when low volumes of resuscitating fluid are needed. At this time the results show promise for HS as a safe choice for resuscitation during surgery where reduced volumes would be beneficial, but more evidence is needed.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of evidence across these trials ranged from high to very low. The majority of trials included in this study cover relatively few participants. The trials were conducted in several eras when other peri-operative practices may have changed. There was also a large variation in the dose of HS given between studies which may have resulted in the high heterogeneity between them. Furthermore, many of the studies did not specify the methods of allocation concealment or randomization, which again probably reflects the era in which many of the studies were reported.</P>
<P>For determining mortality, the trials lacked sufficient size, duration and reporting to adequately assess important differences. Furthermore, only one study (<LINK REF="STD-Lavu-2014" TYPE="STUDY">Lavu 2014</LINK>) explicitly reported the outcome, and we have extrapolated the data on the basis that other outcomes were reported by each study for all included participants. We have assessed the quality of evidence for mortality to be very low, and future studies are likely to change the result reported here (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>We rate the quality of the evidence for fluid balance and diuresis to be low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). There is a systemic lack of blinding of personnel across these studies, leaving these outcomes prone to bias. High-quality study results are likely to change this outcome.</P>
<P>The reporting of peak and final serum sodium is of moderate quality (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The level of blood sodium during surgery is a common hospital measurement that is unlikely to be biased. The difference in the number of samples collected by the different studies impacts the quality of this outcome. Future studies are likely to change this result.</P>
<P>We have rated the quality of the evidence for the maximum intraoperative cardiac index as high (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The measurement during an operation is a common hospital procedure that is unlikely to be biased. The studies that report this outcome are well controlled, and the values reported are consistent across the studies. Future studies are unlikely to change this result.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Having searched the largest medical research data bases, without limit by language of publication, it is highly likely that we have found all published data that met our inclusion criteria.</P>
<P>The review authors tried to reduce the impact of personal bias in the presentation and analysis of the results. When assessing the degree that individual bias components would impact study results, we have undoubtedly relied on our own experiences. We have assumed, in cases where the information was not available, that the reports were conducted by compassionate physicians and dedicated researchers who have performed their work honestly and to the best of their abilities. Because of this, we have left our analysis open to being impacted by fraudulent reports.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>This is the first systematic review of HS compared to IS for peri-operative fluid management. This update confirms the findings of the first version (<LINK REF="REF-McAlister-2006" TYPE="REFERENCE">McAlister 2006</LINK>). The findings are consistent with reviews of HS given for other indications such as fluid management in people with burns (<LINK REF="REF-Bunn-2004" TYPE="REFERENCE">Bunn 2004</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-05-05 16:04:18 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>There was insufficient evidence from the included studies to suggest that the use of HS confers any clinical benefit or harm in terms of mortality or major morbidity compared to the use of IS. There is no reason to prefer HS for the routine management of people having surgery. The reduction in positive fluid balance when using HS may suggest HS would be an appropriate choice when fluid restriction is required in selected individuals or clinical situations.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-05-05 16:04:18 +0100" MODIFIED_BY="[Empty name]">
<P>HS administration to people undergoing surgery should be compared to standard practice, using RCTs of high methodological rigour in order to determine any impact on participant survival and other clinically relevant outcomes. Sample size estimation is problematic, given the very low reported incidence of mortality or significant morbidity in the control groups in these trials. The duration of any future trial should be sufficient to cover the period of peri-operative mortality or major morbidity which is usually considered to be 60 days or at least the postoperative hospital stay.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-05-05 16:05:26 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Associate Professor Mike Bennett (content editor), Dr Harald Herkner (statistical editor), Dr Nathan Pace (statistical editor), Dr Thomas Schricker, Dr Birgitte Brandstrup (peer reviewers) and Rosemary Doolan (consumer) for their help and editorial advice during the preparation of the protocol and review (<LINK REF="REF-McAlister-2006" TYPE="REFERENCE">McAlister 2006</LINK>; <LINK REF="REF-McAlister-2010" TYPE="REFERENCE">McAlister 2010</LINK>). We also acknowledge the help of the copy editor, Kate Cahill, in preparation of this manuscript.</P>
<P>Mark Edward, Kathie Godfrey and Nete Villebro for their help and editorial advice during the preparation of the protocol for the review (<LINK REF="REF-McAlister-2006" TYPE="REFERENCE">McAlister 2006</LINK>); Mr Karen Hovhannisyan, former Trials Search Co-ordinator of the Cochrane Anaesthesia; Critical and Emergency Care Group, for advice regarding electronic searches; Dr Hideaki Tanaka, Ms Christiane Baldwin and Dr Yoshihisa Morita for translations; and Mrs Jane Cracknell, Managing Editor of the Cochrane Anaesthesia, Critical and Emergency Care Group, for patient guidance throughout the whole process. Dr Tammy Znajda was a co-author on the first version of this review. - in the 'Contributions of authors', Dr Znajda's contributions relate to the first review only (<LINK REF="REF-McAlister-2010" TYPE="REFERENCE">McAlister 2010</LINK>).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-04-27 11:41:32 +0100" MODIFIED_BY="[Empty name]">
<P>Shrum, Bradly: none identified<BR/>McArthur, Eric: none identified<BR/>Burns, Karen: none identified<BR/>Chruch, Brian: none identified<BR/>Znadja, Tammy: none identified<BR/>McAlister, Vivian: none identified</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Conceiving the review: T Znajda (TZ), K Burns (KB), V McAlister (VM) B Church (BC)<BR/>Co-ordinating the review: VM<BR/>Undertaking manual searches: TZ, K.B, VM, Eric McArthur (EM), BS<BR/>Screening search results: TZ, KB, VM, BC, EM, BS<BR/>Organizing retrieval of papers: TZ, VM, BS<BR/>Screening retrieved papers against inclusion criteria: TZ, KB, VM, EM, BS<BR/>Appraising quality of papers: TZ, KB, VM, EM, BS<BR/>Abstracting data from papers: TZ, KB, VM, BC, EM, BS<BR/>Writing to authors of papers for additional information: VM, BS<BR/>Obtaining and screening data on unpublished studies: TZ, KB, VM, BS<BR/>Data management for the review: TZ, KB, VM, EM<BR/>Entering data into Review Manager (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>): VM, KB, EM, BS<BR/>RevMan statistical data: VM, KB, EM<BR/>Other statistical analysis not using RevMan: KB<BR/>Double entry of data: (data entered by person one: VM ; data entered by person two: KB ; data entered by person two alternates: EM, BS)<BR/>Interpretation of data: TZ, KB, VM, EM<BR/>Statistical analysis: TZ, KB, VM, EM<BR/>Writing the review: VM<BR/>Securing funding for the review: Not applicable<BR/>Performing previous work that was the foundation of the present study: TZ, KB, VM, BC<BR/>Guarantor for the review (one author) VM<BR/>Persons responsible for reading and checking review before submission: TZ, KB, VM, BC, EM, BS</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Bradly Shrum was added as an author since the initial publication of our protocol (<LINK REF="REF-McAlister-2006" TYPE="REFERENCE">McAlister 2006</LINK>).</P>
<P>Studies did not provide data regarding duration of hospitalization, duration of endotracheal intubation, length of stay in ICU. Studies did not explicitly provide data on adverse outcomes such as: any organ failure, any requirement for dialysis (renal failure) or prolonged ventilation (pulmonary failure); use of medical therapy for either pulmonary oedema or circulatory support (cardiac failure) or for confusion (cerebral failure).</P>
<P>In addition to the prespecified outcomes, we also collected data regarding serum osmolarity and peri-operative haemodynamic parameters including pulmonary wedge pressure and cardiac index, as they were reported in multiple studies. We analysed these outcomes by the same method as all other outcomes.</P>
<P>We have made minor changes to our statistical analysis to be in line with current Cochrane standards. We now use mean difference instead of standardized mean difference for continuous outcomes. We now use risk ratio instead of risk difference for dichotomous outcomes. We have also employed the random-effects model where heterogeneity was detected by an I² value greater than 30%.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-05-13 08:24:03 +0100" MODIFIED_BY="Jane Cracknell">
<STUDIES MODIFIED="2016-05-11 17:21:07 +0100" MODIFIED_BY="Jane Cracknell">
<INCLUDED_STUDIES MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Baraka-1994" MODIFIED="2016-04-27 15:20:03 +0100" MODIFIED_BY="[Empty name]" NAME="Baraka 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-04-27 15:20:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baraka A, Taha S, Ghabach M, Sibaii A, Nader A, Matta M</AU>
<TI>Hypertonic saline prehydration in patients undergoing transurethral resection of the prostate under spinal anaesthesia</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>2</NO>
<PG>227-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837277"/><IDENTIFIER TYPE="MEDLINE" VALUE="7832822"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837276"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruegger-2005" MODIFIED="2016-04-27 15:20:19 +0100" MODIFIED_BY="[Empty name]" NAME="Bruegger 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-04-27 15:20:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruegger D, Bauer A, Rehm M, Niklas M, Jacob M, Irlbeck M, et al</AU>
<TI>Effect of hypertonic saline dextran on acid-base balance in patients undergoing surgery of abdominal aortic aneurysm</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>3</NO>
<PG>556-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837279"/><IDENTIFIER TYPE="MEDLINE" VALUE="15753747"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837278"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cross-1989" NAME="Cross 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cross JS, Gruber DP, Burchard KW, Singh AK, Moran JM, Gann DS</AU>
<TI>Hypertonic saline fluid therapy following surgery: a prospective study</TI>
<SO>The Journal of Trauma</SO>
<YR>1989</YR>
<VL>29</VL>
<NO>6</NO>
<PG>817-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837281"/><IDENTIFIER TYPE="MEDLINE" VALUE="2661843"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cross JS, Gruber DP, Gann DS, Singh AK, Moran JM, Burchard KW</AU>
<TI>Hypertonic saline attenuates the hormonal response to injury</TI>
<SO>Annals of Surgery</SO>
<YR>1989</YR>
<VL>209</VL>
<NO>6</NO>
<PG>684-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837282"/><IDENTIFIER TYPE="MEDLINE" VALUE="2543337"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durasnel-1999" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" NAME="Durasnel 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durasnel P, Cresci L, Madougou M, Idrissa A, Cheriff I, Falandry L, et al</AU>
<TI>Practice of spinal anaesthesia in a developing country: usefulness of vascular preloading with a 7.5% hypertonic saline solution</TI>
<TO>Pratique de la rachianesthesie dans un pays en voie de development: interêt du remplissage vasculaire par un solute sale hypertonique a 7,5%</TO>
<SO>Annales Françaises d'Anesthèsie et de Rèanimation</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>6</NO>
<PG>631-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4142294"/><IDENTIFIER TYPE="MEDLINE" VALUE="10464529"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837283"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishikawa-1996" MODIFIED="2015-01-20 18:34:34 +0000" MODIFIED_BY="[Empty name]" NAME="Ishikawa 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-01-20 18:34:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishikawa G</AU>
<TI>The effect of hypertonic saline infusion on lumbar epidural anesthesia</TI>
<SO>Masui</SO>
<YR>1996</YR>
<VL>45</VL>
<NO>2</NO>
<PG>205-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837286"/><IDENTIFIER TYPE="MEDLINE" VALUE="8865710"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837285"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarvela-2000" MODIFIED="2012-12-31 15:17:39 +0000" MODIFIED_BY="Jane Cracknell" NAME="Jarvela 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-12-31 15:17:39 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Jarvala K</AU>
<SO>Email correspondence (January 4, 2007)</SO>
<YR>2007</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837288"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jarvela K, Honkonen SE, Jarvela T, Koobi T, Kaukinen S</AU>
<TI>The comparison of hypertonic saline (7.5%) and normal saline (0.9%) for initial fluid administration before spinal anaesthesia</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2000</YR>
<VL>91</VL>
<PG>1461-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837289"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvela K, Koobi T, Kauppinen P, Kaukinen S</AU>
<TI>Effects of hypertonic 75 mg/ml (7.5%) saline on extracellular water volume when used for preloading before spinal anaesthesia</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>2001</YR>
<VL>45</VL>
<NO>6</NO>
<PG>776-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837290"/><IDENTIFIER TYPE="MEDLINE" VALUE="11421840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837287"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarvela-2001" MODIFIED="2012-12-31 15:17:39 +0000" MODIFIED_BY="Jane Cracknell" NAME="Jarvela 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-12-31 15:17:39 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Jarvala K</AU>
<SO>Email correspondence (January 4, 2007)</SO>
<YR>2007</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837292"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvela K, Kaukinen S</AU>
<TI>Hypertonic saline (7.5%) after coronary artery bypass grafting</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>2</NO>
<PG>100-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837293"/><IDENTIFIER TYPE="MEDLINE" VALUE="11270018"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jarvela K, Kaukinen S</AU>
<TI>Hypertonic saline (7.5%) decreases perioperative weight gain following cardiac surgery</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>1</NO>
<PG>43-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837294"/><IDENTIFIER TYPE="MEDLINE" VALUE="11854877"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvela K, Koskinen M, Kaukinen S, Koobi T</AU>
<TI>Effects of hypertonic saline (7.5%) on extracellular fluid volumes compared with normal saline (0.9%) and 6% hydroxyethyl starch after aortocoronary bypass graft surgery</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>2</NO>
<PG>210-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837295"/><IDENTIFIER TYPE="MEDLINE" VALUE="11312481"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837291"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kato-1996" MODIFIED="2016-04-27 15:25:53 +0100" MODIFIED_BY="[Empty name]" NAME="Kato 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-04-27 15:25:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kato S, Goto F</AU>
<TI>Hypertonic saline for intraoperative fluid therapy in transurethral resection of the prostate</TI>
<SO>Journal of Anesthesia</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>170-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837297"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837296"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kimura-1994" MODIFIED="2016-04-27 15:26:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kimura 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-04-27 15:26:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimura K, Takaori M</AU>
<TI>The effects of hypertonic lactated Ringer's solution during transurethral surgery</TI>
<SO>Masui. The Japanese Journal of Anesthesiology</SO>
<YR>1994</YR>
<VL>43</VL>
<NO>8</NO>
<PG>1141-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837299"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837298"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-K_x00f8_lsen_x002d_Petersen-2004" MODIFIED="2016-04-27 15:28:12 +0100" MODIFIED_BY="[Empty name]" NAME="Kølsen-Petersen 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-04-27 15:27:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kølsen-Petersen JA, Nielsen JO, Bendtzen K, Tonnesen E</AU>
<TI>Infusion of hypertonic saline (7.5% NaCl) causes minor immunological changes in normovolaemic women</TI>
<SO>Acta Anaesthesiology Scandinavica</SO>
<YR>2004</YR>
<VL>48</VL>
<NO>2</NO>
<PG>224-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837301"/><IDENTIFIER TYPE="MEDLINE" VALUE="14995946"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-27 15:27:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kølsen-Petersen JA, Nielsen JO, Tonnesen EM</AU>
<TI>Effect of hypertonic saline infusion on postoperative cellular immune function: a randomized controlled clinical trial</TI>
<SO>Anesthesiology</SO>
<YR>2004</YR>
<VL>100</VL>
<NO>5</NO>
<PG>1108-18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837302"/><IDENTIFIER TYPE="MEDLINE" VALUE="15114207"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-27 15:28:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kølsen-Petersen JA, Rasmussen TB, Krog J, Hokland M, Tonnesen EK</AU>
<TI>Infusion of hypertonic saline (7.5%) does not change neutrophil oxidative burst or expression of endothelial adhesion molecules after abdominal hysterectomy</TI>
<SO>Journal of Trauma</SO>
<YR>2006</YR>
<VL>61</VL>
<NO>5</NO>
<PG>1100-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837303"/><IDENTIFIER TYPE="MEDLINE" VALUE="17099514"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837300"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lavu-2014" MODIFIED="2016-05-05 16:07:55 +0100" MODIFIED_BY="[Empty name]" NAME="Lavu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-05-05 16:07:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavu H, Sell NM, Carter TI, Winter JM, Maguire DP, Gratch DM, et al</AU>
<TI>The HYSLAR Trial: a prospective randomized controlled trial of the use of a restrictive fluid regimen with 3% hypertonic saline versus lactated Ringers in patients undergoing pancreaticoduodenectomy</TI>
<SO>Annals of Surgery</SO>
<YR>2014</YR>
<VL>290</VL>
<NO>3</NO>
<PG>445-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837305"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-05 16:07:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Lavu, H</AU>
<TI>Personal communication</TI>
<SO>Personal communication</SO>
<YR>January 2015</YR>
<IDENTIFIERS MODIFIED="2016-04-27 15:32:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837306"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837304"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leverve-2008" MODIFIED="2015-05-29 18:42:10 +0100" MODIFIED_BY="[Empty name]" NAME="Leverve 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-29 18:42:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leverve X, Boon C, Hakim T, Anwar M, Siregar E, Mustafa I</AU>
<TI>Half-molar sodium-lactate solution has a beneficial effect in patients after coronary artery bypass grafting</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<PG>1796-1803</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837308"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837307"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shackford-1983" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" NAME="Shackford 1983" YEAR="1983">
<REFERENCE MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shackford SR, Sise MJ, Fridlund PH, Rowley WR, Peters RM, Virgilio RW, et al</AU>
<TI>Hypertonic sodium lactate versus lactated ringer's solution for intravenous fluid therapy in operations on the abdominal aorta</TI>
<SO>Surgery</SO>
<YR>1983</YR>
<VL>94</VL>
<NO>1</NO>
<PG>41-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4142295"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837309"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shackford-1987" MODIFIED="2016-05-05 16:08:16 +0100" MODIFIED_BY="[Empty name]" NAME="Shackford 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-05-05 16:08:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shackford SR, Fortlage DA, Peters RM, Hollingsworth-Fridlund P, Sise MJ</AU>
<TI>Serum osmolar and electrolyte changes associated with large infusions of hypertonic sodium lactate for intravascular volume expansion of patients undergoing aortic reconstruction</TI>
<SO>Surgery, Gynecology and Obstetrics</SO>
<YR>1987</YR>
<VL>164</VL>
<NO>2</NO>
<PG>127-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837312"/><IDENTIFIER TYPE="MEDLINE" VALUE="3810427"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837311"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Shao-2013" MODIFIED="2016-04-27 15:35:10 +0100" MODIFIED_BY="[Empty name]" NAME="Shao 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-04-27 15:35:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shao L, Wang B, Wang S, Mu F, Gu K</AU>
<TI>Comparison of 7.2% hypertonic saline - 6% hydroxyethyl starch solution and 6%hydroxyethyl starch solution after the induction of anaesthesia in patients undergoing elective neurosurgical procedures</TI>
<SO>Clinics (Sao Paulo)</SO>
<YR>2013</YR>
<VL>68</VL>
<NO>3</NO>
<PG>323-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837314"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837313"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veroli-1992" MODIFIED="2016-04-27 15:36:41 +0100" MODIFIED_BY="[Empty name]" NAME="Veroli 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-04-27 15:36:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veroli P, Benhamou D</AU>
<TI>Comparison of hypertonic saline (5%), isotonic saline and Ringer's lactate solutions for fluid preloading before lumbar extradural anaesthesia</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1992</YR>
<VL>69</VL>
<NO>5</NO>
<PG>461-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837316"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837315"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1997" NAME="Wang 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang BW, Chiou YH, Chen WB, Peng TY, Leung HK</AU>
<TI>Intravenous pretreatment of hypertonic saline can prevent systemic hypotension induced by spinal anesthesia</TI>
<SO>Acta Anaesthesiologica Sinica</SO>
<YR>1997</YR>
<VL>35</VL>
<NO>2</NO>
<PG>85-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837318"/><IDENTIFIER TYPE="MEDLINE" VALUE="9293648"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837317"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Younes-1988" MODIFIED="2016-05-05 16:08:33 +0100" MODIFIED_BY="[Empty name]" NAME="Younes 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-05-05 16:08:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Younes RN, Bechara MJ, Langer B, Aun F, Birolini D, Kuznieck S, et al</AU>
<TI>Use of a hypertonic solution of 7.5% NaCl in preventing post-declamping hypotension of the abdominal aorta</TI>
<TO>Emprego da solucao hipertonica de NaCl a 7,5% na prevencao do hipotensao pos-desclampeamento da aorta abdominal</TO>
<SO>AMB: Revista da Associação Médica Brasileira</SO>
<YR>1988</YR>
<VL>34</VL>
<NO>5</NO>
<PG>150-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837320"/><IDENTIFIER TYPE="MEDLINE" VALUE="3251309"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837319"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-05-11 17:21:07 +0100" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Auler-1987" MODIFIED="2016-04-27 15:39:40 +0100" MODIFIED_BY="[Empty name]" NAME="Auler 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-04-27 15:39:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Auler JOC, Pereira MHC, Gomide-Amaral RV, Stolf NG, Jatene AD, Rocha e Silva M</AU>
<TI>Hemodynamic effects of hypertonic sodium chloride during surgical treatment of aortic aneurysms</TI>
<SO>Surgery</SO>
<YR>1987</YR>
<VL>101</VL>
<PG>594-601</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837322"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837321"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auler-1992" MODIFIED="2016-05-05 16:09:11 +0100" MODIFIED_BY="[Empty name]" NAME="Auler 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-05-05 16:09:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Auler JOC Jr, Zin WA, Martins MA, Younes RN, Negri EM, Hoelz C, et al</AU>
<TI>Respiratory system mechanics in patients treated with isotonic or hypertonic NaCl solutions</TI>
<SO>Circulatory Shock</SO>
<YR>1992</YR>
<VL>36</VL>
<NO>4</NO>
<PG>243-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837324"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837323"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014" MODIFIED="2016-05-05 16:08:45 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-05-05 16:08:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Wang B, Wang S, Mu F</AU>
<TI>Effects of hypertonic saline - hydroxyethyl starch and mannitol on serum osmolality, dural tension and hemodynamics in patients undergoing elective neurosurgical procedures</TI>
<SO>International Journal of Clinical and Experimental Medicine</SO>
<YR>2014</YR>
<VL>7</VL>
<NO>8</NO>
<PG>2266-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837326"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837325"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2015" MODIFIED="2016-05-11 17:21:07 +0100" MODIFIED_BY="Jane Cracknell" NAME="Li 2015" YEAR="2014">
<REFERENCE MODIFIED="2016-05-11 17:21:07 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Chen H, Hao JJ, Yin NN, Xu M, Zhou JX</AU>
<TI>Agreement of measured and calculated serum osmolality during the infusion of mannitol or hypertonic saline in patients after craniotomy: a prospective, double-blinded, randomised controlled trial</TI>
<SO>BMC Anesthesiology</SO>
<YR>2015</YR>
<VL>15</VL>
<PG>138</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4142296"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-05 16:09:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02037815</AU>
<TI>Correlation of measured and calculated serum osmolality during mannitol or hypertonic saline infusion in patients after craniotomy: a study protocol and statistical analysis plan for a randomised controlled trial</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02037815</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837329"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837327"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shao-2005" NAME="Shao 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shao YS, Zhang YT, Peng KQ, Quan ZY</AU>
<TI>Effects of 7.5% hypertonic saline on fluid balance after radical surgery for gastrointestinal carcinoma</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>11</NO>
<PG>1577-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837331"/><IDENTIFIER TYPE="MEDLINE" VALUE="15786530"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837330"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-Z-2014" MODIFIED="2016-05-05 16:09:24 +0100" MODIFIED_BY="[Empty name]" NAME="Yang Z 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-05-05 16:09:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang Z, Zong Z, Ke C, Wei Y, Yu D, Wang L, et al</AU>
<TI>Hetastarch with hypertonic saline loading is a better choice for the maintenance of systemic and pulmonary circulation during general and epidural anesthesia</TI>
<SO>Panminerva Medicine</SO>
<YR>2014</YR>
<VL>56</VL>
<NO>1</NO>
<PG>35-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837333"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837332"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yousefshahi-F-2013" MODIFIED="2016-05-05 16:09:39 +0100" MODIFIED_BY="[Empty name]" NAME="Yousefshahi F 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-05-05 16:09:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yousefshahi F, Bashirzadeh M, Abdollahi M, Mojtahedzadeh M, Salehiomran A,Jalali A, et al</AU>
<TI>Effect of hypertonic saline infusion versus normal saline on serum NGAL and cystatin C levels in patients undergoing coronary artery bypass graft</TI>
<SO>Journal of the Tehran Heart Centre</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2837335"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2837334"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-06-18 18:57:11 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-05-11 17:21:49 +0100" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_REFERENCES MODIFIED="2016-05-11 17:21:49 +0100" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Arkili_x00e7_-2003" MODIFIED="2016-05-05 16:09:51 +0100" MODIFIED_BY="[Empty name]" NAME="Arkiliç 2003" TYPE="JOURNAL_ARTICLE">
<AU>Arkiliç CF, Taguchi A, Sharma N, Ratnaraj J, Sessler DI, Read TE, et al</AU>
<TI>Supplemental perioperative fluid administration increases tissue oxygen pressure</TI>
<SO>Surgery</SO>
<YR>2003</YR>
<VL>133</VL>
<NO>1</NO>
<PG>49-55</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12563237"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brandstrup-2003" MODIFIED="2016-05-05 16:10:05 +0100" MODIFIED_BY="[Empty name]" NAME="Brandstrup 2003" TYPE="JOURNAL_ARTICLE">
<AU>Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, et al: Danish Study Group on Perioperative Fluid Therapy</AU>
<TI>Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial</TI>
<SO>Annals of Surgery</SO>
<YR>2003</YR>
<VL>238</VL>
<NO>5</NO>
<PG>641-8</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="14578723"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bunn-2004" MODIFIED="2008-06-04 09:21:41 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bunn 2004" TYPE="COCHRANE_REVIEW">
<AU>Bunn F, Roberts I, Tasker R, Akpa E</AU>
<TI>Hypertonic versus near isotonic crystalloid for fluid resuscitation in critically ill patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-05-30 18:29:34 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2008-05-30 18:29:34 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD002045.pub2"/><IDENTIFIER TYPE="MEDLINE" VALUE="15266460"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clopper-1934" MODIFIED="2016-05-04 19:07:48 +0100" MODIFIED_BY="[Empty name]" NAME="Clopper 1934" TYPE="JOURNAL_ARTICLE">
<AU>Clopper C, Pearson ES</AU>
<TI>The use of confidence or fiducial limits illustrated in the case of the binomial</TI>
<SO>Biometrika</SO>
<YR>1934</YR>
<VL>26</VL>
<NO>4</NO>
<PG>404-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2015-06-15 14:55:54 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="9310563"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2004" MODIFIED="2015-06-23 18:58:13 +0100" MODIFIED_BY="[Empty name]" NAME="GRADE 2004" TYPE="JOURNAL_ARTICLE">
<AU>GRADE Working Group</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490-8</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15205295"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grocott-2005" MODIFIED="2008-06-04 09:21:41 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Grocott 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grocott MP, Mythen MG, Gan TJ</AU>
<TI>Perioperative fluid management and clinical outcomes in adults</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>4</NO>
<PG>1093-106</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15781528"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-10-25 19:06:09 +0100" MODIFIED_BY="Jane Cracknell" NAME="Higgins 2011" TYPE="OTHER">
<TI>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2006" MODIFIED="2008-06-04 09:21:41 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Kumar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kumar S, Fowler M, Gonzalez-Toledo E, Jaffe SL</AU>
<TI>Central pontine myelinolysis, an update</TI>
<SO>Neurological Research</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>3</NO>
<PG>360-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16687066"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lobo-2002" MODIFIED="2016-05-05 16:10:18 +0100" MODIFIED_BY="[Empty name]" NAME="Lobo 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP</AU>
<TI>Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9320</NO>
<PG>1812-8</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12044376"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2012" MODIFIED="2015-06-15 14:25:31 +0100" MODIFIED_BY="[Empty name]" NAME="Lundh 2012" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ogden-2005" MODIFIED="2008-06-04 09:21:41 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Ogden 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ogden AT, Mayer SA, Connolly ES Jr</AU>
<TI>Hyperosmolar agents in neurosurgical practice: the evolving role of hypertonic saline</TI>
<SO>Neurosurgery</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>2</NO>
<PG>207-15</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16094147"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-05-05 16:10:27 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rizoli-2006" MODIFIED="2016-05-05 16:11:01 +0100" MODIFIED_BY="[Empty name]" NAME="Rizoli 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rizoli SB, Rhind SG, Shek PN, Inaba K, Filips D, Tien H, et al</AU>
<TI>The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized, controlled, double-blinded trial</TI>
<SO>Annals of Surgery</SO>
<YR>2006</YR>
<VL>243</VL>
<NO>1</NO>
<PG>47-57</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16371736"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001a" MODIFIED="2016-05-05 16:10:38 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2001a" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JAC, Egger M, Smith GD</AU>
<TI>Investigating and dealing with publication and other biases in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7304</NO>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001b" MODIFIED="2016-05-05 16:10:49 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2001b" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JAC, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wade-1997" MODIFIED="2008-06-04 09:21:41 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wade 1997" TYPE="JOURNAL_ARTICLE">
<AU>Wade CE, Kramer GC, Grady JJ, Fabian TC, Younes RN</AU>
<TI>Efficacy of hypertonic 7.5% saline and 6% dextran-70 in treating trauma: a meta-analysis of controlled clinical studies</TI>
<SO>Surgery</SO>
<YR>1997</YR>
<VL>122</VL>
<NO>3</NO>
<PG>609-16</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="9308620"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2012-12-29 17:11:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-04-12 11:01:24 +0100" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-McAlister-2006" MODIFIED="2016-04-12 11:01:24 +0100" MODIFIED_BY="Jane Cracknell" NAME="McAlister 2006" TYPE="COCHRANE_PROTOCOL">
<AU>McAlister V, Burns KEA, Znajda T, Church B</AU>
<TI>Hypertonic saline for peri-operative fluid management</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-06-16 19:40:41 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-06-16 19:40:41 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006233"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McAlister-2010" MODIFIED="2015-06-16 19:34:28 +0100" MODIFIED_BY="[Empty name]" NAME="McAlister 2010" TYPE="COCHRANE_REVIEW">
<AU>McAlister V, Burns KEA, Znajda T, Church B</AU>
<TI>Hypertonic saline for peri-operative fluid management</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-06-16 19:34:28 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-06-16 19:34:28 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005576"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Funding source" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baraka-1994">
<CHAR_METHODS MODIFIED="2016-05-03 19:47:56 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article</P>
<P>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Lebanon<BR/>Language: English<BR/>Single centre<BR/>Inclusion criteria: consenting adult men undergoing transurethral resection of the prostate under spinal anaesthesia<BR/>Exclusion criteria: ASA IV<BR/>Number eligible: not specified<BR/>Number enrolled: 33 (HS 17; NS 16)<BR/>Number completed study: 33</P>
<P>Age: not reported</P>
<P>Gender: men only</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 3% HS<BR/>Dose: 7 ml/kg<BR/>Duration: before spinal anaesthesia<BR/>
<I>Isotonic salt solution group</I>
<BR/>IV solution: NS<BR/>Dose: 7 ml/kg<BR/>Duration: before spinal anaesthesia<BR/>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:35:05 +0000" MODIFIED_BY="[Empty name]">
<P>Peak serum sodium<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:38:41 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruegger-2005">
<CHAR_METHODS MODIFIED="2016-05-03 19:52:26 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article</P>
<P>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: no<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany<BR/>Language: English<BR/>Single centre<BR/>Inclusion criteria: people undergoing elective infrarenal aortic aneurysm repair<BR/>Exclusion criteria: ASA IV; renal dysfunction; congestive heart failure; recent brain infarction; contra-indication to starch or dextran. Intraoperative exclusion criteria were suprarenal clamping and aortic<BR/>aneurysm that extended into the iliac arteries<BR/>Number eligible: Not specified<BR/>Number enrolled: 28 (HS 14; NS 14)<BR/>Number completed study: 28</P>
<P>Age: not reported</P>
<P>Gender: men 25, women 3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 7.5% NaCl<BR/>Dose: 250 ml</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: NS<BR/>Dose: 250 ml</P>
<P>
<I>Co-interventions: </I>dextran 70 given with HS; hydroxyethyl starch given with NS<BR/>Co-interventions applied differentially between groups: No</P>
<P>Study period: duration of surgery plus 72 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:36:02 +0000" MODIFIED_BY="[Empty name]">
<P>Fluid volume transfused<BR/>Blood transfused<BR/>Fluid loss<BR/>Fluid balance<BR/>Peak serum sodium<BR/>Urine output<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:38:55 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Different colloids given to experimental and control groups. Study included because the effect of the different colloids is equivalent. The study was designed to test a commercially available hypertonic salt-colloid combination with an isotonic salt-colloid comparison</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cross-1989">
<CHAR_METHODS MODIFIED="2016-05-03 19:54:55 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article</P>
<P>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Language: English<BR/>Inclusion criteria: consenting people undergoing coronary artery bypass<BR/>Exclusion criteria: cardiac arrhythmia; cardiac, pulmonary, renal, hepatic failure<BR/>Number eligible: not given<BR/>Number enrolled: 20 (HS 11; ISS 9)<BR/>Number completed study: 20</P>
<P>Age: not reported</P>
<P>Gender: men 19, women 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: HS (1.8%, 304 meq Na/L)<BR/>Dose: 100 cc/hour<BR/>Duration: Postoperative admission to ICU for 24 hours<BR/>Subsequent maintenance: D5/0.45NaCl if serum sodium &gt; 155 meq/L</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: NS<BR/>Dose: 100 cc/hour<BR/>Duration: admission to ICU for 24 hours<BR/>Postoperative maintenance: D5/0.45NaCl if serum sodium &gt; 155 meq/L</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: 24 hours from the beginning of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:36:15 +0000" MODIFIED_BY="[Empty name]">
<P>LOS hospital<BR/>LOS ICU<BR/>Fluid volume transfused<BR/>Blood transfused<BR/>Fluid loss<BR/>Fluid balance<BR/>Peak serum sodium<BR/>Urine output<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:03 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Durasnel-1999">
<CHAR_METHODS MODIFIED="2016-05-03 19:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Niger<BR/>Language: French<BR/>Single centre<BR/>Inclusion criteria: consenting adults undergoing surgery using spinal anaesthesia<BR/>Exclusion criteria: systemic infection, coagulopathy, allergy to local anaesthetic, uncorrected hypovolaemia, congestive heart failure, kidney failure<BR/>Number eligible: not specified<BR/>Number enrolled: 50 (HS 25; ISS 25)<BR/>Number completed study: 48 (1 from each group excluded, cause not given)</P>
<P>Age: not reported</P>
<P>Gender: men 39, women 9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 7.5% HS<BR/>Dose: 100 ml<BR/>Duration: prior to anaesthesia</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: 0.9% NaCl<BR/>Dose: 100 ml<BR/>Duration: prior to anaesthesia</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:36:25 +0000" MODIFIED_BY="[Empty name]">
<P>Haemodynamic parameters<BR/>Fluid volume transfused</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:07 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ishikawa-1996">
<CHAR_METHODS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article</P>
<P>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: no (1 participant in RL group excluded during study)<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Japan<BR/>Language: Japanese<BR/>Inclusion criteria: People undergoing lower limb or pelvic surgery with epidural anaesthesia<BR/>Exclusion criteria: ASA classification II, III or IV; MAP decrease by 50 mm Hg<BR/>Number eligible: 24<BR/>Number enrolled: 24<BR/>Number completed study: 24</P>
<P>Relevant data available on: 15 (HS 8; IS 7)</P>
<P>Age: not reported</P>
<P>Gender: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 7.2% HS<BR/>Dose: 1.8 ml/kg<BR/>Duration: 20 minutes<BR/>Postoperative maintenance: ISS</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: NS<BR/>Dose: 1 - 2 ml/kg/hr<BR/>Duration: study period</P>
<P>Co-interventions: epidural anaesthesia<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Peak serum sodium<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:11 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES>
<P>Translations supplied by Dr Hideaki Tanaka and Dr Yoshihisa Morita</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jarvela-2000">
<CHAR_METHODS MODIFIED="2016-05-03 20:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Finland<BR/>Language: English<BR/>Single centre<BR/>Inclusion criteria: consenting fit people having lower limb surgery under spinal anaesthesia<BR/>Exclusion criteria: ASA III or IV<BR/>Number eligible: not specified<BR/>Number enrolled: 40 (HS 20; ISS 20)<BR/>Number completed study: 40</P>
<P>Age: not reported</P>
<P>Gender: men 30, women 10</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 7.5% HS<BR/>Dose: 4 ml/kg<BR/>Duration: 30 minute<BR/>Postoperative maintenance: D5 / 0.3% NaCl at 1 ml/kg/hour</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: NS<BR/>Dose: 4 ml/kg<BR/>Duration: 30 minute<BR/>Post-operative maintenance: D5/0.3% NaCl at 1 ml/kg/hour</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery and post-anaesthetic recovery period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:39:14 +0000" MODIFIED_BY="[Empty name]">
<P>Fluid volume transfused<BR/>Fluid loss<BR/>Fluid balance<BR/>Peak serum sodium<BR/>Urine output<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:17 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jarvela-2001">
<CHAR_METHODS MODIFIED="2016-05-03 20:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article</P>
<P>Study type: RCT</P>
<P>Baseline comparison: yes</P>
<P>Baseline similarity: yes</P>
<P>Control of co-interventions: yes</P>
<P>Completeness of follow-up: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Finland<BR/>Language: English<BR/>Single centre<BR/>Inclusion criteria: People undergoing elective coronary artery bypass graft<BR/>Exclusion criteria: not specified<BR/>Number eligible: not specified<BR/>Number enrolled: 72 (HS 36; ISS 36)<BR/>Number completed study: 72</P>
<P>Age: not reported</P>
<P>Gender: men 59, women 13</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 7.5% HS<BR/>Dose: 4 ml/kg<BR/>Duration: 30 minutes<BR/>Postoperative maintenance: D5/0.3% NaCl at 1 ml/kg/hour</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: NS<BR/>Dose: 4 ml/kg<BR/>Duration: 30 minutes<BR/>Postoperative maintenance: D5/0.3% NaCl at 1 ml/kg/hour</P>
<P>
<I>Co-interventions:</I> 4% albumin to maintain cardiac index at 2.5 L/min/m³<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery and postoperative period until next morning</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:39:28 +0000" MODIFIED_BY="[Empty name]">
<P>Fluid volume transfused<BR/>Weight gain<BR/>Fluid loss<BR/>Fluid balance<BR/>Peak serum sodium<BR/>Urine output<BR/>Haemodynamic parameters<BR/>Extubation times</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:22 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kato-1996">
<CHAR_METHODS MODIFIED="2016-05-03 20:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article</P>
<P>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Japan<BR/>Language: English<BR/>Inclusion criteria: consenting people undergoing transurethral resection of the prostate<BR/>Exclusion criteria: not given<BR/>Number eligible: not given<BR/>Number enrolled: 40 (HS 20; ISS 20)<BR/>Number completed study: 40</P>
<P>Age: not reported</P>
<P>Gender: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 3% HS<BR/>Dose: 4 ml/kg/min<BR/>Duration: adjusted to maintain mean arterial pressure at 80% of preoperative value</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: RL<BR/>Dose: 4 ml/kg/min<BR/>Duration: adjusted to maintain mean arterial pressure at 80% of preoperative value<BR/>Postoperative maintenance:</P>
<P>Co-interventions:<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery plus first postoperative day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:39:50 +0000" MODIFIED_BY="[Empty name]">
<P>Fluid volume transfused<BR/>Peak serum sodium<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kimura-1994">
<CHAR_METHODS MODIFIED="2016-05-03 20:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: unclear</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Japan<BR/>Language: Japanese<BR/>Inclusion criteria: people undergoing transurethral resection of the prostate, spinal anaesthesia<BR/>Exclusion criteria: ASA III, IV; hypertension; diabetes; endocrine disease<BR/>Number eligible: 14<BR/>Number enrolled: 14 (HS 7; ISS 7)<BR/>Number completed study: 14</P>
<P>Age: not reported</P>
<P>Gender: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: HS (213 meq Na / L)<BR/>Dose: 8 ml/kg/hour for 1st hour; 4 ml/kg/hour for 2nd hour; 2 ml/kg/hour for 3rd hour</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: RL<BR/>Dose: 8 ml/kg/hour for 1st hour; 4 ml/kg/hour for 2nd hour; 2 ml/kg/hour for 3rd hour</P>
<P>
<I>Co-interventions</I>: spinal anaesthesia<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Peak serum sodium<BR/>Haemodynamic parameters<BR/>Plasma aldosterone, ADH</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:32 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES>
<P>Translation provided by Dr Hideaki Tanaka and Dr Yoshihisa Morita</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004">
<CHAR_METHODS MODIFIED="2016-05-03 20:15:40 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article</P>
<P>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: December 2001 - January 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Denmark<BR/>Language: English<BR/>Inclusion criteria: adult women undergoing elective hysterectomy<BR/>Exclusion criteria: ASA III or IV; cardiac failure; renal failure; anaemia; diabetes mellitus; certain medications that effect the immune response<BR/>Number eligible: 192 screened<BR/>Number enrolled: 62 (HS 21; NS-4 21; NS-32 20)<BR/>Number completed study: 58 (1 HS participant withdrew consent; 1 HS had anaphylactoid reaction to anaesthetic agent; 1 NS-4 participant transferred to another hospital; 1 NS-32 participant returned to the operating room for haemorrhage)</P>
<P>Study data used: HS (19) and NS-4 (20).</P>
<P>Age: 32 - 53</P>
<P>Gender: women only</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 7.5% NaCl<BR/>Dose: 4 ml/kg<BR/>Duration: over 10 minutes before hysterectomy<BR/>Postoperative maintenance: not specified</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: NS<BR/>Dose - 2 groups: 'NS-4' received 4 ml/kg; 'NS-32' received 32 ml/kg<BR/>Duration: over 10 minutes before hysterectomy<BR/>Postoperative maintenance: not specified</P>
<P>Co-interventions: anaesthesia, analgesia<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery plus 48 hours after closure of the wound</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:40:24 +0000" MODIFIED_BY="[Empty name]">
<P>Peak serum sodium<BR/>Urine output<BR/>Immunological parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:37 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lavu-2014">
<CHAR_METHODS MODIFIED="2016-05-03 20:21:23 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article</P>
<P>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: May 2011 - November 2013</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>English<BR/>Inclusion criteria: People undergoing pancreaticoduodenectomy<BR/>Exclusion criteria: metabolic acidosis, active sepsis or bacteraemia, congestive heart failure, chronic renal insufficiency, pregnancy, sickle-cell anaemia, hyponatraemia (serum sodium &lt;120 mmol/L), hypernatraemia<BR/>(serum sodium &gt;150 mmol/L), morbid obesity (body mass index &gt;50), and extension of surgery to total pancreatectomy,unresectable disease or distant metastasis.<BR/>Number eligible: 259<BR/>Number enrolled: 264 (LR 132, HS 132; 4 from LR became ineligible (2 unresectable, 2 total pancreatectomies), 1 from HS became ineligible (1 total pancreatectomy))<BR/>Number completed study: 259 (HS 131, LR 128)</P>
<P>Age: 25 - 91</P>
<P>Gender: men 54%, women 46%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Lactated Ringer's group</I>
<BR/>IV solution: lactated Ringer's<BR/>Dose: 15 mL/kg/hr during the operation, with blood loss replaced in a 3:1 ratio. Then at a rate of 2 mL/kg/hr.<BR/>Duration: Until 8 AM POD 1.</P>
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 1 mL/kg/hr of HYS (3.0% NaCl) and 9 mL/kg/hr of LR<BR/>Dose: a 1 mL/kg bolus of HYS for more than 15 minutes on randomization, and then they were continued on 1 mL/kg/hr of HYS and 9 mL/kg/hr of LR for a total infused volume rate of 10 mL/kg/hr during the operation. Blood loss was replaced at a 1:1 ratio with LR. Maintained on HYS alone at a rate of 1 mL/kg/hr<BR/>Duration: until 8 AM on the morning of POD 1.</P>
<P>
<I>Co-interventions</I>: None<BR/>Co-interventions applied differentially between groups: NA</P>
<P>Study period: 90 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>90-day mortality</P>
<P>Postoperative complication rate<BR/>
</P>
<P>Total number of complications<BR/>Intraoperative estimated blood loss</P>
<P>Number of required fluid boluses</P>
<P>Postoperative hospital LOS</P>
<P>Readmission rate</P>
<P>Peri-operative mortality</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:41 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary author was contacted for additional data. Author provided mean and standard deviation values for published results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leverve-2008">
<CHAR_METHODS MODIFIED="2016-05-03 20:27:07 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: no (22 had to be excluded due to major protocol violation or incomplete data collection)<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Indonesia<BR/>Language: English<BR/>Inclusion criteria: men or women, 18&#8211;75 years, in postoperative period in ICU post-CABG surgery, either on-pump or off-pump, and requiring postoperative fluid resuscitation<BR/>Exclusion criteria: people having undergone combined operations, those needing an intra-aortic balloon pump, severe arrhythmia (ventricular tachycardia, atrial flutter with rapid response, heart block), severe haemodynamic imbalance, severe bleeding and/or re-operation, liver dysfunction (SGOT and SGPT more than twice normal value) and renal failure (creatinine more than 20 mg L-1)<BR/>Number eligible: 230<BR/>Number enrolled: 230<BR/>Number completed study: 208 (HL 109; RL 99)</P>
<P>Age: 54 - 57</P>
<P>Gender: men 198, women 10</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: HL (504.15 mmol L-1)<BR/>Dose: titrated to maintain CVP between 8 and 12 mm Hg<BR/>Duration: during operation<BR/>Postoperative maintenance:</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: RL (Na = 130.5 mmol L-1)<BR/>Dose: titrated to maintain PAOP between 11 and 15 mm Hg<BR/>Duration: during operation<BR/>Postoperative maintenance:</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: 12 hours post-surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Fluid volume transfused<BR/>Fluid balance<BR/>Peak serum sodium<BR/>Urine output</P>
<P>MAP</P>
<P>Cardiac index<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:45 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>12-hour data only available; urine output, MAP and CI determined from graphs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shackford-1983">
<CHAR_METHODS MODIFIED="2016-05-03 20:28:52 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Language: English<BR/>Inclusion criteria: people undergoing aortic surgery<BR/>Exclusion criteria: not specified<BR/>Number eligible: 61<BR/>Number enrolled: 58 (HS 30; ISS 28)<BR/>Number completed study: 58</P>
<P>Age: not reported</P>
<P>Gender: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: HSL (250 meq Na/L)<BR/>Dose: titrated to maintain CVP within 3 torr of preoperative value<BR/>Duration: during operation<BR/>Postoperative maintenance: D5/0.25 NaCl</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: RL<BR/>Dose: titrated to maintain CVP within 3 torr of preoperative value<BR/>Duration: during operation<BR/>Postoperative maintenance: D5/0.25 NaCl</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of hospital stay for surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:42:56 +0000" MODIFIED_BY="[Empty name]">
<P>Fluid volume transfused<BR/>Blood transfused<BR/>Fluid loss<BR/>Fluid balance<BR/>Peak serum sodium<BR/>Urine output<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shackford-1987">
<CHAR_METHODS MODIFIED="2016-05-03 20:29:51 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Blinding of care givers: no<BR/>Additional features to blind fluid administered: no<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Language: English<BR/>Inclusion criteria: People undergoing aortic aneurysm repair or aorto-bifemoral bypass<BR/>Exclusion criteria: not specified<BR/>Number eligible: 52<BR/>Number enrolled: 52 (HS 26; ISS 26)<BR/>Number completed study: 52</P>
<P>Age: not reported</P>
<P>Gender: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: HSL (250 meq Na/L)<BR/>Dose: titrated to maintain CVP within 3 torr of preoperative value<BR/>Duration: during operation<BR/>Postoperative maintenance: D5/0.25 NaCl</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: RL<BR/>Dose: titrated to maintain CVP within 3 torr of preoperative value<BR/>Duration: during operation<BR/>Postoperative maintenance: D5/0.25 NaCl</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery plus first4 postoperative days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluid volume transfused<BR/>Blood transfused<BR/>Fluid loss<BR/>Fluid balance<BR/>Weight change<BR/>Peak serum sodium<BR/>Urine output</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:50 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shao-2013">
<CHAR_METHODS MODIFIED="2016-05-03 20:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Blinding of care givers: not defined<BR/>Additional features to blind fluid administered: not defined<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: complete<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Language: English<BR/>Inclusion criteria: ASA I - II patients scheduled for elective neurosurgical procedures<BR/>Exclusion criteria: The exclusion criteria were age, less than18 years or greater than 80 years; clinical signs of significantly increased ICP such as severe headache, blurred vision and/or papilledema; history of cardiac, pulmonary and renal dysfunction; fluid or electrolyte disturbances; preoperative coagulation disorders; and preoperative treatment with diuretics and/or osmotic agents<BR/>Number eligible: 40<BR/>Number enrolled: 40<BR/>Number completed study: 40 (HS-HES 20; HES 20)</P>
<P>Age: 27 - 53</P>
<P>Gender: men 21, women 19</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 250 mL of a 7.2% HS - 6% HES<BR/>Dose: 250 mL<BR/>Duration: intraoperative infusion</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: 6% HES<BR/>Dose: 1000 mL</P>
<P>Duration: intraoperative infusion</P>
<P>
<I>Co-interventions:</I> Ringer's lactated solution to maintain CVP at 8 - 12 mm Hg and the MAP at greater than 65 mm Hg. 250 mL 20% mannitol<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Volume of Ringer&#8217;s solution</P>
<P>Volume of PRBC infused</P>
<P>Intraoperative total urine output<BR/>Blood loss</P>
<P>Operative duration</P>
<P>Intraoperative bleeding severity score</P>
<P>Dural tension score</P>
<P>Fluid balance</P>
<P>Haemodynamic parameters</P>
<P>Laboratory parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:55 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Author was contacted for further information but did not respond</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veroli-1992">
<CHAR_METHODS MODIFIED="2016-05-03 20:32:31 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France<BR/>Language: English<BR/>Inclusion criteria: consenting people having lower limb surgery with lumbar extradural anaesthesia<BR/>Exclusion criteria: not specified<BR/>Number eligible: not specified<BR/>Number enrolled: 30 (HS 10; RL 10; NS 10)<BR/>Number completed study: 30</P>
<P>Age: 26 - 65</P>
<P>Gender: men 15, women 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: HS 5%<BR/>Dose: 2.3 ml.kg<BR/>Duration: preoperative bolus</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: RL or NS<BR/>Dose: 15 ml RL/kg or 13 ml NS/kg<BR/>Duration: preoperative bolus</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:43:49 +0000" MODIFIED_BY="[Empty name]">
<P>Fluid volume transfused<BR/>Fluid loss<BR/>Fluid balance<BR/>Peak serum sodium<BR/>Urine output<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:39:58 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1997">
<CHAR_METHODS MODIFIED="2016-05-03 20:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Blinding of care givers: unclear<BR/>Additional features to blind fluid administered: no<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Language: English<BR/>Single centre<BR/>Inclusion criteria: consenting fit people having herniorrhaphy under spinal anaesthesia<BR/>Exclusion criteria: ASA II, III or IV<BR/>Number eligible: not specified<BR/>Number enrolled: 60 (HS 30; ISS 30)<BR/>Number completed study: 60</P>
<P>Age: not reported</P>
<P>Gender: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 3% HS<BR/>Dose: 7 ml/kg<BR/>Duration: bolus before surgery</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: 0.9% NaCl<BR/>Dose: 7 ml/kg<BR/>Duration: bolus before surgery</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hypotension<BR/>Peak serum sodium<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:40:01 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Younes-1988">
<CHAR_METHODS MODIFIED="2016-05-03 20:39:22 +0100" MODIFIED_BY="[Empty name]">
<P>Publication type: full article<BR/>Study type: RCT<BR/>Baseline comparison: yes<BR/>Baseline similarity: yes<BR/>Blinding of care givers: unclear<BR/>Additional features to blind fluid administered: no<BR/>Control of co-interventions: yes<BR/>Completeness of follow-up: yes<BR/>Intention-to-treat analysis: yes</P>
<P>Study dates: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Brazil<BR/>Language: Portuguese<BR/>Single centre<BR/>Inclusion criteria: Adults undergoing aortic aneurysm repair or aortobifemoral bypass<BR/>Exclusion criteria: not given<BR/>Number eligible: not given<BR/>Number enrolled: 31 (HS 18; ISS 13)<BR/>Number completed study: 31</P>
<P>Age: not reported</P>
<P>Gender: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hypertonic saline group</I>
<BR/>IV solution: 7.5% HS<BR/>Dose: 4 ml/kg<BR/>Duration: 15 minute bolus<BR/>Postoperative maintenance: ISS to maintain CVP and MAP within 10% of starting value</P>
<P>
<I>Isotonic salt solution group</I>
<BR/>IV solution: 0.9% NaCl<BR/>Dose: 4 ml/kg<BR/>Duration: 15-minute bolus<BR/>Postoperative maintenance: ISS to maintain CVP and MAP within 10% of starting value</P>
<P>
<I>Co-interventions:</I>
<BR/>Co-interventions applied differentially between groups: no</P>
<P>Study period: duration of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-13 16:44:14 +0000" MODIFIED_BY="[Empty name]">
<P>LOS hospital<BR/>LOS ICU<BR/>Fluid volume transfused<BR/>Blood transfused<BR/>Fluid loss<BR/>Fluid balance<BR/>Peak serum sodium<BR/>Urine output<BR/>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-06-18 16:40:04 +0100" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES>
<P>Translation provided by Ms. Christiane Baldwin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ASA: American Society Anesthesiology classification<BR/>CABG: coronary artery bypass graft<BR/>CVP: central venous pressure<BR/>D5/0.45NS: dextrose 5% in 0.45% saline<BR/>HS: hypertonic saline<BR/>HSL: hypertonic saline lactate<BR/>ICU: intensive care unit<BR/>IS: isotonic saline<BR/>ISS: isotonic salt solution<BR/>IV: intravenous<BR/>LOS: length of stay<BR/>MAP: mean arterial pressure<BR/>NS: normal saline (154 meq Na per litre)<BR/>PAOP: pulmonary artery occlusion pressure<BR/>POD: postoperative day<BR/>PRBC: packed red blood cells<BR/>RCT: randomized control trial<BR/>RL: Ringer's Lactate (130 meq Na per litre)<BR/>SGOT: serum glutamic oxaloacetic transaminase<BR/>SGPT: serum glutamate pyruvate transaminase <BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Auler-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Consecutive participants enrolled. Study not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Auler-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>Study of intraoperative respiratory physiology but did not measure outcomes such as weight gain, fluid balance or peak serum sodium or determine postoperative survival</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Li-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>No comparison to IS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-04 18:13:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-04 18:13:25 +0100" MODIFIED_BY="[Empty name]">
<P>No comparison to IS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Shao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>Dr Shao kindly responded to an email query on November 30, 2006: "I performed this project non-randomly, allocated distinct groups on the basis of different diseases and operation methods, but single-blinded (for patients)"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Yang-Z-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>No outcomes of interest reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yousefshahi-F-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>No measured outcomes were relevant to this review. Authors were contacted for additional information but did not respond</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-06-18 18:57:11 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-03 19:26:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baraka-1994">
<DESCRIPTION>
<P>Quote: "Patients were allocated randomly to two groups."</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Bruegger-2005">
<DESCRIPTION>
<P>Quote: "The patients were randomly assigned"</P>
<P>Sequence generation is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Cross-1989">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned", "the code was not broken"</P>
<P>The sequence generation is not described. Randomization was probably performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Durasnel-1999">
<DESCRIPTION>
<P>Quote: "prospective, randomized, double-blinded study"</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Ishikawa-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Jarvela-2000">
<DESCRIPTION>
<P>Quote: "randomized, double-blinded study"</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jarvela-2001">
<DESCRIPTION>
<P>Quote: "randomly allocated according to a list of random digits"</P>
<P>Random-digit table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Kato-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Kimura-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004">
<DESCRIPTION>
<P>Quote: "prospective, randomized, double-blind study"</P>
<P>Randomly assorted envelopes used for study arm selection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lavu-2014">
<DESCRIPTION>
<P>Quote: "computer-generated random permuted blocks with a 1:1 allocation (blocks of 6) (investigators were blinded to block size during study accrual)"</P>
<P>Computer randomized allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Leverve-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Shackford-1983">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Shackford-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Shao-2013">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Veroli-1992">
<DESCRIPTION>
<P>Quote: "prospective double-blinded study"</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Younes-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-03 19:27:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baraka-1994">
<DESCRIPTION>
<P>Quote: "Patients were allocated randomly to two groups."</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Bruegger-2005">
<DESCRIPTION>
<P>Quote: "The patients were randomly assigned"</P>
<P>Allocation concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Cross-1989">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned", "the code was not broken"</P>
<P>A code was used to conceal allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Durasnel-1999">
<DESCRIPTION>
<P>Quote: "prospective, randomized, double-blinded study"</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Ishikawa-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jarvela-2000">
<DESCRIPTION>
<P>Quote: "randomized, double-blinded study"</P>
<P>Assessed following communication with the study author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jarvela-2001">
<DESCRIPTION>
<P>Assessed following communication with the study author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Kato-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Kimura-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004">
<DESCRIPTION>
<P>Quote: "The study-group assignments were placed in sealed, opaque, randomly assorted envelopes, which were opened by a hospital staff member who was not one of the study investigators"</P>
<P>Concealment is adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lavu-2014">
<DESCRIPTION>
<P>Quote: "administrator would open in sequence, a numbered, opaque envelope containing the assignment"</P>
<P>Assignment in opaque numbered envelope and provided at the time of surgery by a third-party administrator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Leverve-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Shackford-1983">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Shackford-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Shao-2013">
<DESCRIPTION>
<P>Operative team made aware of treatment at time of operation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Veroli-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Younes-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Baraka-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Bruegger-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Cross-1989">
<DESCRIPTION>
<P>Quote: "Physicians and nurses directly involved in patient care did not know the identity of the solution"</P>
<P>Likely as stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Durasnel-1999">
<DESCRIPTION>
<P>Quote: "prospective, randomized, double-blinded study"</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ishikawa-1996">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Jarvela-2000">
<DESCRIPTION>
<P>Quote: "randomized, double-blinded study"</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-08 20:04:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jarvela-2001">
<DESCRIPTION>
<P>Quote from correspondence: "Patients, investigators and outcome assessors were not blinded".</P>
<P>Not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kato-1996">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Kimura-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004">
<DESCRIPTION>
<P>Quote: "The study fluid was subsequently hidden in an opaque box and connected to the i.v. line in such a way that neither the patient nor the investigator was aware of the nature of the fluid"</P>
<P>Participants and personnel adequately blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lavu-2014">
<DESCRIPTION>
<P>Quote: "surgeons and anaesthesia staff blinded to the process until the assignment was revealed"</P>
<P>Participants and personnel were blinded to allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Leverve-2008">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned immediately after CABG surgery"</P>
<P>Participants were blinded. It is unknown if personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shackford-1983">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shackford-1987">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Shao-2013">
<DESCRIPTION>
<P>Quote: "after the induction of anaesthesia, the patients were randomly assigned"</P>
<P>Participants are blinded to treatment. Personnel are not blinded to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veroli-1992">
<DESCRIPTION>
<P>Quote: "patients were transferred to the operating theatre and were cared for by a physician (P.V.) blinded to the fluid preload administered previously"</P>
<P>Participants and personnel blinded to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Younes-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Baraka-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Bruegger-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cross-1989">
<DESCRIPTION>
<P>Quote: "Physicians and nurses directly involved in patient care did not know the identity of the solution", "the code was not broken until after the end of the study"</P>
<P>Likely as stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Durasnel-1999">
<DESCRIPTION>
<P>Quote: "prospective, randomized, double-blinded study"</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ishikawa-1996">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Jarvela-2000">
<DESCRIPTION>
<P>Quote: "randomized, double-blinded study"</P>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Jarvela-2001">
<DESCRIPTION>
<P>Quote from correspondence: "Patients, investigators and outcome assessors were not blinded"</P>
<P>Not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kato-1996">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Kimura-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004">
<DESCRIPTION>
<P>Outcome assessment is adequately blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lavu-2014">
<DESCRIPTION>
<P>Outcome assessors were likely unaware of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Leverve-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shackford-1983">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shackford-1987">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shao-2013">
<DESCRIPTION>
<P>Not described</P>
<P>Outcome assessors are probably not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Veroli-1992">
<DESCRIPTION>
<P>Outcome assessors were blinded to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Younes-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-06-09 18:55:25 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baraka-1994">
<DESCRIPTION>
<P>Outcomes are reported for all enrolled participants</P>
<P>We note a discrepancy between the number of participants enrolled to hypertonic saline described in the text (n = 17) and the number reported in table 1 (n = 19). It is our assessment that, given the age of this publication, the error is typographical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bruegger-2005">
<DESCRIPTION>
<P>Outcomes are reported for all enrolled patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cross-1989">
<DESCRIPTION>
<P>Outcomes are reported for all participants enrolled in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Durasnel-1999">
<DESCRIPTION>
<P>50 participants were enrolled but 1 from each group was removed without explanation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ishikawa-1996">
<DESCRIPTION>
<P>Reasons for enrolled participants not completing the study not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jarvela-2000">
<DESCRIPTION>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jarvela-2001">
<DESCRIPTION>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Kato-1996">
<DESCRIPTION>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Kimura-1994">
<DESCRIPTION>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004">
<DESCRIPTION>
<P>Quote: "Four patients were excluded from the final analysis. One patient (HS group)<BR/>did not wish to finish the study..."</P>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lavu-2014">
<DESCRIPTION>
<P>Quote: "Five patients were excluded from the analysis after accrual due to unresectability..."</P>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Leverve-2008">
<DESCRIPTION>
<P>Quote: "From the 230 patients enrolled in this study, 22 had to be excluded due to major protocol violation or incomplete data collection, but they were included in the safety evaluation"</P>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Shackford-1983">
<DESCRIPTION>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Shackford-1987">
<DESCRIPTION>
<P>Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-16 02:51:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shao-2013">
<DESCRIPTION>
<P>No incomplete data identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veroli-1992">
<DESCRIPTION>
<P>Outcomes reported for all participants enrolled. Reasons for missing outcomes are reported and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-1997">
<DESCRIPTION>
<P>No missing outcomes detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Younes-1988">
<DESCRIPTION>
<P>No missing outcomes detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baraka-1994">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bruegger-2005">
<DESCRIPTION>
<P>Quote: "We studied 28 patients (three female)"</P>
<P>We note the disproportionately low number of women enrolled in the study but there is insufficient evidence to prove bias</P>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cross-1989">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Durasnel-1999">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ishikawa-1996">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jarvela-2000">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jarvela-2001">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kato-1996">
<DESCRIPTION>
<P>Clinically relevant outcomes are defined and reported.There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kimura-1994">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004">
<DESCRIPTION>
<P>Clinically relevant outcomes are defined and reported.There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lavu-2014">
<DESCRIPTION>
<P>Clinically relevant outcomes are identified and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leverve-2008">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shackford-1983">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shackford-1987">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shao-2013">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veroli-1992">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1997">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Younes-1988">
<DESCRIPTION>
<P>There is no explicit reference to participant survival. Other clinically relevant outcomes that fit the trial design are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Baraka-1994">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Bruegger-2005">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Cross-1989">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Durasnel-1999">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Ishikawa-1996">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jarvela-2000">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jarvela-2001">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Kato-1996">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Kimura-1994">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lavu-2014">
<DESCRIPTION>
<P>No other source of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Leverve-2008">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Shackford-1983">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Shackford-1987">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-16 17:31:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shao-2013">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Veroli-1992">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Wang-1997">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Younes-1988">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-05-05 15:31:25 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-06-22 18:05:12 +0100" MODIFIED_BY="[Empty name]">Hypertonic salt compared to isotonic salt solution for peri-operative resuscitation</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Hypertonic salt compared to isotonic salt solution for peri-operative resuscitation</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>any people undergoing surgery with fluid resuscitation<BR/>
<B>Settings: </B>people undergoing non-emergency surgery that requires fluid resuscitation in a hospital operating room in;Brazil, China,Denmark, Finland, France, Germany, Indonesia, Japan, Lebanon, Niger, USA.<BR/>
<B>Intervention: </B>hypertonic salt solution<BR/>
<B>Comparison: </B>isotonic salt solution</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>isotonic salt solution for </B>peri-operative<B> resuscitation</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hypertonic salt</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Mortality</P>
<P>Follow-up: range 1 to 90 days</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1087<BR/>(18 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Any recorded death during the study period. The risk of bias impacting this outcome is considered to be low. Only one study had incidents of mortality</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serious adverse events</P>
<P>Follow-up: range 1 to 90 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1087</P>
<P>(18 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Other adverse outcomes are collected as defined by each trial or if any of the following occurred: any organ failure, including renal, pulmonary, cardiac, or cerebral</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluid balance (L)</P>
<P>Follow-up: range 1 to 3 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean fluid balance (L) was 4.375</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean fluid balance (L) in the intervention group was 1.92 lower (2.61 lower to 1.22 lower)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>737<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The change in participant fluid volume at the end of fluid administration. A neutral fluid balance would be optimal</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total volume of crystalloid administered (L)</P>
<P>Follow-up: range 1 to 3 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean total volume of crystalloid administered (L) was 2.43</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean total volume of crystalloid administered (L) in the intervention group was 0.91 lower (1.24 lower to 0.59 lower)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>871<BR/>(13 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The total volume of fluid delivered intravenously over the study period. There are no defined minimum or maximum values for fluid delivery during surgery. Less resuscitating fluid is preferred</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Peak serum sodium</P>
<P>Follow-up: range 1 to 3 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean peak serum sodium (meq/L) was 139.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean peak serum sodium (meq/L) in the intervention group was 7.73 higher (5.84 higher to 9.62 higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>780<BR/>(16 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The measurement of this variable is a common practice in operative procedures. Measured as the peak amount of sodium in the blood, given in milliequivelants per litre, over the study period. The normal acceptable range is 136 to 146 meq/L</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Final serum sodium</P>
<P>Follow-up: range 1 to 3 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean final serum sodium (meq/L) was 138.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean final serum sodium (meq/L) in the intervention group was 3.45 higher (2.46 higher to 4.44 higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>640<BR/>(12 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The measurement of this variable is common practice in operative procedures. Measured as the final amount of sodium in the blood, given in milliequivelants per litre, at the end of the study. The normal acceptable range is 136 to 146 meq/L</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Maximum intraoperative cardiac index</P>
<P>Follow-up: 1 to 3 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean maximum intraoperative cardiac index (L/min/M²) was 2.9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean maximum intraoperative cardiac index (L/min/m²) in the intervention group was 0.34 higher (0.19 higher to 0.49 higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>418<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The measurement of this variable is common practice in operative procedures. Measured by the volume of blood passing through one square meter each minute (L/min/M²). The normal range is 2.5 - 4.0 L/min/M²</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI: </B>Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded (2 levels) for indirectness: The majority of studies have an insufficient follow-up period to adequately measure the outcome.<BR/>
<SUP>2</SUP>Downgraded (1 level) for publication bias: Only one study contributes explicit evidence for the outcome.<BR/>
<SUP>3</SUP>Downgraded (1 level) for risk of bias: The majority of the studies have not confirmed blinding of outcome assessors; bias could seriously impact this result.<BR/>
<SUP>4</SUP>Downgraded (1 level) for imprecision: The volume of crystalloid solution delivered between studies has a large range.<BR/>
<SUP>5</SUP>Downgraded (1 level) for imprecision: The duration of sample collection varies widely from study to study.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-01-16 16:42:07 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell">
<COMPARISON ID="CMP-001" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<NAME>Hypertonic salt versus isotonic salt solution for peri-operative resuscitation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-05-04 18:29:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="545" TOTAL_2="542" WEIGHT="0.0" Z="0.0">
<NAME>Mortality during the study period</NAME>
<GROUP_LABEL_1>Hypertonic Saline</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic Solution</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [Hypertonic]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [Isotonic]</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-05 21:03:15 +0100" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="0.0" STUDY_ID="STD-Baraka-1994" TOTAL_1="17" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-08 19:48:19 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.0" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-08 19:49:11 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.0" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-08 19:50:19 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.0" STUDY_ID="STD-Durasnel-1999" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-08 19:51:07 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.0" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-08 19:51:41 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.0" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-08 20:02:23 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.0" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-08 20:06:03 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.0" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-08 20:07:06 +0100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.0" STUDY_ID="STD-Kimura-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-09 18:12:22 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.0" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-05-04 18:29:53 +0100" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.0" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-09 18:30:48 +0100" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.0" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-09 18:31:59 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.0" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-09 18:32:54 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.0" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-09 18:34:13 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.0" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-09 18:40:15 +0100" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.0" STUDY_ID="STD-Veroli-1992" TOTAL_1="10" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-09 18:45:53 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-1997" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-09 18:48:25 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.0" STUDY_ID="STD-Younes-1988" TOTAL_1="13" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-11 15:15:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="545" TOTAL_2="542" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events during the study period</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [Hypertonic]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [Isotonic]</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="0.0" STUDY_ID="STD-Baraka-1994" TOTAL_1="17" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.0" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.0" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.0" STUDY_ID="STD-Durasnel-1999" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.0" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.0" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.0" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.0" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.0" STUDY_ID="STD-Kimura-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.0" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:13:01 +0100" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.0" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.0" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.0" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.0" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.0" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.0" STUDY_ID="STD-Veroli-1992" TOTAL_1="10" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-1997" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-11 15:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.0" STUDY_ID="STD-Younes-1988" TOTAL_1="13" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="78.26019172775793" CI_END="-1.2218776155392699" CI_START="-2.6131089252801574" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9174932704097136" ESTIMABLE="YES" I2="91.05547808475764" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="3.0753177782116836E-14" P_Q="1.0" P_Z="6.563727781999716E-8" Q="0.0" RANDOM="YES" SCALE="7.72" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.738328191298456" TOTALS="YES" TOTAL_1="377" TOTAL_2="360" UNITS="" WEIGHT="100.0" Z="5.4027216384325305">
<NAME>Fluid balance (L) measured at the end of the recovery period</NAME>
<GROUP_LABEL_1>Hypertonic salt solution</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic salt solution</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyperonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5143531202191245" CI_START="-2.9056468797808748" EFFECT_SIZE="-1.7099999999999995" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="5.31" MODIFIED="2015-06-02 19:07:58 +0100" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="2.0" SD_2="1.1" SE="0.6100351277941763" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="11.343191710575008"/>
<CONT_DATA CI_END="-1.2970760864478588" CI_START="-2.682923913552141" EFFECT_SIZE="-1.99" ESTIMABLE="YES" MEAN_1="-1.72" MEAN_2="0.27" MODIFIED="2015-06-02 19:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="0.73" SD_2="0.83" SE="0.353539105319198" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="14.59055026555251"/>
<CONT_DATA CI_END="-0.42974835498725894" CI_START="-1.7702516450127408" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.9" MODIFIED="2015-06-02 19:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="1.5" SD_2="1.4" SE="0.3419714088113865" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="14.727801948874179"/>
<CONT_DATA CI_END="1.137748827459163" CI_START="-2.1977488274591632" EFFECT_SIZE="-0.5300000000000002" ESTIMABLE="YES" MEAN_1="6.47" MEAN_2="7.0" MODIFIED="2015-06-02 19:08:43 +0100" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="7.9" SD_2="5.63" SE="0.8509078945399778" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="8.613596426556589"/>
<CONT_DATA CI_END="-0.8029547216714215" CI_START="-0.8570452783285787" EFFECT_SIZE="-0.8300000000000001" ESTIMABLE="YES" MEAN_1="-0.79" MEAN_2="0.04" MODIFIED="2015-06-02 19:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="205" SD_1="0.07" SD_2="0.12" SE="0.013798864949513509" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="17.056152671015504"/>
<CONT_DATA CI_END="-4.2836866426479" CI_START="-6.916313357352101" EFFECT_SIZE="-5.6000000000000005" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="9.8" MODIFIED="2015-06-02 19:07:58 +0100" MODIFIED_BY="[Empty name]" ORDER="234" SD_1="1.6" SD_2="3.2" SE="0.6716007884507128" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="10.590669393089367"/>
<CONT_DATA CI_END="-2.256627728175272" CI_START="-6.343372271824729" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="9.8" MODIFIED="2015-06-02 19:07:58 +0100" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="1.5" SD_2="5.1" SE="1.0425560305916783" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="6.901124360694989"/>
<CONT_DATA CI_END="-0.8063935541196074" CI_START="-1.593606445880392" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="2.24" MEAN_2="3.44" MODIFIED="2015-06-02 19:08:06 +0100" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="0.71" SD_2="0.55" SE="0.20082330542046162" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.176913223641858"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1147.7681563691617" CI_END="-0.5876685996795319" CI_START="-1.237811650437319" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9127401250584255" ESTIMABLE="YES" I2="98.95449268796926" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2016-04-26 14:32:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="3.729318727073689E-8" Q="0.0" RANDOM="YES" SCALE="12.09" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.26195269809443933" TOTALS="YES" TOTAL_1="447" TOTAL_2="424" UNITS="" WEIGHT="99.99999999999999" Z="5.503212778399976">
<NAME>Total volume of crystalloid administered (L)</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2887965612659614" CI_START="-1.3112034387340392" EFFECT_SIZE="-0.8000000000000003" ESTIMABLE="YES" MEAN_1="1.92" MEAN_2="2.72" MODIFIED="2015-06-05 18:35:21 +0100" MODIFIED_BY="[Empty name]" ORDER="277" SD_1="0.7" SD_2="0.68" SE="0.26082287366826445" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="8.336281802397908"/>
<CONT_DATA CI_END="-1.0298348458314603" CI_START="-2.170165154168539" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="4.17" MEAN_2="5.77" MODIFIED="2015-06-05 18:35:27 +0100" MODIFIED_BY="[Empty name]" ORDER="279" SD_1="0.41" SD_2="0.79" SE="0.2909059343263087" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="7.937056671116394"/>
<CONT_DATA CI_END="-0.07463859470030929" CI_START="-0.38536140529969065" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.62" MODIFIED="2015-06-05 18:35:13 +0100" MODIFIED_BY="[Empty name]" ORDER="271" SD_1="0.22" SD_2="0.32" SE="0.07926747967062743" STUDY_ID="STD-Durasnel-1999" TOTAL_1="24" TOTAL_2="24" WEIGHT="10.255210076046554"/>
<CONT_DATA CI_END="-0.7680195590720921" CI_START="-0.9919804409279079" EFFECT_SIZE="-0.88" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.98" MODIFIED="2015-06-05 18:35:13 +0100" MODIFIED_BY="[Empty name]" ORDER="273" SD_1="0.02" SD_2="0.15" SE="0.057133927873774915" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="10.371948329827655"/>
<CONT_DATA CI_END="-0.8286562340675815" CI_START="-0.9713437659324186" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="1.03" MODIFIED="2015-06-05 18:35:21 +0100" MODIFIED_BY="[Empty name]" ORDER="274" SD_1="0.03" SD_2="0.16" SE="0.03640054944640259" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.448347399596676"/>
<CONT_DATA CI_END="-0.7468924273917499" CI_START="-1.03310757260825" EFFECT_SIZE="-0.8899999999999999" ESTIMABLE="YES" MEAN_1="0.55" MEAN_2="1.44" MODIFIED="2015-06-05 18:35:21 +0100" MODIFIED_BY="[Empty name]" ORDER="276" SD_1="0.18" SD_2="0.23" SE="0.07301540933255117" STUDY_ID="STD-Jarvela-2001" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.291739821520778"/>
<CONT_DATA CI_END="-0.4979715176294116" CI_START="-1.1220284823705886" EFFECT_SIZE="-0.81" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="1.62" MODIFIED="2015-06-05 18:35:13 +0100" MODIFIED_BY="[Empty name]" ORDER="272" SD_1="0.35" SD_2="0.62" SE="0.15920113064925134" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.574796006032031"/>
<CONT_DATA CI_END="9.378247553764684" CI_START="-2.398247553764679" EFFECT_SIZE="3.490000000000002" ESTIMABLE="YES" MEAN_1="30.05" MEAN_2="26.56" MODIFIED="2016-04-26 14:32:02 +0100" MODIFIED_BY="[Empty name]" ORDER="254" SD_1="30.19" SD_2="16.27" SE="3.0042631396344146" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="0.29618327094581837"/>
<CONT_DATA CI_END="-1.0829547216714215" CI_START="-1.1370452783285787" EFFECT_SIZE="-1.11" ESTIMABLE="YES" MEAN_1="1.32" MEAN_2="2.43" MODIFIED="2016-04-26 14:31:55 +0100" MODIFIED_BY="[Empty name]" ORDER="201" SD_1="0.07" SD_2="0.12" SE="0.013798864949513509" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="10.493569280415352"/>
<CONT_DATA CI_END="-3.0600393259744694" CI_START="-9.13996067402553" EFFECT_SIZE="-6.1" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="12.5" MODIFIED="2016-04-26 14:32:01 +0100" MODIFIED_BY="[Empty name]" ORDER="278" SD_1="4.6" SD_2="6.9" SE="1.5510288444095668" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="1.0311787118958344"/>
<CONT_DATA CI_END="-0.7872655352249378" CI_START="-5.6127344647750625" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="9.5" MODIFIED="2016-04-26 14:32:03 +0100" MODIFIED_BY="[Empty name]" ORDER="280" SD_1="2.4" SD_2="5.8" SE="1.231009591914139" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="1.5477179438000086"/>
<CONT_DATA CI_END="-0.8216268756660776" CI_START="-1.6583731243339228" EFFECT_SIZE="-1.2400000000000002" ESTIMABLE="YES" MEAN_1="4.26" MEAN_2="5.5" MODIFIED="2015-06-05 18:35:13 +0100" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="0.67" SD_2="0.68" SE="0.21345959805077871" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.945231020206363"/>
<CONT_DATA CI_END="-0.055897686838329914" CI_START="-0.1641023131616703" EFFECT_SIZE="-0.1100000000000001" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.81" MODIFIED="2015-06-05 18:35:21 +0100" MODIFIED_BY="[Empty name]" ORDER="275" SD_1="0.05" SD_2="0.09" SE="0.027603728225835945" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="10.470739666198615"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="25.736325408245563" CI_END="0.30969435545609836" CI_START="-0.09046200737360323" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10961617404124756" ESTIMABLE="YES" I2="68.91553136238745" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2016-04-26 14:33:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0011651379936964412" P_Q="1.0" P_Z="0.28291278974502754" Q="0.0" RANDOM="YES" SCALE="9.9" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.04061003548149704" TOTALS="YES" TOTAL_1="397" TOTAL_2="380" UNITS="" WEIGHT="100.0" Z="1.0737990105900317">
<NAME>Diuresis during study period (L)</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.45390402009358743" CI_START="-1.0539040200935874" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.5" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="285" SD_1="0.55" SD_2="1.33" SE="0.384651976281343" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="5.526334621284709"/>
<CONT_DATA CI_END="1.0376132101302233" CI_START="0.3623867898697769" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="3.8" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="283" SD_1="0.5" SD_2="0.25" SE="0.1722548030439708" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="14.827252974647267"/>
<CONT_DATA CI_END="0.1904718040573017" CI_START="-0.15047180405730168" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="0.43" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="286" SD_1="0.28" SD_2="0.27" SE="0.08697700845625814" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="21.631231107054102"/>
<CONT_DATA CI_END="0.8487601172753829" CI_START="-0.02876011727538258" EFFECT_SIZE="0.41000000000000014" ESTIMABLE="YES" MEAN_1="3.35" MEAN_2="2.94" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="282" SD_1="1.04" SD_2="0.85" SE="0.22386131619573957" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="11.486334319450483"/>
<CONT_DATA CI_END="9.351656217605717" CI_START="-1.3116562176057176" EFFECT_SIZE="4.02" ESTIMABLE="YES" MEAN_1="23.58" MEAN_2="19.56" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="256" SD_1="27.86" SD_2="13.74" SE="2.7202827499184377" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="0.14005491095249303"/>
<CONT_DATA CI_END="-0.0049930544373319175" CI_START="-0.07500694556266815" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="1.61" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="209" SD_1="0.1" SD_2="0.15" SE="0.017861014711902073" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="25.460774004722172"/>
<CONT_DATA CI_END="0.6581566786760505" CI_START="-0.6581566786760505" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.8" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="284" SD_1="0.8" SD_2="1.6" SE="0.3358003942253564" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="6.794497901226264"/>
<CONT_DATA CI_END="1.8455853233048043" CI_START="-2.645585323304805" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.1" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="281" SD_1="0.7" SD_2="5.8" SE="1.1457278506226107" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.7700314208034729"/>
<CONT_DATA CI_END="0.2188869437303685" CI_START="-0.5388869437303687" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="1.59" MODIFIED="2015-06-05 18:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="229" SD_1="0.57" SD_2="0.65" SE="0.1933132173442882" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.363488739859037"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="482.1529378525524" CI_END="9.620079195038407" CI_START="5.843179982137752" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="7.7316295885880795" ESTIMABLE="YES" I2="96.88895393507129" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2016-04-26 14:44:26 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="-4.440892098500626E-16" P_Q="1.0" P_Z="1.0200553226717736E-15" Q="0.0" RANDOM="YES" SCALE="22.92" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="13.290349587536676" TOTALS="YES" TOTAL_1="395" TOTAL_2="385" UNITS="" WEIGHT="100.00000000000001" Z="8.024421453279304">
<NAME>Peak serum sodium (meq/L)</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.294642147882273" CI_START="-1.2946421478822732" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="138.5" MEAN_2="137.0" MODIFIED="2015-06-05 18:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="5.0" SD_2="3.0" SE="1.4258640311383544" STUDY_ID="STD-Baraka-1994" TOTAL_1="17" TOTAL_2="16" WEIGHT="6.058406471290779"/>
<CONT_DATA CI_END="17.656471900648683" CI_START="14.343528099351317" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="159.0" MEAN_2="143.0" MODIFIED="2015-06-05 18:40:03 +0100" MODIFIED_BY="[Empty name]" ORDER="330" SD_1="3.0" SD_2="1.0" SE="0.8451542547285166" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="6.628920558622435"/>
<CONT_DATA CI_END="7.45418540826402" CI_START="5.345814591735992" EFFECT_SIZE="6.400000000000006" ESTIMABLE="YES" MEAN_1="145.4" MEAN_2="139.0" MODIFIED="2015-06-05 18:40:09 +0100" MODIFIED_BY="[Empty name]" ORDER="334" SD_1="1.4" SD_2="1.0" SE="0.5378595813899101" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="6.836381351954321"/>
<CONT_DATA CI_END="8.60334995855648" CI_START="1.596650041443508" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="144.1" MEAN_2="139.0" MODIFIED="2015-06-05 18:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="325" SD_1="3.4" SD_2="3.5" SE="1.7874562931719478" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="5.631401043411657"/>
<CONT_DATA CI_END="6.239590064609123" CI_START="3.760409935390877" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="140.0" MODIFIED="2015-06-05 18:40:03 +0100" MODIFIED_BY="[Empty name]" ORDER="327" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.781098924805761"/>
<CONT_DATA CI_END="11.177791774053645" CI_START="8.822208225946355" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="140.0" MODIFIED="2015-06-05 18:40:03 +0100" MODIFIED_BY="[Empty name]" ORDER="326" SD_1="3.0" SD_2="2.0" SE="0.6009252125773316" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="6.800416227800119"/>
<CONT_DATA CI_END="7.296559190823639" CI_START="2.9034408091763497" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.9" MODIFIED="2015-06-05 18:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="324" SD_1="4.4" SD_2="2.4" SE="1.120714058089752" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.382055807857222"/>
<CONT_DATA CI_END="7.342605027587306" CI_START="2.657394972412694" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="137.0" MODIFIED="2015-06-05 18:40:09 +0100" MODIFIED_BY="[Empty name]" ORDER="332" SD_1="1.0" SD_2="3.0" SE="1.1952286093343936" STUDY_ID="STD-Kimura-1994" TOTAL_1="7" TOTAL_2="7" WEIGHT="6.3072296377338"/>
<CONT_DATA CI_END="10.883691816105333" CI_START="7.116308183894668" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="141.0" MODIFIED="2015-06-05 18:40:03 +0100" MODIFIED_BY="[Empty name]" ORDER="328" SD_1="3.0" SD_2="3.0" SE="0.9610849132757812" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="6.531264536665943"/>
<CONT_DATA CI_END="4.108845105227348" CI_START="3.8911548947726513" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="140.0" MEAN_2="136.0" MODIFIED="2015-06-05 18:40:03 +0100" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="0.4" SD_2="0.4" SE="0.055534237407373274" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="6.98356928607776"/>
<CONT_DATA CI_END="15.914137131395655" CI_START="8.085862868604345" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="151.0" MEAN_2="139.0" MODIFIED="2015-06-05 18:40:09 +0100" MODIFIED_BY="[Empty name]" ORDER="333" SD_1="7.6" SD_2="7.6" SE="1.9970454366865256" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="5.372885355236106"/>
<CONT_DATA CI_END="20.9138926645475" CI_START="13.0861073354525" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="157.0" MEAN_2="140.0" MODIFIED="2015-06-05 18:40:09 +0100" MODIFIED_BY="[Empty name]" ORDER="331" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="5.373040268752607"/>
<CONT_DATA CI_END="15.43672033930391" CI_START="11.163279660696112" EFFECT_SIZE="13.300000000000011" ESTIMABLE="YES" MEAN_1="152.5" MEAN_2="139.2" MODIFIED="2015-06-05 18:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="4.4" SD_2="2.1" SE="1.0901834707974618" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.411808777140167"/>
<CONT_DATA CI_END="5.06624387107141" CI_START="2.4337561289285903" EFFECT_SIZE="3.75" ESTIMABLE="YES" MEAN_1="143.7" MEAN_2="139.95" MODIFIED="2015-06-05 18:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="321" SD_1="1.7" SD_2="1.8" SE="0.6715653356152326" STUDY_ID="STD-Veroli-1992" TOTAL_1="10" TOTAL_2="20" WEIGHT="6.755931379000888"/>
<CONT_DATA CI_END="5.086540996510735" CI_START="0.9134590034892653" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="139.0" MODIFIED="2015-06-05 18:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="323" SD_1="5.0" SD_2="3.0" SE="1.0645812948447542" STUDY_ID="STD-Wang-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.436332202917026"/>
<CONT_DATA CI_END="14.967291566049926" CI_START="5.032708433950074" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="147.0" MEAN_2="137.0" MODIFIED="2015-06-05 18:40:03 +0100" MODIFIED_BY="[Empty name]" ORDER="329" SD_1="9.0" SD_2="5.0" SE="2.534379001467011" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="4.709258170733422"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="94.4547874060651" CI_END="4.4369375035101815" CI_START="2.4597054741159945" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="3.4483214888130878" ESTIMABLE="YES" I2="88.354216549437" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2015-06-22 16:32:19 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.7763568394002505E-15" P_Q="1.0" P_Z="8.12014632468207E-12" Q="0.0" RANDOM="YES" SCALE="18.073540871342168" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.904266477092112" TOTALS="YES" TOTAL_1="329" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="6.836411533612457">
<NAME>Final serum sodium (meq/L)</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [Hypertonic]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [Isotonic]</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.313033022740777" CI_START="-2.313033022740777" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="143.0" MEAN_2="140.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="402" SD_1="5.3" SD_2="4.0" SE="2.710780945287415" STUDY_ID="STD-Bruegger-2005" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.74976336792354"/>
<CONT_DATA CI_END="5.850452840520893" CI_START="3.149547159479107" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="144.0" MEAN_2="139.5" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="409" SD_1="2.0" SD_2="1.0" SE="0.6890192121758832" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="10.694540062318946"/>
<CONT_DATA CI_END="6.239590064609123" CI_START="3.760409935390877" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="140.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="404" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.041457344322213"/>
<CONT_DATA CI_END="2.6197950323045616" CI_START="1.3802049676954384" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="141.0" MEAN_2="139.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="410" SD_1="1.0" SD_2="1.0" SE="0.31622776601683794" STUDY_ID="STD-Jarvela-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.694150357529976"/>
<CONT_DATA CI_END="3.55072667538626" CI_START="0.44927332461374014" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="140.6" MEAN_2="138.6" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="406" SD_1="2.6" SD_2="2.4" SE="0.7912016177940993" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.055249218652936"/>
<CONT_DATA CI_END="2.0004004767154084" CI_START="-4.004767154086597E-4" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="138.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="411" SD_1="2.0" SD_2="1.0" SE="0.5104177855340404" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="11.752838470465049"/>
<CONT_DATA CI_END="4.108845105227348" CI_START="3.8911548947726513" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="140.0" MEAN_2="136.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="202" SD_1="0.4" SD_2="0.4" SE="0.055534237407373274" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="13.339163218843941"/>
<CONT_DATA CI_END="16.25248844742248" CI_START="3.74751155257752" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="146.0" MEAN_2="136.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="405" SD_1="7.6" SD_2="15.2" SE="3.1901037451408856" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="2.10598462420462"/>
<CONT_DATA CI_END="9.9138926645475" CI_START="2.0861073354524997" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="403" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="4.318166665128002"/>
<CONT_DATA CI_END="6.945358657929768" CI_START="3.4546413420702087" EFFECT_SIZE="5.199999999999989" ESTIMABLE="YES" MEAN_1="141.5" MEAN_2="136.3" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="2.5" SD_2="3.1" SE="0.8905054744357275" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.432683137853463"/>
<CONT_DATA CI_END="6.086540996510735" CI_START="1.9134590034892653" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="138.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="408" SD_1="5.0" SD_2="3.0" SE="1.0645812948447542" STUDY_ID="STD-Wang-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="8.375843298857962"/>
<CONT_DATA CI_END="2.5929500903498006" CI_START="-6.592950090349801" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="136.0" MEAN_2="138.0" MODIFIED="2015-06-05 18:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="407" SD_1="7.0" SD_2="6.0" SE="2.3433849430797733" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="3.44016023389936"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="66.36207707542962" CI_END="18.310865510612718" CI_START="12.2658877469868" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="15.28837662879976" ESTIMABLE="YES" I2="86.4380375108358" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2016-04-26 15:00:39 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="7.833178550242792E-11" P_Q="1.0" P_Z="3.622062947377434E-23" Q="0.0" RANDOM="YES" SCALE="34.16" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="17.657957509227252" TOTALS="YES" TOTAL_1="188" TOTAL_2="181" UNITS="" WEIGHT="100.0" Z="9.913904979050878">
<NAME>Maximum intraoperative serum osmolarity (mOsm/kg H2O)</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.448090820445316" CI_START="6.151909179554707" EFFECT_SIZE="14.300000000000011" ESTIMABLE="YES" MEAN_1="295.8" MEAN_2="281.5" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="366" SD_1="4.4" SD_2="10.2" SE="4.1572655848354385" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="6.806129615421173"/>
<CONT_DATA CI_END="12.555480384424818" CI_START="7.444519615575182" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="302.0" MEAN_2="292.0" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="371" SD_1="5.0" SD_2="3.0" SE="1.3038404810405297" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.284958951745672"/>
<CONT_DATA CI_END="26.16034696414883" CI_START="19.83965303585117" EFFECT_SIZE="23.0" ESTIMABLE="YES" MEAN_1="313.0" MEAN_2="290.0" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="368" SD_1="6.0" SD_2="4.0" SE="1.61245154965971" STUDY_ID="STD-Jarvela-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.739175249142138"/>
<CONT_DATA CI_END="16.98219526694472" CI_START="10.817804733055235" EFFECT_SIZE="13.899999999999977" ESTIMABLE="YES" MEAN_1="298.2" MEAN_2="284.3" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="372" SD_1="6.1" SD_2="3.5" SE="1.5725775020646835" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.813234083947076"/>
<CONT_DATA CI_END="14.972494374154119" CI_START="3.0275056258458815" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="296.0" MEAN_2="287.0" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="369" SD_1="4.0" SD_2="7.0" SE="3.04724700110022" STUDY_ID="STD-Kimura-1994" TOTAL_1="7" TOTAL_2="7" WEIGHT="8.826254832689173"/>
<CONT_DATA CI_END="17.92560596802116" CI_START="16.07439403197884" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="302.0" MEAN_2="285.0" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="365" SD_1="2.0" SD_2="0.5" SE="0.4722566206941663" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="13.299699598060075"/>
<CONT_DATA CI_END="23.12443757676568" CI_START="10.875562423234319" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="301.0" MEAN_2="284.0" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="370" SD_1="15.2" SD_2="7.6" SE="3.1247704677608685" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="8.672249654438259"/>
<CONT_DATA CI_END="31.188407668697728" CI_START="18.811592331302272" EFFECT_SIZE="25.0" ESTIMABLE="YES" MEAN_1="309.0" MEAN_2="284.0" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="373" SD_1="14.4" SD_2="7.2" SE="3.1574088695053053" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="8.607886947942676"/>
<CONT_DATA CI_END="20.205588392784342" CI_START="10.194411607215637" EFFECT_SIZE="15.199999999999989" ESTIMABLE="YES" MEAN_1="328.7" MEAN_2="313.5" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="245" SD_1="8.7" SD_2="7.4" SE="2.5539185578244266" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.834872367478772"/>
<CONT_DATA CI_END="13.688418132961722" CI_START="0.31158186703827795" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="327.0" MEAN_2="320.0" MODIFIED="2015-06-05 18:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="367" SD_1="11.0" SD_2="8.0" SE="3.4125209369759397" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="8.115538699134984"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5232604557285614" CI_END="2.0157499279263598" CI_START="-1.6933763691329917" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.16118677939668394" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2016-04-26 15:01:17 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7697956333048103" P_Q="1.0" P_Z="0.8647368209202476" Q="0.0" RANDOM="NO" SCALE="5.51" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="0.17034754661871154">
<NAME>Maximum intraoperative pulmonary artery wedge pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Isotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hypertonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1984736507772" CI_START="-1.7984736507772014" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="8.4" MODIFIED="2015-06-05 18:45:38 +0100" MODIFIED_BY="[Empty name]" ORDER="223" SD_1="3.5" SD_2="4.5" SE="1.2747548783981961" STUDY_ID="STD-Jarvela-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="55.09772971353109"/>
<CONT_DATA CI_END="2.9141371313956554" CI_START="-4.9141371313956554" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="11.0" MODIFIED="2015-06-05 18:45:38 +0100" MODIFIED_BY="[Empty name]" ORDER="224" SD_1="7.6" SD_2="7.6" SE="1.9970454366865256" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="22.449732859803326"/>
<CONT_DATA CI_END="3.9138926645475003" CI_START="-3.9138926645475003" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="11.0" MODIFIED="2015-06-05 18:45:38 +0100" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="22.452537426665586"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.388461338051378" CI_END="0.48966379635810797" CI_START="0.18733278065580283" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3384982885069554" ESTIMABLE="YES" I2="40.39431311056755" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2016-04-26 15:01:49 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.13608649008338203" P_Q="1.0" P_Z="1.1394568443269113E-5" Q="0.0" RANDOM="YES" SCALE="1.54" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.013002310268957143" TOTALS="YES" TOTAL_1="216" TOTAL_2="202" UNITS="" WEIGHT="99.99999999999999" Z="4.388861346302305">
<NAME>Maximum intraoperative cardiac index (L/min/M<SUP>2</SUP>)</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Isotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hypertonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7142814897619627" CI_START="0.18571851023803765" EFFECT_SIZE="0.4500000000000002" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="2.65" MODIFIED="2015-06-05 18:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="379" SD_1="0.3" SD_2="0.3" SE="0.13483997249264842" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="19.07548646380225"/>
<CONT_DATA CI_END="0.5294009638910836" CI_START="-0.18940096389108374" EFFECT_SIZE="0.16999999999999993" ESTIMABLE="YES" MEAN_1="3.19" MEAN_2="3.02" MODIFIED="2015-06-05 18:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="377" SD_1="0.5" SD_2="0.65" SE="0.1833712082089225" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.757596711390569"/>
<CONT_DATA CI_END="1.3899909961350139" CI_START="0.4100090038649868" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="2.3" MODIFIED="2015-06-05 18:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="380" SD_1="1.0" SD_2="0.5" SE="0.25" STUDY_ID="STD-Jarvela-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.878598920075822"/>
<CONT_DATA CI_END="0.32721127630683744" CI_START="0.2727887236931631" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="2.8" MODIFIED="2015-06-05 18:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="216" SD_1="0.1" SD_2="0.1" SE="0.013883559351843319" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="45.081436753496014"/>
<CONT_DATA CI_END="0.5120144348837534" CI_START="-0.3120144348837532" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="3.0" MODIFIED="2015-06-05 18:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="378" SD_1="0.8" SD_2="0.8" SE="0.21021530912489747" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="10.400829492197627"/>
<CONT_DATA CI_END="0.9523154440912504" CI_START="-0.3523154440912498" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.4" MODIFIED="2015-06-05 18:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="381" SD_1="1.2" SD_2="1.2" SE="0.3328201177351375" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="4.806051659037697"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-05-05 16:13:12 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Sensitivity analysis - hypertonic salt versus isotonic salt solution for peri-operative resuscitation</NAME>
<CONT_OUTCOME CHI2="2.5106175235860895" CI_END="-0.0920456463636552" CI_START="-2.8382655495271387" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.465155597945397" ESTIMABLE="YES" I2="60.169161945001065" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2016-05-05 16:11:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11308190467770973" P_Q="1.0" P_Z="0.036496785160805" Q="0.0" RANDOM="YES" SCALE="4.26" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.6412829280098212" TOTALS="YES" TOTAL_1="142" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="2.0913490579630944">
<NAME>Fluid balance (L) measured during the study period: studies at low risk of bias</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.2970760864478588" CI_START="-2.682923913552141" EFFECT_SIZE="-1.99" ESTIMABLE="YES" MEAN_1="-1.72" MEAN_2="0.27" MODIFIED="2016-04-26 13:59:48 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="0.73" SD_2="0.83" SE="0.353539105319198" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="64.0517532839313"/>
<CONT_DATA CI_END="1.137748827459163" CI_START="-2.1977488274591632" EFFECT_SIZE="-0.5300000000000002" ESTIMABLE="YES" MEAN_1="6.47" MEAN_2="7.0" MODIFIED="2016-04-26 13:59:48 +0100" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="7.9" SD_2="5.63" SE="0.8509078945399778" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="35.9482467160687"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.8960956965631155" CI_END="-0.2436590032311745" CI_START="-1.921271361303973" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0824651822675737" ESTIMABLE="YES" I2="74.67102632924615" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2016-05-05 16:12:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.019292368841126173" P_Q="1.0" P_Z="0.011429017287952058" Q="0.0" RANDOM="YES" SCALE="10.26968653262357" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.32099005805228825" TOTALS="YES" TOTAL_1="162" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="2.529300361378198">
<NAME>Total volume of crystalloid administered (L): studies at low risk of bias</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [Hypertonic]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [Isotonic]</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0298348458314603" CI_START="-2.170165154168539" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="4.17" MEAN_2="5.77" MODIFIED="2016-04-26 14:18:52 +0100" MODIFIED_BY="[Empty name]" ORDER="279" SD_1="0.41" SD_2="0.79" SE="0.2909059343263087" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="45.15560222895551"/>
<CONT_DATA CI_END="-0.4979715176294116" CI_START="-1.1220284823705886" EFFECT_SIZE="-0.81" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="1.62" MODIFIED="2016-04-26 14:18:52 +0100" MODIFIED_BY="[Empty name]" ORDER="272" SD_1="0.35" SD_2="0.62" SE="0.15920113064925134" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="52.88476811194741"/>
<CONT_DATA CI_END="9.378247553764684" CI_START="-2.398247553764679" EFFECT_SIZE="3.490000000000002" ESTIMABLE="YES" MEAN_1="30.05" MEAN_2="26.56" MODIFIED="2016-04-26 14:18:52 +0100" MODIFIED_BY="[Empty name]" ORDER="254" SD_1="30.19" SD_2="16.27" SE="3.0042631396344146" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="1.9596296590970805"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4835772085311594" CI_END="3.6692418659537847" CI_START="-1.169201661836943" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2500201020584207" ESTIMABLE="YES" I2="32.59535167771505" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2016-05-05 16:12:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.22321601418517323" P_Q="1.0" P_Z="0.31119391315918066" Q="0.0" RANDOM="YES" SCALE="10.55" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.796395021662243" TOTALS="YES" TOTAL_1="142" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="1.0127200476407234">
<NAME>Diuresis during study period (L): studies at low risk of bias</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0376132101302233" CI_START="0.3623867898697769" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="3.8" MODIFIED="2016-04-26 14:36:36 +0100" MODIFIED_BY="[Empty name]" ORDER="283" SD_1="0.5" SD_2="0.25" SE="0.1722548030439708" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="83.43312945607167"/>
<CONT_DATA CI_END="9.351656217605717" CI_START="-1.3116562176057176" EFFECT_SIZE="4.02" ESTIMABLE="YES" MEAN_1="23.58" MEAN_2="19.56" MODIFIED="2016-04-26 14:36:36 +0100" MODIFIED_BY="[Empty name]" ORDER="256" SD_1="27.86" SD_2="13.74" SE="2.7202827499184377" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="16.566870543928335"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="22.013636201580276" CI_END="8.093298482764029" CI_START="3.963391826348188" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="6.028345154556108" ESTIMABLE="YES" I2="86.37208331904458" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2016-05-05 16:12:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="6.480665887520498E-5" P_Q="1.0" P_Z="1.0537446921986752E-8" Q="0.0" RANDOM="YES" SCALE="11.145163094046708" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="3.7423171009525684" TOTALS="YES" TOTAL_1="60" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="5.721843311374267">
<NAME>Peak serum sodium (meq/L): studies at low risk of bias</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [Hypertonic]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [Isotonic]</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.45418540826402" CI_START="5.345814591735992" EFFECT_SIZE="6.400000000000006" ESTIMABLE="YES" MEAN_1="145.4" MEAN_2="139.0" MODIFIED="2016-04-26 14:45:46 +0100" MODIFIED_BY="[Empty name]" ORDER="334" SD_1="1.4" SD_2="1.0" SE="0.5378595813899101" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="27.532508465194205"/>
<CONT_DATA CI_END="7.296559190823639" CI_START="2.9034408091763497" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.9" MODIFIED="2016-04-26 14:45:46 +0100" MODIFIED_BY="[Empty name]" ORDER="324" SD_1="4.4" SD_2="2.4" SE="1.120714058089752" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="22.207542067497435"/>
<CONT_DATA CI_END="10.883691816105333" CI_START="7.116308183894668" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="141.0" MODIFIED="2016-04-26 14:45:46 +0100" MODIFIED_BY="[Empty name]" ORDER="328" SD_1="3.0" SD_2="3.0" SE="0.9610849132757812" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="23.789178329852326"/>
<CONT_DATA CI_END="5.06624387107141" CI_START="2.4337561289285903" EFFECT_SIZE="3.75" ESTIMABLE="YES" MEAN_1="143.7" MEAN_2="139.95" MODIFIED="2016-04-26 14:45:46 +0100" MODIFIED_BY="[Empty name]" ORDER="321" SD_1="1.7" SD_2="1.8" SE="0.6715653356152326" STUDY_ID="STD-Veroli-1992" TOTAL_1="10" TOTAL_2="20" WEIGHT="26.470771137456023"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.733069364870687" CI_END="4.624830912158972" CI_START="0.3262296455533451" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.475530278856158" ESTIMABLE="YES" I2="88.04762021605679" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2016-05-05 16:13:03 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="2.3252142956098343E-4" P_Q="1.0" P_Z="0.02397963717625821" Q="0.0" RANDOM="YES" SCALE="6.17" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="3.160130534149615" TOTALS="YES" TOTAL_1="50" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="2.2574553387352396">
<NAME>Final serum sodium (meq/L): studies at low risk of bias</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.850452840520893" CI_START="3.149547159479107" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="144.0" MEAN_2="139.5" MODIFIED="2016-04-26 14:46:53 +0100" MODIFIED_BY="[Empty name]" ORDER="409" SD_1="2.0" SD_2="1.0" SE="0.6890192121758832" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="33.08326100993484"/>
<CONT_DATA CI_END="3.55072667538626" CI_START="0.44927332461374014" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="140.6" MEAN_2="138.6" MODIFIED="2016-04-26 14:46:53 +0100" MODIFIED_BY="[Empty name]" ORDER="406" SD_1="2.6" SD_2="2.4" SE="0.7912016177940993" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="31.761614350843892"/>
<CONT_DATA CI_END="2.0004004767154084" CI_START="-4.004767154086597E-4" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="138.0" MODIFIED="2016-04-26 14:46:53 +0100" MODIFIED_BY="[Empty name]" ORDER="411" SD_1="2.0" SD_2="1.0" SE="0.5104177855340404" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="35.15512463922127"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.56450526603486" CI_END="18.766405595684002" CI_START="12.859392366964528" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="15.812898981324265" ESTIMABLE="YES" I2="71.94561586067185" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2016-05-05 16:13:12 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.05902748273783964" P_Q="1.0" P_Z="9.250561716571342E-26" Q="0.0" RANDOM="YES" SCALE="21.74504014745838" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="3.456986842105339" TOTALS="YES" TOTAL_1="39" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="10.493530755570792">
<NAME>Maximum intraoperative serum osmolarity (mOsm/kg H2O): studies at low risk of bias</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [Hypertonic]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [Isotonic]</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.98219526694472" CI_START="10.817804733055235" EFFECT_SIZE="13.899999999999977" ESTIMABLE="YES" MEAN_1="298.2" MEAN_2="284.3" MODIFIED="2016-04-26 14:47:16 +0100" MODIFIED_BY="[Empty name]" ORDER="372" SD_1="6.1" SD_2="3.5" SE="1.5725775020646835" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="38.2935812476041"/>
<CONT_DATA CI_END="17.92560596802116" CI_START="16.07439403197884" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="302.0" MEAN_2="285.0" MODIFIED="2016-04-26 14:47:16 +0100" MODIFIED_BY="[Empty name]" ORDER="365" SD_1="2.0" SD_2="0.5" SE="0.4722566206941663" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="61.7064187523959"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" NO="3">
<NAME>Subgroup analysis - hypertonic salt versus isotonic salt solution for peri-operative resuscitation</NAME>
<CONT_OUTCOME CHI2="78.26019172775793" CI_END="-1.221877615539272" CI_START="-2.613108925280149" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9174932704097105" ESTIMABLE="YES" I2="91.05547808475764" I2_Q="34.002235623294276" ID="CMP-003.01" MODIFIED="2016-04-26 14:06:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.0753177782116836E-14" P_Q="0.20825806456084983" P_Z="6.563727781998548E-8" Q="4.5456085192165485" RANDOM="YES" SCALE="7.31" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.7383281912984421" TOTALS="YES" TOTAL_1="377" TOTAL_2="360" UNITS="" WEIGHT="100.0" Z="5.4027216384325625">
<NAME>Fluid balance (L) by type of surgery</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="18.917790267235034" CI_END="-1.2312126037074425" CI_START="-6.453196605773838" DF="2" EFFECT_SIZE="-3.8422046047406404" ESTIMABLE="YES" I2="89.42794072802504" ID="CMP-003.01.01" MODIFIED="2016-04-26 14:05:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="7.799325909996213E-5" P_Z="0.003924287696317019" STUDIES="3" TAU2="4.705695343358102" TOTAL_1="70" TOTAL_2="68" WEIGHT="28.83498546435926" Z="2.8841844952208495">
<NAME>Aortic surgery</NAME>
<CONT_DATA CI_END="-0.5143531202191245" CI_START="-2.9056468797808748" EFFECT_SIZE="-1.7099999999999995" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="5.31" MODIFIED="2015-06-10 15:31:53 +0100" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="2.0" SD_2="1.1" SE="0.6100351277941763" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="11.343191710574985"/>
<CONT_DATA CI_END="-4.2836866426479" CI_START="-6.916313357352101" EFFECT_SIZE="-5.6000000000000005" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="9.8" MODIFIED="2015-06-10 15:31:53 +0100" MODIFIED_BY="[Empty name]" ORDER="234" SD_1="1.6" SD_2="3.2" SE="0.6716007884507128" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="10.590669393089335"/>
<CONT_DATA CI_END="-2.256627728175272" CI_START="-6.343372271824729" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="9.8" MODIFIED="2015-06-10 15:31:53 +0100" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="1.5" SD_2="5.1" SE="1.0425560305916783" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="6.901124360694939"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8063935541196074" CI_START="-1.593606445880392" DF="0" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" MODIFIED="2016-04-26 14:05:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.2952335001848546E-9" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.176913223641904" Z="5.975402095327395">
<NAME>Neurosurgery</NAME>
<CONT_DATA CI_END="-0.8063935541196074" CI_START="-1.593606445880392" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="2.24" MEAN_2="3.44" MODIFIED="2015-06-10 15:31:55 +0100" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="0.71" SD_2="0.55" SE="0.20082330542046162" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.176913223641904"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.137748827459163" CI_START="-2.1977488274591632" DF="0" EFFECT_SIZE="-0.5300000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" MODIFIED="2016-04-26 14:05:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5333738191682953" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="128" WEIGHT="8.613596426556542" Z="0.6228641236035677">
<NAME>Hepatobiliary surgery</NAME>
<CONT_DATA CI_END="1.137748827459163" CI_START="-2.1977488274591632" EFFECT_SIZE="-0.5300000000000002" ESTIMABLE="YES" MEAN_1="6.47" MEAN_2="7.0" MODIFIED="2015-06-10 15:32:16 +0100" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="7.9" SD_2="5.63" SE="0.8509078945399778" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="8.613596426556542"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.363548025284942" CI_END="-0.5713993996564629" CI_START="-1.9183341094607647" DF="2" EFFECT_SIZE="-1.2448667545586138" ESTIMABLE="YES" I2="82.39986318049772" ID="CMP-003.01.04" MODIFIED="2016-04-26 14:05:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0034075171928351633" P_Z="2.913366630969274E-4" STUDIES="3" TAU2="0.2835256375150366" TOTAL_1="156" TOTAL_2="144" WEIGHT="46.3745048854423" Z="3.6228838513496204">
<NAME>Coronary artery bypass surgery</NAME>
<CONT_DATA CI_END="-1.2970760864478588" CI_START="-2.682923913552141" EFFECT_SIZE="-1.99" ESTIMABLE="YES" MEAN_1="-1.72" MEAN_2="0.27" MODIFIED="2015-06-10 15:31:50 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="0.73" SD_2="0.83" SE="0.353539105319198" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="14.590550265552526"/>
<CONT_DATA CI_END="-0.42974835498725894" CI_START="-1.7702516450127408" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.9" MODIFIED="2015-06-10 15:31:50 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="1.5" SD_2="1.4" SE="0.3419714088113865" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="14.727801948874198"/>
<CONT_DATA CI_END="-0.8029547216714215" CI_START="-0.8570452783285787" EFFECT_SIZE="-0.8300000000000001" ESTIMABLE="YES" MEAN_1="-0.79" MEAN_2="0.04" MODIFIED="2015-06-10 15:31:50 +0100" MODIFIED_BY="[Empty name]" ORDER="205" SD_1="0.07" SD_2="0.12" SE="0.013798864949513509" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="17.056152671015575"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="77.82679892092494" CI_END="-1.2182340460339696" CI_START="-2.6087730463622485" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.913503546198109" ESTIMABLE="YES" I2="91.00566887363274" I2_Q="57.52049450589065" ID="CMP-003.02" MODIFIED="2016-04-26 14:07:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.863576125695545E-14" P_Q="0.0949814007157832" P_Z="6.884313887278382E-8" Q="4.708152735622925" RANDOM="YES" SCALE="7.51" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.7352241379891218" TOTALS="YES" TOTAL_1="377" TOTAL_2="360" UNITS="" WEIGHT="100.0" Z="5.394164469968228">
<NAME>Fluid balance (L) by dose of HS</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8063935541196074" CI_START="-1.593606445880392" DF="0" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" MODIFIED="2015-06-10 15:40:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.2952335001848546E-9" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.225498747464634" Z="5.975402095327395">
<NAME>&lt; 7.1 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="-0.8063935541196074" CI_START="-1.593606445880392" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="2.24" MEAN_2="3.44" MODIFIED="2015-06-10 15:40:20 +0100" MODIFIED_BY="[Empty name]" ORDER="226" SD_1="0.71" SD_2="0.55" SE="0.20082330542046162" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.225498747464634"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.6541502967910127" CI_END="-0.6242003711055" CI_START="-1.2207700778916846" DF="2" EFFECT_SIZE="-0.9224852244985923" ESTIMABLE="YES" I2="24.64631703720433" ID="CMP-003.02.02" MODIFIED="2015-06-10 15:40:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2652521182001044" P_Z="1.3490237987917246E-9" STUDIES="3" TAU2="0.029309851829139512" TOTAL_1="159" TOTAL_2="149" WEIGHT="43.155672071981854" Z="6.061446954884024">
<NAME>7.1 - 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="-0.500888974829077" CI_START="-2.9191110251709222" EFFECT_SIZE="-1.7099999999999995" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="5.31" MODIFIED="2015-06-10 15:40:22 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="2.04" SD_2="1.08" SE="0.6169047159581685" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="11.277829982174097"/>
<CONT_DATA CI_END="-0.42974835498725894" CI_START="-1.7702516450127408" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.9" MODIFIED="2015-06-10 15:40:22 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="1.5" SD_2="1.4" SE="0.3419714088113865" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="14.766740940621945"/>
<CONT_DATA CI_END="-0.8029547216714215" CI_START="-0.8570452783285787" EFFECT_SIZE="-0.8300000000000001" ESTIMABLE="YES" MEAN_1="-0.79" MEAN_2="0.04" MODIFIED="2015-06-10 15:40:22 +0100" MODIFIED_BY="[Empty name]" ORDER="206" SD_1="0.07" SD_2="0.12" SE="0.013798864949513509" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="17.111101149185814"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="31.399789585491085" CI_END="-0.9373442545206538" CI_START="-5.225029523395988" DF="3" EFFECT_SIZE="-3.081186888958321" ESTIMABLE="YES" I2="90.44579584894349" ID="CMP-003.02.03" MODIFIED="2015-06-10 15:40:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="7.002523338961453E-7" P_Z="0.004848785908004973" STUDIES="4" TAU2="4.206984024953716" TOTAL_1="198" TOTAL_2="191" WEIGHT="40.618829180553526" Z="2.8169116683227857">
<NAME>&gt; 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="-1.2970760864478588" CI_START="-2.682923913552141" EFFECT_SIZE="-1.99" ESTIMABLE="YES" MEAN_1="-1.72" MEAN_2="0.27" MODIFIED="2015-06-10 15:40:25 +0100" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="0.73" SD_2="0.83" SE="0.353539105319198" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="14.628629798609536"/>
<CONT_DATA CI_END="1.137748827459163" CI_START="-2.1977488274591632" EFFECT_SIZE="-0.5300000000000002" ESTIMABLE="YES" MEAN_1="6.47" MEAN_2="7.0" MODIFIED="2015-06-10 15:40:25 +0100" MODIFIED_BY="[Empty name]" ORDER="248" SD_1="7.9" SD_2="5.63" SE="0.8509078945399778" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="8.623329910595068"/>
<CONT_DATA CI_END="-4.2836866426479" CI_START="-6.916313357352101" EFFECT_SIZE="-5.6000000000000005" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="9.8" MODIFIED="2015-06-10 15:40:25 +0100" MODIFIED_BY="[Empty name]" ORDER="234" SD_1="1.6" SD_2="3.2" SE="0.6716007884507128" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="10.607816143214281"/>
<CONT_DATA CI_END="-2.219723309285971" CI_START="-6.38027669071403" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="9.8" MODIFIED="2015-06-10 15:40:25 +0100" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="1.5" SD_2="5.2" SE="1.061385161728984" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="6.759053328134639"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="77.82679892092496" CI_END="-1.2182340460339696" CI_START="-2.6087730463622485" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.913503546198109" ESTIMABLE="YES" I2="91.00566887363276" I2_Q="32.78692629264838" ID="CMP-003.03" MODIFIED="2016-04-26 14:08:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="3.774758283725532E-14" P_Q="0.22255756614585454" P_Z="6.884313887278382E-8" Q="1.4878057866450798" RANDOM="YES" SCALE="7.51" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.7352241379891219" TOTALS="YES" TOTAL_1="377" TOTAL_2="360" UNITS="" WEIGHT="100.0" Z="5.394164469968228">
<NAME>Fluid balance (L) by volume given to control group</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.01" MODIFIED="2015-06-10 15:41:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; 2000 mL</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.387212948244706" CI_END="-0.7016791565637364" CI_START="-1.9224114558263354" DF="3" EFFECT_SIZE="-1.312045306195036" ESTIMABLE="YES" I2="77.5905559163205" ID="CMP-003.03.02" MODIFIED="2015-06-10 15:41:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.00386985418043706" P_Z="2.5183844327920946E-5" STUDIES="4" TAU2="0.27147897800188586" TOTAL_1="170" TOTAL_2="158" WEIGHT="57.784301870591385" Z="4.21314574502614">
<NAME>2000 - 5000 mL</NAME>
<CONT_DATA CI_END="-0.500888974829077" CI_START="-2.9191110251709222" EFFECT_SIZE="-1.7099999999999995" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="5.31" MODIFIED="2015-06-10 15:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="236" SD_1="2.04" SD_2="1.08" SE="0.6169047159581685" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="11.277829982174097"/>
<CONT_DATA CI_END="-1.2970760864478588" CI_START="-2.682923913552141" EFFECT_SIZE="-1.99" ESTIMABLE="YES" MEAN_1="-1.72" MEAN_2="0.27" MODIFIED="2015-06-10 15:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="0.73" SD_2="0.83" SE="0.353539105319198" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="14.628629798609532"/>
<CONT_DATA CI_END="-0.42974835498725894" CI_START="-1.7702516450127408" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.9" MODIFIED="2015-06-10 15:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="1.5" SD_2="1.4" SE="0.3419714088113865" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="14.766740940621943"/>
<CONT_DATA CI_END="-0.8029547216714215" CI_START="-0.8570452783285787" EFFECT_SIZE="-0.8300000000000001" ESTIMABLE="YES" MEAN_1="-0.79" MEAN_2="0.04" MODIFIED="2015-06-10 15:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="207" SD_1="0.07" SD_2="0.12" SE="0.013798864949513509" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="17.111101149185814"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="47.49206426701476" CI_END="-0.44477720372549046" CI_START="-5.287227548498654" DF="3" EFFECT_SIZE="-2.8660023761120725" ESTIMABLE="YES" I2="93.68315518328895" ID="CMP-003.03.03" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="2.7312119232902887E-10" P_Z="0.02034045201038319" STUDIES="4" TAU2="5.544471554848179" TOTAL_1="207" TOTAL_2="202" WEIGHT="42.21569812940862" Z="2.320007862485996">
<NAME>&gt; 5000 mL</NAME>
<CONT_DATA CI_END="1.137748827459163" CI_START="-2.1977488274591632" EFFECT_SIZE="-0.5300000000000002" ESTIMABLE="YES" MEAN_1="6.47" MEAN_2="7.0" MODIFIED="2016-04-12 11:22:41 +0100" MODIFIED_BY="Jane Cracknell" ORDER="249" SD_1="7.9" SD_2="5.63" SE="0.8509078945399778" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="8.623329910595068"/>
<CONT_DATA CI_END="-4.2836866426479" CI_START="-6.916313357352101" EFFECT_SIZE="-5.6000000000000005" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="9.8" MODIFIED="2015-06-10 15:41:30 +0100" MODIFIED_BY="[Empty name]" ORDER="239" SD_1="1.6" SD_2="3.2" SE="0.6716007884507128" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="10.607816143214281"/>
<CONT_DATA CI_END="-2.219723309285971" CI_START="-6.38027669071403" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="9.8" MODIFIED="2015-06-10 15:41:30 +0100" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="1.5" SD_2="5.2" SE="1.061385161728984" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="6.759053328134639"/>
<CONT_DATA CI_END="-0.8063935541196074" CI_START="-1.593606445880392" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="2.24" MEAN_2="3.44" MODIFIED="2015-06-10 15:41:30 +0100" MODIFIED_BY="[Empty name]" ORDER="227" SD_1="0.71" SD_2="0.55" SE="0.20082330542046162" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.22549874746463"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1147.7681563691615" CI_END="-0.5876685996795319" CI_START="-1.237811650437319" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9127401250584255" ESTIMABLE="YES" I2="98.95449268796925" I2_Q="20.661824892753895" ID="CMP-003.04" MODIFIED="2016-04-26 14:22:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.2615703228060774" P_Z="3.729318727073689E-8" Q="1.2604272768414964" RANDOM="YES" SCALE="9.63" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.2619526980944393" TOTALS="YES" TOTAL_1="447" TOTAL_2="424" UNITS="" WEIGHT="99.99999999999999" Z="5.503212778399976">
<NAME>Total volume of crystalloid administered (L) by type of surgery</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1070.5363273357166" CI_END="-0.5666078384622656" CI_START="-1.7145986523460635" DF="6" EFFECT_SIZE="-1.1406032454041646" ESTIMABLE="YES" I2="99.43953326507543" ID="CMP-003.04.01" MODIFIED="2015-06-10 15:47:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="9.831937141229537E-5" STUDIES="7" TAU2="0.4342169396797417" TOTAL_1="224" TOTAL_2="205" WEIGHT="50.10828389734489" Z="3.894702387170756">
<NAME>Cardiovascular surgery</NAME>
<CONT_DATA CI_END="-0.2887965612659614" CI_START="-1.3112034387340392" EFFECT_SIZE="-0.8000000000000003" ESTIMABLE="YES" MEAN_1="1.92" MEAN_2="2.72" MODIFIED="2015-06-10 15:47:02 +0100" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="0.7" SD_2="0.68" SE="0.26082287366826445" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="8.336281802397908"/>
<CONT_DATA CI_END="-1.0298348458314603" CI_START="-2.170165154168539" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="4.17" MEAN_2="5.77" MODIFIED="2015-06-10 15:47:02 +0100" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="0.41" SD_2="0.79" SE="0.2909059343263087" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="7.937056671116393"/>
<CONT_DATA CI_END="-0.7468924273917499" CI_START="-1.03310757260825" EFFECT_SIZE="-0.8899999999999999" ESTIMABLE="YES" MEAN_1="0.55" MEAN_2="1.44" MODIFIED="2015-06-10 15:47:02 +0100" MODIFIED_BY="[Empty name]" ORDER="248" SD_1="0.18" SD_2="0.23" SE="0.07301540933255117" STUDY_ID="STD-Jarvela-2001" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.291739821520778"/>
<CONT_DATA CI_END="-1.0829547216714215" CI_START="-1.1370452783285787" EFFECT_SIZE="-1.11" ESTIMABLE="YES" MEAN_1="1.32" MEAN_2="2.43" MODIFIED="2015-06-10 15:47:02 +0100" MODIFIED_BY="[Empty name]" ORDER="208" SD_1="0.07" SD_2="0.12" SE="0.013798864949513509" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="10.493569280415352"/>
<CONT_DATA CI_END="-3.0600393259744694" CI_START="-9.13996067402553" EFFECT_SIZE="-6.1" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="12.5" MODIFIED="2015-06-10 15:47:02 +0100" MODIFIED_BY="[Empty name]" ORDER="245" SD_1="4.6" SD_2="6.9" SE="1.5510288444095668" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="1.0311787118958342"/>
<CONT_DATA CI_END="-0.7872655352249378" CI_START="-5.6127344647750625" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="9.5" MODIFIED="2015-06-10 15:47:02 +0100" MODIFIED_BY="[Empty name]" ORDER="249" SD_1="2.4" SD_2="5.8" SE="1.231009591914139" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="1.5477179438000084"/>
<CONT_DATA CI_END="-0.055897686838329914" CI_START="-0.1641023131616703" EFFECT_SIZE="-0.1100000000000001" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.81" MODIFIED="2015-06-10 15:47:02 +0100" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="0.05" SD_2="0.09" SE="0.027603728225835945" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="10.470739666198616"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="67.23102985712569" CI_END="-0.502862438469128" CI_START="-1.049916856064594" DF="5" EFFECT_SIZE="-0.776389647266861" ESTIMABLE="YES" I2="92.56295789217326" ID="CMP-003.04.02" MODIFIED="2016-04-26 14:22:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.8613556796462944E-13" P_Z="2.6482107610902842E-8" STUDIES="6" TAU2="0.08378390023015328" TOTAL_1="223" TOTAL_2="219" WEIGHT="49.891716102655096" Z="5.563233556549259">
<NAME>Non-cardiovascular surgery</NAME>
<CONT_DATA CI_END="-0.07463859470030929" CI_START="-0.38536140529969065" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.62" MODIFIED="2015-06-10 15:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="251" SD_1="0.22" SD_2="0.32" SE="0.07926747967062743" STUDY_ID="STD-Durasnel-1999" TOTAL_1="24" TOTAL_2="24" WEIGHT="10.255210076046554"/>
<CONT_DATA CI_END="-0.7680195590720921" CI_START="-0.9919804409279079" EFFECT_SIZE="-0.88" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.98" MODIFIED="2015-06-10 15:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="254" SD_1="0.02" SD_2="0.15" SE="0.057133927873774915" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="10.371948329827655"/>
<CONT_DATA CI_END="-0.8286562340675815" CI_START="-0.9713437659324186" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="1.03" MODIFIED="2015-06-10 15:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="252" SD_1="0.03" SD_2="0.16" SE="0.03640054944640259" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.448347399596676"/>
<CONT_DATA CI_END="-0.4979715176294116" CI_START="-1.1220284823705886" EFFECT_SIZE="-0.81" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="1.62" MODIFIED="2015-06-10 15:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="0.35" SD_2="0.62" SE="0.15920113064925134" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.574796006032031"/>
<CONT_DATA CI_END="9.378247553764684" CI_START="-2.398247553764679" EFFECT_SIZE="3.490000000000002" ESTIMABLE="YES" MEAN_1="30.05" MEAN_2="26.56" MODIFIED="2015-06-10 15:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="30.19" SD_2="16.27" SE="3.0042631396344146" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="0.2961832709458183"/>
<CONT_DATA CI_END="-0.8216268756660776" CI_START="-1.6583731243339228" EFFECT_SIZE="-1.2400000000000002" ESTIMABLE="YES" MEAN_1="4.26" MEAN_2="5.5" MODIFIED="2015-06-10 15:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="0.67" SD_2="0.68" SE="0.21345959805077871" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.945231020206363"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1147.7681563691617" CI_END="-0.587668599679532" CI_START="-1.2378116504373193" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9127401250584256" ESTIMABLE="YES" I2="98.95449268796926" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2015-06-22 17:25:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.39531625838165874" P_Z="3.7293187270737087E-8" Q="1.8561386457418814" RANDOM="YES" SCALE="10.26968653262357" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.26195269809443933" TOTALS="YES" TOTAL_1="447" TOTAL_2="424" UNITS="" WEIGHT="100.0" Z="5.503212778399975">
<NAME>Total volume of crystalloid administered (L) by dose of HS</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [Hypertonic]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [Isotonic]</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="51.936341254264775" CI_END="-0.3476159960306454" CI_START="-1.187144660443086" DF="3" EFFECT_SIZE="-0.7673803282368657" ESTIMABLE="YES" I2="94.22369784326374" ID="CMP-003.05.01" MODIFIED="2015-06-10 15:48:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.090216971202153E-11" P_Z="3.396018055663149E-4" STUDIES="4" TAU2="0.16485475418418225" TOTAL_1="72" TOTAL_2="71" WEIGHT="39.14718543211261" Z="3.5830528951418477">
<NAME>&lt; 7.1 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="-0.07463859470030929" CI_START="-0.38536140529969065" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.62" MODIFIED="2015-06-10 15:48:29 +0100" MODIFIED_BY="[Empty name]" ORDER="271" SD_1="0.22" SD_2="0.32" SE="0.07926747967062743" STUDY_ID="STD-Durasnel-1999" TOTAL_1="24" TOTAL_2="24" WEIGHT="10.255210076046556"/>
<CONT_DATA CI_END="-0.7680195590720921" CI_START="-0.9919804409279079" EFFECT_SIZE="-0.88" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.98" MODIFIED="2015-06-10 15:48:29 +0100" MODIFIED_BY="[Empty name]" ORDER="273" SD_1="0.02" SD_2="0.15" SE="0.057133927873774915" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="10.371948329827656"/>
<CONT_DATA CI_END="-0.4979715176294116" CI_START="-1.1220284823705886" EFFECT_SIZE="-0.81" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="1.62" MODIFIED="2015-06-10 15:48:29 +0100" MODIFIED_BY="[Empty name]" ORDER="272" SD_1="0.35" SD_2="0.62" SE="0.15920113064925134" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.574796006032033"/>
<CONT_DATA CI_END="-0.8216268756660776" CI_START="-1.6583731243339228" EFFECT_SIZE="-1.2400000000000002" ESTIMABLE="YES" MEAN_1="4.26" MEAN_2="5.5" MODIFIED="2015-06-10 15:48:29 +0100" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="0.67" SD_2="0.68" SE="0.21345959805077871" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.945231020206364"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1050.3148896266314" CI_END="-0.2735242411371229" CI_START="-1.246903664252872" DF="4" EFFECT_SIZE="-0.7602139526949975" ESTIMABLE="YES" I2="99.61916183046571" ID="CMP-003.05.02" MODIFIED="2015-06-10 15:48:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.002202439673958988" STUDIES="5" TAU2="0.2951866068667929" TOTAL_1="177" TOTAL_2="162" WEIGHT="50.04067797012934" Z="3.061482362258339">
<NAME>7.1 - 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="-0.2887965612659614" CI_START="-1.3112034387340392" EFFECT_SIZE="-0.8000000000000003" ESTIMABLE="YES" MEAN_1="1.92" MEAN_2="2.72" MODIFIED="2015-06-10 15:48:31 +0100" MODIFIED_BY="[Empty name]" ORDER="277" SD_1="0.7" SD_2="0.68" SE="0.26082287366826445" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="8.33628180239791"/>
<CONT_DATA CI_END="-0.8286562340675815" CI_START="-0.9713437659324186" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="1.03" MODIFIED="2015-06-10 15:48:31 +0100" MODIFIED_BY="[Empty name]" ORDER="274" SD_1="0.03" SD_2="0.16" SE="0.03640054944640259" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.448347399596678"/>
<CONT_DATA CI_END="-0.7468924273917499" CI_START="-1.03310757260825" EFFECT_SIZE="-0.8899999999999999" ESTIMABLE="YES" MEAN_1="0.55" MEAN_2="1.44" MODIFIED="2015-06-10 15:48:31 +0100" MODIFIED_BY="[Empty name]" ORDER="276" SD_1="0.18" SD_2="0.23" SE="0.07301540933255117" STUDY_ID="STD-Jarvela-2001" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.29173982152078"/>
<CONT_DATA CI_END="-1.0829547216714215" CI_START="-1.1370452783285787" EFFECT_SIZE="-1.11" ESTIMABLE="YES" MEAN_1="1.32" MEAN_2="2.43" MODIFIED="2015-06-10 15:48:31 +0100" MODIFIED_BY="[Empty name]" ORDER="201" SD_1="0.07" SD_2="0.12" SE="0.013798864949513509" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="10.493569280415354"/>
<CONT_DATA CI_END="-0.055897686838329914" CI_START="-0.1641023131616703" EFFECT_SIZE="-0.1100000000000001" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.81" MODIFIED="2015-06-10 15:48:31 +0100" MODIFIED_BY="[Empty name]" ORDER="275" SD_1="0.05" SD_2="0.09" SE="0.027603728225835945" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="10.470739666198616"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.548174816757939" CI_END="-0.021362041444394464" CI_START="-4.986044515185616" DF="3" EFFECT_SIZE="-2.503703278315005" ESTIMABLE="YES" I2="76.09214053988525" ID="CMP-003.05.03" MODIFIED="2015-06-10 15:48:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.00572296041524456" P_Z="0.048060775339019514" STUDIES="4" TAU2="4.307215318609912" TOTAL_1="198" TOTAL_2="191" WEIGHT="10.812136597758059" Z="1.9768306551030619">
<NAME>&gt; 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="-1.0298348458314603" CI_START="-2.170165154168539" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="4.17" MEAN_2="5.77" MODIFIED="2015-06-10 15:48:33 +0100" MODIFIED_BY="[Empty name]" ORDER="279" SD_1="0.41" SD_2="0.79" SE="0.2909059343263087" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="7.9370566711163955"/>
<CONT_DATA CI_END="9.378247553764684" CI_START="-2.398247553764679" EFFECT_SIZE="3.490000000000002" ESTIMABLE="YES" MEAN_1="30.05" MEAN_2="26.56" MODIFIED="2015-06-10 15:48:33 +0100" MODIFIED_BY="[Empty name]" ORDER="254" SD_1="30.19" SD_2="16.27" SE="3.0042631396344146" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="0.29618327094581837"/>
<CONT_DATA CI_END="-3.0600393259744694" CI_START="-9.13996067402553" EFFECT_SIZE="-6.1" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="12.5" MODIFIED="2015-06-10 15:48:33 +0100" MODIFIED_BY="[Empty name]" ORDER="278" SD_1="4.6" SD_2="6.9" SE="1.5510288444095668" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="1.0311787118958344"/>
<CONT_DATA CI_END="-0.7872655352249378" CI_START="-5.6127344647750625" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="9.5" MODIFIED="2015-06-10 15:48:33 +0100" MODIFIED_BY="[Empty name]" ORDER="280" SD_1="2.4" SD_2="5.8" SE="1.231009591914139" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="1.5477179438000088"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="27.134505654792314" CI_END="0.31370454216524435" CI_START="-0.09683075040772546" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10843689587875943" ESTIMABLE="YES" I2="70.51724434645415" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" NO="6" P_CHI2="6.7015212695265E-4" P_Q="0.5393458330320449" P_Z="0.30048605034337394" Q="0.37675409790250625" RANDOM="YES" SCALE="9.63" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.043811383456055175" TOTALS="YES" TOTAL_1="397" TOTAL_2="380" UNITS="" WEIGHT="100.0" Z="1.0353916672336383">
<NAME>Diuresis during study period (L) by type of surgery</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="23.16682273274468" CI_END="0.5239645518794716" CI_START="-0.221566620822869" DF="5" EFFECT_SIZE="0.1511989655283013" ESTIMABLE="YES" I2="78.4174115817235" ID="CMP-003.06.01" MODIFIED="2015-06-10 15:50:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.1365677782180246E-4" P_Z="0.4266199294683526" STUDIES="6" TAU2="0.1316033989080814" TOTAL_1="226" TOTAL_2="212" WEIGHT="64.99243696435033" Z="0.7949889629994096">
<NAME>Cardiovascular surgery</NAME>
<CONT_DATA CI_END="0.45390402009358743" CI_START="-1.0539040200935874" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.5" MODIFIED="2015-06-10 15:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="265" SD_1="0.55" SD_2="1.33" SE="0.384651976281343" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="5.719624161503549"/>
<CONT_DATA CI_END="1.0376132101302233" CI_START="0.3623867898697769" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="3.8" MODIFIED="2015-06-10 15:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="269" SD_1="0.5" SD_2="0.25" SE="0.1722548030439708" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="14.9264781581951"/>
<CONT_DATA CI_END="0.8587601172753827" CI_START="-0.018760117275382793" EFFECT_SIZE="0.41999999999999993" ESTIMABLE="YES" MEAN_1="3.36" MEAN_2="2.94" MODIFIED="2015-06-10 15:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="266" SD_1="1.04" SD_2="0.85" SE="0.22386131619573957" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="11.677835678652029"/>
<CONT_DATA CI_END="-0.0049930544373319175" CI_START="-0.07500694556266815" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="1.61" MODIFIED="2015-06-10 15:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="211" SD_1="0.1" SD_2="0.15" SE="0.017861014711902073" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="24.854610741136547"/>
<CONT_DATA CI_END="0.4581566786760506" CI_START="-0.8581566786760505" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.8" MODIFIED="2015-06-10 15:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="268" SD_1="0.8" SD_2="1.6" SE="0.3358003942253564" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="7.005306645856605"/>
<CONT_DATA CI_END="1.8455853233048043" CI_START="-2.645585323304805" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.1" MODIFIED="2015-06-10 15:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="267" SD_1="0.7" SD_2="5.8" SE="1.1457278506226107" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.8085815790065056"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.325433972159283" CI_END="0.30344388107435305" CI_START="-0.3017716265366135" DF="2" EFFECT_SIZE="8.36127268869803E-4" ESTIMABLE="YES" I2="39.857473738943234" ID="CMP-003.06.02" MODIFIED="2016-05-11 17:19:58 +0100" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.1896232786886719" P_Z="0.9956790587116373" STUDIES="3" TAU2="0.029624614952809006" TOTAL_1="171" TOTAL_2="168" WEIGHT="35.007563035649675" Z="0.005415523273504955">
<NAME>Non-cardiovascular surgery</NAME>
<CONT_DATA CI_END="0.2404718040573017" CI_START="-0.10047180405730169" EFFECT_SIZE="0.07" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.43" MODIFIED="2015-06-10 15:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="0.28" SD_2="0.27" SE="0.08697700845625814" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="21.34918463957438"/>
<CONT_DATA CI_END="9.351656217605717" CI_START="-1.3116562176057176" EFFECT_SIZE="4.02" ESTIMABLE="YES" MEAN_1="23.58" MEAN_2="19.56" MODIFIED="2015-06-10 15:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="258" SD_1="27.86" SD_2="13.74" SE="2.7202827499184377" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="0.1473509927219659"/>
<CONT_DATA CI_END="0.2188869437303685" CI_START="-0.5388869437303687" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="1.59" MODIFIED="2015-06-10 15:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="0.57" SD_2="0.65" SE="0.1933132173442882" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.511027403353333"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="25.987785787300858" CI_END="0.29716899369096944" CI_START="-0.10488571822275455" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09614163773410744" ESTIMABLE="YES" I2="69.21630774750628" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2016-04-26 14:40:41 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0010553676522431221" P_Q="0.5402911239555551" P_Z="0.3485756074587386" Q="1.2312954307983466" RANDOM="YES" SCALE="9.9" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.04118579256085691" TOTALS="YES" TOTAL_1="397" TOTAL_2="380" UNITS="" WEIGHT="100.0" Z="0.937355746816783">
<NAME>Diuresis during study period (L) by dose of HS</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2188869437303685" CI_START="-0.5388869437303687" DF="0" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" MODIFIED="2015-06-10 15:54:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4078561044125847" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.39170655981497" Z="0.8276723247280208">
<NAME>&lt; 7.1 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="0.2188869437303685" CI_START="-0.5388869437303687" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="1.59" MODIFIED="2015-06-10 15:54:05 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="0.57" SD_2="0.65" SE="0.1933132173442882" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.39170655981497"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.903839504641755" CI_END="0.1269917606377432" CI_START="-0.12147877730814209" DF="3" EFFECT_SIZE="0.0027564916648005608" ESTIMABLE="YES" I2="38.82344646148524" ID="CMP-003.07.02" MODIFIED="2015-06-10 15:54:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1789755710754487" P_Z="0.9653132935658217" STUDIES="4" TAU2="0.006248337182516899" TOTAL_1="179" TOTAL_2="169" WEIGHT="64.00978612808261" Z="0.04348704221721932">
<NAME>7.1 - 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="0.45390402009358743" CI_START="-1.0539040200935874" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.5" MODIFIED="2015-06-10 15:54:07 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="0.55" SD_2="1.33" SE="0.384651976281343" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="5.5619107328741295"/>
<CONT_DATA CI_END="0.1904718040573017" CI_START="-0.15047180405730168" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="0.43" MODIFIED="2015-06-10 15:54:07 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="0.28" SD_2="0.27" SE="0.08697700845625814" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="21.579056817085725"/>
<CONT_DATA CI_END="0.8487601172753829" CI_START="-0.02876011727538258" EFFECT_SIZE="0.41000000000000014" ESTIMABLE="YES" MEAN_1="3.35" MEAN_2="2.94" MODIFIED="2015-06-10 15:54:07 +0100" MODIFIED_BY="[Empty name]" ORDER="108" SD_1="1.04" SD_2="0.85" SE="0.22386131619573957" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="11.522451183225026"/>
<CONT_DATA CI_END="-0.0049930544373319175" CI_START="-0.07500694556266815" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="1.61" MODIFIED="2015-06-10 15:54:07 +0100" MODIFIED_BY="[Empty name]" ORDER="210" SD_1="0.1" SD_2="0.15" SE="0.017861014711902073" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="25.34636739489773"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.982573066392742" CI_END="1.1141515104921953" CI_START="-0.5001693162345833" DF="3" EFFECT_SIZE="0.30699109712880596" ESTIMABLE="YES" I2="62.41813291217797" ID="CMP-003.07.03" MODIFIED="2015-06-10 15:54:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04637335448376556" P_Z="0.4560044019591556" STUDIES="4" TAU2="0.32117730911183495" TOTAL_1="198" TOTAL_2="191" WEIGHT="22.59850731210241" Z="0.7454422739089555">
<NAME>&gt; 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="1.0376132101302233" CI_START="0.3623867898697769" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="3.8" MODIFIED="2015-06-10 15:54:09 +0100" MODIFIED_BY="[Empty name]" ORDER="109" SD_1="0.5" SD_2="0.25" SE="0.1722548030439708" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="14.846642600326604"/>
<CONT_DATA CI_END="9.351656217605717" CI_START="-1.3116562176057176" EFFECT_SIZE="4.02" ESTIMABLE="YES" MEAN_1="23.58" MEAN_2="19.56" MODIFIED="2015-06-10 15:54:09 +0100" MODIFIED_BY="[Empty name]" ORDER="257" SD_1="27.86" SD_2="13.74" SE="2.7202827499184377" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="0.14137596927769477"/>
<CONT_DATA CI_END="0.4581566786760506" CI_START="-0.8581566786760505" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.8" MODIFIED="2015-06-10 15:54:09 +0100" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="0.8" SD_2="1.6" SE="0.3358003942253564" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="6.833464487247969"/>
<CONT_DATA CI_END="1.8455853233048043" CI_START="-2.645585323304805" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.1" MODIFIED="2015-06-10 15:54:09 +0100" MODIFIED_BY="[Empty name]" ORDER="111" SD_1="0.7" SD_2="5.8" SE="1.1457278506226107" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.7770242552501413"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="25.814418510289137" CI_END="0.295287317802969" CI_START="-0.10546014388304006" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09491358695996446" ESTIMABLE="YES" I2="69.00956728189965" I2_Q="19.35113197918661" ID="CMP-003.08" MODIFIED="2016-04-26 14:41:24 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0011299075978491446" P_Q="0.2894007970542595" P_Z="0.3531995074302897" Q="2.479886015863052" RANDOM="YES" SCALE="9.63" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.04078884160801157" TOTALS="YES" TOTAL_1="397" TOTAL_2="380" UNITS="" WEIGHT="100.0" Z="0.9284011996103205">
<NAME>Diuresis during study period (L) by volume given to control group</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6584271417483043" CI_END="0.1707083957204346" CI_START="-0.16183965401622158" DF="1" EFFECT_SIZE="0.004434370852106512" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" MODIFIED="2015-06-10 15:55:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.41711606480425156" P_Z="0.9583132510201168" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="27.152380942890147" Z="0.05227038421127712">
<NAME>&lt; 2000 mL</NAME>
<CONT_DATA CI_END="0.45390402009358743" CI_START="-1.0539040200935874" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.5" MODIFIED="2015-06-10 15:55:29 +0100" MODIFIED_BY="[Empty name]" ORDER="288" SD_1="0.55" SD_2="1.33" SE="0.384651976281343" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="5.5374225664246195"/>
<CONT_DATA CI_END="0.1904718040573017" CI_START="-0.15047180405730168" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="0.43" MODIFIED="2015-06-10 15:55:29 +0100" MODIFIED_BY="[Empty name]" ORDER="287" SD_1="0.28" SD_2="0.27" SE="0.08697700845625814" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="21.614958376465527"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="21.961865835625645" CI_END="0.8545476122914575" CI_START="-0.1903343231501371" DF="2" EFFECT_SIZE="0.3321066445706602" ESTIMABLE="YES" I2="90.89330562817808" ID="CMP-003.08.02" MODIFIED="2015-06-10 15:55:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.7023366923885064E-5" P_Z="0.21279560970998246" STUDIES="3" TAU2="0.18844533990120169" TOTAL_1="156" TOTAL_2="144" WEIGHT="51.75596110580682" Z="1.2459150461048867">
<NAME>2000 - 5000 mL</NAME>
<CONT_DATA CI_END="1.0376132101302233" CI_START="0.3623867898697769" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="3.8" MODIFIED="2015-06-10 15:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="289" SD_1="0.5" SD_2="0.25" SE="0.1722548030439708" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="14.83335204545763"/>
<CONT_DATA CI_END="0.8387601172753827" CI_START="-0.03876011727538281" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.34" MEAN_2="2.94" MODIFIED="2015-06-10 15:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="290" SD_1="1.04" SD_2="0.85" SE="0.22386131619573957" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="11.49763343725978"/>
<CONT_DATA CI_END="-0.0049930544373319175" CI_START="-0.07500694556266815" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="1.61" MODIFIED="2015-06-10 15:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="0.1" SD_2="0.15" SE="0.017861014711902073" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="25.42497562308941"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4192028962947414" CI_END="0.16505395619629049" CI_START="-0.48355855358999866" DF="3" EFFECT_SIZE="-0.1592522986968541" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.03" MODIFIED="2015-06-22 19:06:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.49007022666549716" P_Z="0.3358232872161959" STUDIES="4" TAU2="0.0" TOTAL_1="207" TOTAL_2="202" WEIGHT="21.091657951303027" Z="0.9624506625809363">
<NAME>&gt; 5000 mL</NAME>
<CONT_DATA CI_END="9.351656217605717" CI_START="-1.3116562176057176" EFFECT_SIZE="4.02" ESTIMABLE="YES" MEAN_1="23.58" MEAN_2="19.56" MODIFIED="2015-06-22 19:06:48 +0100" MODIFIED_BY="[Empty name]" ORDER="259" SD_1="27.86" SD_2="13.74" SE="2.7202827499184377" STUDY_ID="STD-Lavu-2014" TOTAL_1="131" TOTAL_2="128" WEIGHT="0.1404656107267414"/>
<CONT_DATA CI_END="0.4581566786760506" CI_START="-0.8581566786760505" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.8" MODIFIED="2015-06-10 15:55:34 +0100" MODIFIED_BY="[Empty name]" ORDER="292" SD_1="0.8" SD_2="1.6" SE="0.3358003942253564" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="6.806650559558243"/>
<CONT_DATA CI_END="1.8455853233048043" CI_START="-2.645585323304805" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.1" MODIFIED="2015-06-10 15:55:34 +0100" MODIFIED_BY="[Empty name]" ORDER="291" SD_1="0.7" SD_2="5.8" SE="1.1457278506226107" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.7722060068879976"/>
<CONT_DATA CI_END="0.2188869437303685" CI_START="-0.5388869437303687" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="1.59" MODIFIED="2015-06-10 15:55:34 +0100" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="0.57" SD_2="0.65" SE="0.1933132173442882" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.372335774130045"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="482.1529378525524" CI_END="9.620079195038407" CI_START="5.843179982137752" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="7.7316295885880795" ESTIMABLE="YES" I2="96.88895393507129" I2_Q="78.71359481267028" ID="CMP-003.09" MODIFIED="2016-04-26 14:48:56 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="-4.440892098500626E-16" P_Q="0.00911502710260459" P_Z="1.0200553226717736E-15" Q="9.395668185394019" RANDOM="YES" SCALE="22.92" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="13.290349587536676" TOTALS="YES" TOTAL_1="395" TOTAL_2="385" UNITS="" WEIGHT="100.0" Z="8.024421453279304">
<NAME>Peak serum sodium (meq/L) by type of surgery</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="378.33234287828884" CI_END="14.307390122955217" CI_START="6.914933328584754" DF="6" EFFECT_SIZE="10.611161725769986" ESTIMABLE="YES" I2="98.41409276448505" ID="CMP-003.09.01" MODIFIED="2015-06-10 15:56:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.551115123125783E-16" P_Z="1.8371095248869662E-8" STUDIES="7" TAU2="22.85003945230232" TOTAL_1="244" TOTAL_2="225" WEIGHT="42.70447121917677" Z="5.626680113295178">
<NAME>Cardiovascular surgery</NAME>
<CONT_DATA CI_END="17.656471900648683" CI_START="14.343528099351317" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="159.0" MEAN_2="143.0" MODIFIED="2015-06-10 15:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="294" SD_1="3.0" SD_2="1.0" SE="0.8451542547285166" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="6.628920558622435"/>
<CONT_DATA CI_END="7.45418540826402" CI_START="5.345814591735992" EFFECT_SIZE="6.400000000000006" ESTIMABLE="YES" MEAN_1="145.4" MEAN_2="139.0" MODIFIED="2015-06-10 15:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="296" SD_1="1.4" SD_2="1.0" SE="0.5378595813899101" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="6.836381351954321"/>
<CONT_DATA CI_END="11.177791774053645" CI_START="8.822208225946355" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="293" SD_1="3.0" SD_2="2.0" SE="0.6009252125773316" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="6.800416227800119"/>
<CONT_DATA CI_END="4.108845105227348" CI_START="3.8911548947726513" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="140.0" MEAN_2="136.0" MODIFIED="2015-06-10 15:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="0.4" SD_2="0.4" SE="0.055534237407373274" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="6.98356928607776"/>
<CONT_DATA CI_END="15.914137131395655" CI_START="8.085862868604345" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="151.0" MEAN_2="139.0" MODIFIED="2015-06-10 15:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="297" SD_1="7.6" SD_2="7.6" SE="1.9970454366865256" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="5.372885355236106"/>
<CONT_DATA CI_END="20.9138926645475" CI_START="13.0861073354525" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="157.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="298" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="5.373040268752607"/>
<CONT_DATA CI_END="14.967291566049926" CI_START="5.032708433950074" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="147.0" MEAN_2="137.0" MODIFIED="2015-06-10 15:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="295" SD_1="9.0" SD_2="5.0" SE="2.534379001467011" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="4.709258170733422"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.6772501110926274" CI_END="6.1566048674164" CI_START="1.861789819600947" DF="2" EFFECT_SIZE="4.009197343508673" ESTIMABLE="YES" I2="57.23983211295941" ID="CMP-003.09.02" MODIFIED="2015-06-10 15:56:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09646036595240648" P_Z="2.529630195031588E-4" STUDIES="3" TAU2="2.0578110095893876" TOTAL_1="44" TOTAL_2="43" WEIGHT="18.7476919168818" Z="3.6592413469295044">
<NAME>Transurethral resection of the prostate</NAME>
<CONT_DATA CI_END="4.294642147882273" CI_START="-1.2946421478822732" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="138.5" MEAN_2="137.0" MODIFIED="2015-06-10 15:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="300" SD_1="5.0" SD_2="3.0" SE="1.4258640311383544" STUDY_ID="STD-Baraka-1994" TOTAL_1="17" TOTAL_2="16" WEIGHT="6.058406471290779"/>
<CONT_DATA CI_END="7.296559190823639" CI_START="2.9034408091763497" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.9" MODIFIED="2015-06-10 15:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="299" SD_1="4.4" SD_2="2.4" SE="1.120714058089752" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.382055807857222"/>
<CONT_DATA CI_END="7.342605027587306" CI_START="2.657394972412694" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="137.0" MODIFIED="2015-06-10 15:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="301" SD_1="1.0" SD_2="3.0" SE="1.1952286093343936" STUDY_ID="STD-Kimura-1994" TOTAL_1="7" TOTAL_2="7" WEIGHT="6.3072296377338"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="76.3666265706159" CI_END="9.395827097809843" CI_START="3.6413403952110683" DF="5" EFFECT_SIZE="6.518583746510456" ESTIMABLE="YES" I2="93.45263733055366" ID="CMP-003.09.03" MODIFIED="2015-06-10 15:57:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="4.551914400963142E-15" P_Z="8.978051173292466E-6" STUDIES="6" TAU2="11.776644538915606" TOTAL_1="107" TOTAL_2="117" WEIGHT="38.54783686394144" Z="4.440427107981267">
<NAME>Other surgery</NAME>
<CONT_DATA CI_END="8.60334995855648" CI_START="1.596650041443508" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="144.1" MEAN_2="139.0" MODIFIED="2015-06-10 15:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="306" SD_1="3.4" SD_2="3.5" SE="1.7874562931719478" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="5.631401043411657"/>
<CONT_DATA CI_END="6.239590064609123" CI_START="3.760409935390877" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="304" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.781098924805761"/>
<CONT_DATA CI_END="10.883691816105333" CI_START="7.116308183894668" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="141.0" MODIFIED="2015-06-10 15:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="302" SD_1="3.0" SD_2="3.0" SE="0.9610849132757812" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="6.531264536665943"/>
<CONT_DATA CI_END="15.43672033930391" CI_START="11.163279660696112" EFFECT_SIZE="13.300000000000011" ESTIMABLE="YES" MEAN_1="152.5" MEAN_2="139.2" MODIFIED="2015-06-10 15:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="4.4" SD_2="2.1" SE="1.0901834707974618" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.411808777140167"/>
<CONT_DATA CI_END="5.06624387107141" CI_START="2.4337561289285903" EFFECT_SIZE="3.75" ESTIMABLE="YES" MEAN_1="143.7" MEAN_2="139.95" MODIFIED="2015-06-10 15:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="305" SD_1="1.7" SD_2="1.8" SE="0.6715653356152326" STUDY_ID="STD-Veroli-1992" TOTAL_1="10" TOTAL_2="20" WEIGHT="6.755931379000888"/>
<CONT_DATA CI_END="5.086540996510735" CI_START="0.9134590034892653" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="139.0" MODIFIED="2015-06-10 15:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="303" SD_1="5.0" SD_2="3.0" SE="1.0645812948447542" STUDY_ID="STD-Wang-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.436332202917026"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="482.1529378525524" CI_END="9.620079195038407" CI_START="5.843179982137752" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="7.7316295885880795" ESTIMABLE="YES" I2="96.88895393507129" I2_Q="39.17046227255586" ID="CMP-003.10" MODIFIED="2016-04-26 14:49:42 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="-4.440892098500626E-16" P_Q="0.19321779443352693" P_Z="1.0200553226717736E-15" Q="3.287876375061898" RANDOM="YES" SCALE="21.75" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="13.290349587536676" TOTALS="YES" TOTAL_1="395" TOTAL_2="385" UNITS="" WEIGHT="99.99999999999997" Z="8.024421453279304">
<NAME>Peak serum sodium (meq/L) by dose of HS</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="70.86785481733155" CI_END="8.625621192806491" CI_START="1.9998721047827344" DF="5" EFFECT_SIZE="5.3127466487946124" ESTIMABLE="YES" I2="92.94461499802983" ID="CMP-003.10.01" MODIFIED="2015-06-10 15:58:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.772360450213455E-14" P_Z="0.001671521510527464" STUDIES="6" TAU2="15.641700682907626" TOTAL_1="105" TOTAL_2="113" WEIGHT="37.67593568161772" Z="3.1431290114637">
<NAME>&lt; 7.1 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="4.294642147882273" CI_START="-1.2946421478822732" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="138.5" MEAN_2="137.0" MODIFIED="2015-06-10 15:58:08 +0100" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="5.0" SD_2="3.0" SE="1.4258640311383544" STUDY_ID="STD-Baraka-1994" TOTAL_1="17" TOTAL_2="16" WEIGHT="6.058406471290777"/>
<CONT_DATA CI_END="8.60334995855648" CI_START="1.596650041443508" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="144.1" MEAN_2="139.0" MODIFIED="2015-06-10 15:58:08 +0100" MODIFIED_BY="[Empty name]" ORDER="325" SD_1="3.4" SD_2="3.5" SE="1.7874562931719478" STUDY_ID="STD-Ishikawa-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="5.631401043411655"/>
<CONT_DATA CI_END="7.296559190823639" CI_START="2.9034408091763497" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.9" MODIFIED="2015-06-10 15:58:08 +0100" MODIFIED_BY="[Empty name]" ORDER="324" SD_1="4.4" SD_2="2.4" SE="1.120714058089752" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.3820558078572205"/>
<CONT_DATA CI_END="15.43672033930391" CI_START="11.163279660696112" EFFECT_SIZE="13.300000000000011" ESTIMABLE="YES" MEAN_1="152.5" MEAN_2="139.2" MODIFIED="2015-06-10 15:58:08 +0100" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="4.4" SD_2="2.1" SE="1.0901834707974618" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.411808777140165"/>
<CONT_DATA CI_END="5.06624387107141" CI_START="2.4337561289285903" EFFECT_SIZE="3.75" ESTIMABLE="YES" MEAN_1="143.7" MEAN_2="139.95" MODIFIED="2015-06-10 15:58:08 +0100" MODIFIED_BY="[Empty name]" ORDER="321" SD_1="1.7" SD_2="1.8" SE="0.6715653356152326" STUDY_ID="STD-Veroli-1992" TOTAL_1="10" TOTAL_2="20" WEIGHT="6.755931379000886"/>
<CONT_DATA CI_END="5.086540996510735" CI_START="0.9134590034892653" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="139.0" MODIFIED="2015-06-10 15:58:08 +0100" MODIFIED_BY="[Empty name]" ORDER="323" SD_1="5.0" SD_2="3.0" SE="1.0645812948447542" STUDY_ID="STD-Wang-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.436332202917024"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="331.0852501546143" CI_END="12.699498546878337" CI_START="5.156555708153212" DF="5" EFFECT_SIZE="8.928027127515774" ESTIMABLE="YES" I2="98.48981493507638" ID="CMP-003.10.02" MODIFIED="2015-06-10 15:58:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="-4.440892098500626E-16" P_Z="3.4886353769318742E-6" STUDIES="6" TAU2="20.9358850170795" TOTAL_1="216" TOTAL_2="202" WEIGHT="38.434527704705424" Z="4.639730671983999">
<NAME>7.1 - 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="17.656471900648683" CI_START="14.343528099351317" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="159.0" MEAN_2="143.0" MODIFIED="2015-06-10 15:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="330" SD_1="3.0" SD_2="1.0" SE="0.8451542547285166" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="6.628920558622434"/>
<CONT_DATA CI_END="6.239590064609123" CI_START="3.760409935390877" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="327" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.781098924805759"/>
<CONT_DATA CI_END="11.177791774053645" CI_START="8.822208225946355" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="326" SD_1="3.0" SD_2="2.0" SE="0.6009252125773316" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="6.800416227800117"/>
<CONT_DATA CI_END="10.883691816105333" CI_START="7.116308183894668" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="141.0" MODIFIED="2015-06-10 15:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="328" SD_1="3.0" SD_2="3.0" SE="0.9610849132757812" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="6.531264536665941"/>
<CONT_DATA CI_END="4.108845105227348" CI_START="3.8911548947726513" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="140.0" MEAN_2="136.0" MODIFIED="2015-06-10 15:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="0.4" SD_2="0.4" SE="0.055534237407373274" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="6.983569286077757"/>
<CONT_DATA CI_END="14.967291566049926" CI_START="5.032708433950074" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="147.0" MEAN_2="137.0" MODIFIED="2015-06-10 15:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="329" SD_1="9.0" SD_2="5.0" SE="2.534379001467011" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="4.7092581707334205"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="35.37234968122518" CI_END="13.994677224066082" CI_START="5.4983062550918" DF="3" EFFECT_SIZE="9.746491739578941" ESTIMABLE="YES" I2="91.51879921171216" ID="CMP-003.10.03" MODIFIED="2015-06-10 15:58:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0163920727279674E-7" P_Z="6.901953447983406E-6" STUDIES="4" TAU2="16.508707361237516" TOTAL_1="74" TOTAL_2="70" WEIGHT="23.889536613676825" Z="4.496689905595784">
<NAME>&gt; 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="7.45418540826402" CI_START="5.345814591735992" EFFECT_SIZE="6.400000000000006" ESTIMABLE="YES" MEAN_1="145.4" MEAN_2="139.0" MODIFIED="2015-06-10 15:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="334" SD_1="1.4" SD_2="1.0" SE="0.5378595813899101" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="6.836381351954318"/>
<CONT_DATA CI_END="7.342605027587306" CI_START="2.657394972412694" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="137.0" MODIFIED="2015-06-10 15:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="332" SD_1="1.0" SD_2="3.0" SE="1.1952286093343936" STUDY_ID="STD-Kimura-1994" TOTAL_1="7" TOTAL_2="7" WEIGHT="6.307229637733799"/>
<CONT_DATA CI_END="15.914137131395655" CI_START="8.085862868604345" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="151.0" MEAN_2="139.0" MODIFIED="2015-06-10 15:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="333" SD_1="7.6" SD_2="7.6" SE="1.9970454366865256" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="5.372885355236105"/>
<CONT_DATA CI_END="20.9138926645475" CI_START="13.0861073354525" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="157.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="331" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="5.3730402687526055"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="451.4913044911148" CI_END="11.531583224492888" CI_START="6.659102185742769" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="9.095342705117828" ESTIMABLE="YES" I2="97.78511791909897" I2_Q="94.81504320983497" ID="CMP-003.11" MODIFIED="2016-04-26 14:50:19 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.1102230246251565E-16" P_Q="4.20689527658169E-9" P_Z="2.531325537673359E-13" Q="38.57312762555045" RANDOM="YES" SCALE="23.53" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="15.467744788831522" TOTALS="YES" TOTAL_1="314" TOTAL_2="305" UNITS="" WEIGHT="100.0" Z="7.3172348901137605">
<NAME>Peak serum sodium (meq/L) by volume given to control group</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.718802162558247" CI_END="6.343225571459901" CI_START="3.5268441100558627" DF="3" EFFECT_SIZE="4.935034840757882" ESTIMABLE="YES" I2="55.349183866165184" ID="CMP-003.11.01" MODIFIED="2015-06-10 15:59:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0814216319018416" P_Z="6.477318874011351E-12" STUDIES="4" TAU2="1.037786659031118" TOTAL_1="68" TOTAL_2="73" WEIGHT="35.739674943108355" Z="6.868736130306599">
<NAME>&lt; 2000 mL/kg</NAME>
<CONT_DATA CI_END="6.239590064609123" CI_START="3.760409935390877" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:59:07 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.737084418942466"/>
<CONT_DATA CI_END="7.296559190823639" CI_START="2.9034408091763497" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.9" MODIFIED="2015-06-10 15:59:07 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="4.4" SD_2="2.4" SE="1.120714058089752" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.238694592509512"/>
<CONT_DATA CI_END="5.06624387107141" CI_START="2.4337561289285903" EFFECT_SIZE="3.75" ESTIMABLE="YES" MEAN_1="143.7" MEAN_2="139.95" MODIFIED="2015-06-10 15:59:07 +0100" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="1.7" SD_2="1.8" SE="0.6715653356152326" STUDY_ID="STD-Veroli-1992" TOTAL_1="10" TOTAL_2="20" WEIGHT="9.705889038153746"/>
<CONT_DATA CI_END="14.967291566049926" CI_START="5.032708433950074" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="147.0" MEAN_2="137.0" MODIFIED="2015-06-10 15:59:07 +0100" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="9.0" SD_2="5.0" SE="2.534379001467011" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="7.058006893502634"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="315.9604409689593" CI_END="13.558385281986526" CI_START="4.5368432404140595" DF="3" EFFECT_SIZE="9.047614261200293" ESTIMABLE="YES" I2="99.05051404827773" ID="CMP-003.11.02" MODIFIED="2015-06-10 15:59:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.551115123125783E-16" P_Z="8.450304012491207E-5" STUDIES="4" TAU2="20.847877686955567" TOTAL_1="170" TOTAL_2="158" WEIGHT="39.10137139013587" Z="3.93125654488945">
<NAME>2000 - 5000 mL</NAME>
<CONT_DATA CI_END="17.656471900648683" CI_START="14.343528099351317" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="159.0" MEAN_2="143.0" MODIFIED="2015-06-10 15:59:09 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="3.0" SD_2="1.0" SE="0.8451542547285166" STUDY_ID="STD-Bruegger-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="9.547971777541987"/>
<CONT_DATA CI_END="7.45418540826402" CI_START="5.345814591735992" EFFECT_SIZE="6.400000000000006" ESTIMABLE="YES" MEAN_1="145.4" MEAN_2="139.0" MODIFIED="2015-06-10 15:59:09 +0100" MODIFIED_BY="[Empty name]" ORDER="152" SD_1="1.4" SD_2="1.0" SE="0.5378595813899101" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="9.805496014607346"/>
<CONT_DATA CI_END="11.177791774053645" CI_START="8.822208225946355" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:59:09 +0100" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="3.0" SD_2="2.0" SE="0.6009252125773316" STUDY_ID="STD-Jarvela-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="9.761006829789062"/>
<CONT_DATA CI_END="4.108845105227348" CI_START="3.8911548947726513" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="140.0" MEAN_2="136.0" MODIFIED="2015-06-10 15:59:09 +0100" MODIFIED_BY="[Empty name]" ORDER="215" SD_1="0.4" SD_2="0.4" SE="0.055534237407373274" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="9.986896768197468"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.587045675054313" CI_END="16.419151530600594" CI_START="11.435303954609632" DF="2" EFFECT_SIZE="13.927227742605112" ESTIMABLE="YES" I2="44.243810054921674" ID="CMP-003.11.03" MODIFIED="2015-06-10 15:59:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16637309172372883" P_Z="6.34833011081534E-28" STUDIES="3" TAU2="2.197856758317195" TOTAL_1="76" TOTAL_2="74" WEIGHT="25.158953666755778" Z="10.954133072404623">
<NAME>&gt; 5000 mL</NAME>
<CONT_DATA CI_END="15.914137131395655" CI_START="8.085862868604345" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="151.0" MEAN_2="139.0" MODIFIED="2015-06-10 15:59:11 +0100" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="7.6" SD_2="7.6" SE="1.9970454366865256" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="7.941307803632448"/>
<CONT_DATA CI_END="20.9138926645475" CI_START="13.0861073354525" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="157.0" MEAN_2="140.0" MODIFIED="2015-06-10 15:59:11 +0100" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="7.941511145729693"/>
<CONT_DATA CI_END="15.43672033930391" CI_START="11.163279660696112" EFFECT_SIZE="13.300000000000011" ESTIMABLE="YES" MEAN_1="152.5" MEAN_2="139.2" MODIFIED="2015-06-10 15:59:11 +0100" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="4.4" SD_2="2.1" SE="1.0901834707974618" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.276134717393637"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="94.45478740606508" CI_END="4.436937503510181" CI_START="2.4597054741159945" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="3.4483214888130873" ESTIMABLE="YES" I2="88.35421654943698" I2_Q="39.391069260586484" ID="CMP-003.12" MODIFIED="2016-04-26 14:50:57 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="2.220446049250313E-15" P_Q="0.1920651017894628" P_Z="8.120146324681952E-12" Q="3.299843728639508" RANDOM="YES" SCALE="17.14" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.9042664770921094" TOTALS="YES" TOTAL_1="329" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="6.836411533612459">
<NAME>Final serum sodium (meq/L) by type of surgery</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="44.242237443773945" CI_END="5.279774658030549" CI_START="2.549541902356658" DF="5" EFFECT_SIZE="3.914658280193603" ESTIMABLE="YES" I2="88.69858242057866" ID="CMP-003.12.01" MODIFIED="2015-06-10 16:00:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.0682446866260307E-8" P_Z="1.9044383398693893E-8" STUDIES="6" TAU2="1.6081565247958638" TOTAL_1="202" TOTAL_2="188" WEIGHT="45.901768295949026" Z="5.62046530649522">
<NAME>Cardiovascular surgery</NAME>
<CONT_DATA CI_END="8.313033022740777" CI_START="-2.313033022740777" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="143.0" MEAN_2="140.0" MODIFIED="2015-06-10 16:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="395" SD_1="5.3" SD_2="4.0" SE="2.710780945287415" STUDY_ID="STD-Bruegger-2005" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.7497633679235376"/>
<CONT_DATA CI_END="5.850452840520893" CI_START="3.149547159479107" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="144.0" MEAN_2="139.5" MODIFIED="2015-06-10 16:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="392" SD_1="2.0" SD_2="1.0" SE="0.6890192121758832" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="10.694540062318946"/>
<CONT_DATA CI_END="2.6197950323045616" CI_START="1.3802049676954384" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="141.0" MEAN_2="139.0" MODIFIED="2015-06-10 16:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="393" SD_1="1.0" SD_2="1.0" SE="0.31622776601683794" STUDY_ID="STD-Jarvela-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.694150357529978"/>
<CONT_DATA CI_END="4.108845105227348" CI_START="3.8911548947726513" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="140.0" MEAN_2="136.0" MODIFIED="2015-06-10 16:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="204" SD_1="0.4" SD_2="0.4" SE="0.055534237407373274" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="13.339163218843947"/>
<CONT_DATA CI_END="16.25248844742248" CI_START="3.74751155257752" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="146.0" MEAN_2="136.0" MODIFIED="2015-06-10 16:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="396" SD_1="7.6" SD_2="15.2" SE="3.1901037451408856" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="2.105984624204618"/>
<CONT_DATA CI_END="9.9138926645475" CI_START="2.0861073354524997" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.0" MODIFIED="2015-06-10 16:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="394" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="4.3181666651279995"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.55072667538626" CI_START="0.44927332461374014" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.02" MODIFIED="2015-06-10 16:00:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.01147794885155641" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.055249218652936" Z="2.5278006958277937">
<NAME>Transurethral resection of prostate</NAME>
<CONT_DATA CI_END="3.55072667538626" CI_START="0.44927332461374014" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="140.6" MEAN_2="138.6" MODIFIED="2015-06-10 16:00:26 +0100" MODIFIED_BY="[Empty name]" ORDER="397" SD_1="2.6" SD_2="2.4" SE="0.7912016177940993" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.055249218652936"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="36.89126708777913" CI_END="5.324741073315581" CI_START="0.7743215701306707" DF="4" EFFECT_SIZE="3.0495313217231255" ESTIMABLE="YES" I2="89.15732552508324" ID="CMP-003.12.03" MODIFIED="2015-06-10 16:00:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.896657119138112E-7" P_Z="0.00861418299574892" STUDIES="5" TAU2="5.514301679967745" TOTAL_1="107" TOTAL_2="103" WEIGHT="44.042982485398035" Z="2.626998041002936">
<NAME>Other surgery</NAME>
<CONT_DATA CI_END="6.239590064609123" CI_START="3.760409935390877" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="140.0" MODIFIED="2015-06-10 16:00:28 +0100" MODIFIED_BY="[Empty name]" ORDER="401" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.041457344322213"/>
<CONT_DATA CI_END="2.0004004767154084" CI_START="-4.004767154086597E-4" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="138.0" MODIFIED="2015-06-10 16:00:28 +0100" MODIFIED_BY="[Empty name]" ORDER="399" SD_1="2.0" SD_2="1.0" SE="0.5104177855340404" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="11.75283847046505"/>
<CONT_DATA CI_END="6.945358657929768" CI_START="3.4546413420702087" EFFECT_SIZE="5.199999999999989" ESTIMABLE="YES" MEAN_1="141.5" MEAN_2="136.3" MODIFIED="2015-06-10 16:00:28 +0100" MODIFIED_BY="[Empty name]" ORDER="243" SD_1="2.5" SD_2="3.1" SE="0.8905054744357275" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.432683137853461"/>
<CONT_DATA CI_END="6.086540996510735" CI_START="1.9134590034892653" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="138.0" MODIFIED="2015-06-10 16:00:28 +0100" MODIFIED_BY="[Empty name]" ORDER="398" SD_1="5.0" SD_2="3.0" SE="1.0645812948447542" STUDY_ID="STD-Wang-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="8.375843298857959"/>
<CONT_DATA CI_END="2.5929500903498006" CI_START="-6.592950090349801" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="136.0" MEAN_2="138.0" MODIFIED="2015-06-10 16:00:28 +0100" MODIFIED_BY="[Empty name]" ORDER="400" SD_1="7.0" SD_2="6.0" SE="2.3433849430797733" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="3.4401602338993573"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="94.45478740606511" CI_END="4.4369375035101815" CI_START="2.4597054741159954" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="3.4483214888130886" ESTIMABLE="YES" I2="88.354216549437" I2_Q="52.57832183425146" ID="CMP-003.13" MODIFIED="2016-04-26 14:51:32 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.5543122344752192E-15" P_Q="0.12139085158303842" P_Z="8.120146324681921E-12" Q="4.217480437975198" RANDOM="YES" SCALE="16.69" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.90426647709211" TOTALS="YES" TOTAL_1="329" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="6.83641153361246">
<NAME>Final serum sodium (meq/L) by dose of HS</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.449700293988379" CI_END="5.677274801861241" CI_START="1.7030959650109607" DF="2" EFFECT_SIZE="3.6901853834361007" ESTIMABLE="YES" I2="73.15328239964335" ID="CMP-003.13.01" MODIFIED="2015-06-10 16:01:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02411680313579767" P_Z="2.728379487521434E-4" STUDIES="3" TAU2="2.2468729267336887" TOTAL_1="70" TOTAL_2="70" WEIGHT="27.863775655364357" Z="3.6398112640260956">
<NAME>&lt; 7.1 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="3.55072667538626" CI_START="0.44927332461374014" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="140.6" MEAN_2="138.6" MODIFIED="2015-06-10 16:01:23 +0100" MODIFIED_BY="[Empty name]" ORDER="382" SD_1="2.6" SD_2="2.4" SE="0.7912016177940993" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.055249218652936"/>
<CONT_DATA CI_END="6.945358657929768" CI_START="3.4546413420702087" EFFECT_SIZE="5.199999999999989" ESTIMABLE="YES" MEAN_1="141.5" MEAN_2="136.3" MODIFIED="2015-06-10 16:01:23 +0100" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="2.5" SD_2="3.1" SE="0.8905054744357275" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.432683137853461"/>
<CONT_DATA CI_END="6.086540996510735" CI_START="1.9134590034892653" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="138.0" MODIFIED="2015-06-10 16:01:23 +0100" MODIFIED_BY="[Empty name]" ORDER="383" SD_1="5.0" SD_2="3.0" SE="1.0645812948447542" STUDY_ID="STD-Wang-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="8.375843298857959"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="81.05406162660152" CI_END="4.095220096213602" CI_START="1.1735404990365779" DF="5" EFFECT_SIZE="2.63438029762509" ESTIMABLE="YES" I2="93.83127766868252" ID="CMP-003.13.02" MODIFIED="2015-06-10 16:01:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="-4.440892098500626E-16" P_Z="4.0859798335963045E-4" STUDIES="6" TAU2="2.366022783230948" TOTAL_1="192" TOTAL_2="178" WEIGHT="55.01753299298407" Z="3.5344673042971197">
<NAME>7.1 - 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="8.313033022740777" CI_START="-2.313033022740777" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="143.0" MEAN_2="140.0" MODIFIED="2015-06-10 16:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="387" SD_1="5.3" SD_2="4.0" SE="2.710780945287415" STUDY_ID="STD-Bruegger-2005" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.7497633679235385"/>
<CONT_DATA CI_END="6.239590064609123" CI_START="3.760409935390877" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="140.0" MODIFIED="2015-06-10 16:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="386" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.041457344322215"/>
<CONT_DATA CI_END="2.6197950323045616" CI_START="1.3802049676954384" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="141.0" MEAN_2="139.0" MODIFIED="2015-06-10 16:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="384" SD_1="1.0" SD_2="1.0" SE="0.31622776601683794" STUDY_ID="STD-Jarvela-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.694150357529976"/>
<CONT_DATA CI_END="2.0004004767154084" CI_START="-4.004767154086597E-4" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="138.0" MODIFIED="2015-06-10 16:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="388" SD_1="2.0" SD_2="1.0" SE="0.5104177855340404" STUDY_ID="STD-K_x00f8_lsen_x002d_Petersen-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="11.752838470465049"/>
<CONT_DATA CI_END="4.108845105227348" CI_START="3.8911548947726513" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="140.0" MEAN_2="136.0" MODIFIED="2015-06-10 16:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="203" SD_1="0.4" SD_2="0.4" SE="0.055534237407373274" STUDY_ID="STD-Leverve-2008" TOTAL_1="109" TOTAL_2="99" WEIGHT="13.339163218843945"/>
<CONT_DATA CI_END="2.5929500903498006" CI_START="-6.592950090349801" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="136.0" MEAN_2="138.0" MODIFIED="2015-06-10 16:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="385" SD_1="7.0" SD_2="6.0" SE="2.3433849430797733" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="3.4401602338993587"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.194527102496506" CI_END="7.959558274526254" CI_START="3.1613479191831484" DF="2" EFFECT_SIZE="5.560453096854701" ESTIMABLE="YES" I2="37.39292434122688" ID="CMP-003.13.03" MODIFIED="2015-06-10 16:01:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2024498867681861" P_Z="5.555224679506543E-6" STUDIES="3" TAU2="1.9300471203979936" TOTAL_1="67" TOTAL_2="63" WEIGHT="17.118691351651563" Z="4.542646945615256">
<NAME>&gt; 10 mL 3% HS/kg</NAME>
<CONT_DATA CI_END="5.850452840520893" CI_START="3.149547159479107" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="144.0" MEAN_2="139.5" MODIFIED="2015-06-10 16:01:27 +0100" MODIFIED_BY="[Empty name]" ORDER="391" SD_1="2.0" SD_2="1.0" SE="0.6890192121758832" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="10.694540062318945"/>
<CONT_DATA CI_END="16.25248844742248" CI_START="3.74751155257752" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="146.0" MEAN_2="136.0" MODIFIED="2015-06-10 16:01:27 +0100" MODIFIED_BY="[Empty name]" ORDER="389" SD_1="7.6" SD_2="15.2" SE="3.1901037451408856" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="2.1059846242046185"/>
<CONT_DATA CI_END="9.9138926645475" CI_START="2.0861073354524997" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.0" MODIFIED="2015-06-10 16:01:27 +0100" MODIFIED_BY="[Empty name]" ORDER="390" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="4.318166665128"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="44.063585815498406" CI_END="5.173570044963917" CI_START="2.291948917834621" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="3.732759481399269" ESTIMABLE="YES" I2="81.84441903231085" I2_Q="62.08893540449533" ID="CMP-003.14" MODIFIED="2016-04-26 14:52:00 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="5.534363918258123E-7" P_Q="0.07152198065451032" P_Z="3.8193314334362517E-7" Q="5.275504714360228" RANDOM="YES" SCALE="17.14" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="3.0582267426077716" TOTALS="YES" TOTAL_1="171" TOTAL_2="162" UNITS="" WEIGHT="100.0" Z="5.077748825211685">
<NAME>Final serum sodium (meq/L) by volume given to control group</NAME>
<GROUP_LABEL_1>Hypertonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Isotonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Isotonic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.698811244937922" CI_END="5.387530281983101" CI_START="-0.7388015466427689" DF="2" EFFECT_SIZE="2.324364367670166" ESTIMABLE="YES" I2="86.3934574934502" ID="CMP-003.14.01" MODIFIED="2015-06-10 16:02:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.429794799132083E-4" P_Z="0.13695078223895146" STUDIES="3" TAU2="5.7329002205780135" TOTAL_1="58" TOTAL_2="53" WEIGHT="36.6153350780178" Z="1.4872424723371782">
<NAME>&lt; 2000 mL</NAME>
<CONT_DATA CI_END="6.239590064609123" CI_START="3.760409935390877" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="140.0" MODIFIED="2015-06-10 16:02:19 +0100" MODIFIED_BY="[Empty name]" ORDER="337" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Jarvela-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="15.626586522811797"/>
<CONT_DATA CI_END="3.55072667538626" CI_START="0.44927332461374014" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="140.6" MEAN_2="138.6" MODIFIED="2015-06-10 16:02:19 +0100" MODIFIED_BY="[Empty name]" ORDER="336" SD_1="2.6" SD_2="2.4" SE="0.7912016177940993" STUDY_ID="STD-Kato-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.668011277343673"/>
<CONT_DATA CI_END="2.5929500903498006" CI_START="-6.592950090349801" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="136.0" MEAN_2="138.0" MODIFIED="2015-06-10 16:02:19 +0100" MODIFIED_BY="[Empty name]" ORDER="335" SD_1="7.0" SD_2="6.0" SE="2.3433849430797733" STUDY_ID="STD-Younes-1988" TOTAL_1="18" TOTAL_2="13" WEIGHT="6.320737277862327"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.917303889242117" CI_END="5.269861450538045" CI_START="1.0167063478797194" DF="2" EFFECT_SIZE="3.1432838992088823" ESTIMABLE="YES" I2="81.68045865270092" ID="CMP-003.14.02" MODIFIED="2015-06-10 16:02:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.004259312714329999" P_Z="0.003767339045521845" STUDIES="3" TAU2="2.403421735924749" TOTAL_1="37" TOTAL_2="35" WEIGHT="37.59983466403084" Z="2.897013199346263">
<NAME>2000 - 5000 mL</NAME>
<CONT_DATA CI_END="8.313033022740777" CI_START="-2.313033022740777" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="143.0" MEAN_2="140.0" MODIFIED="2015-06-10 16:02:21 +0100" MODIFIED_BY="[Empty name]" ORDER="338" SD_1="5.3" SD_2="4.0" SE="2.710780945287415" STUDY_ID="STD-Bruegger-2005" TOTAL_1="6" TOTAL_2="6" WEIGHT="5.192905149685101"/>
<CONT_DATA CI_END="5.850452840520893" CI_START="3.149547159479107" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="144.0" MEAN_2="139.5" MODIFIED="2015-06-10 16:02:21 +0100" MODIFIED_BY="[Empty name]" ORDER="340" SD_1="2.0" SD_2="1.0" SE="0.6890192121758832" STUDY_ID="STD-Cross-1989" TOTAL_1="11" TOTAL_2="9" WEIGHT="15.295973331307247"/>
<CONT_DATA CI_END="2.6197950323045616" CI_START="1.3802049676954384" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="141.0" MEAN_2="139.0" MODIFIED="2015-06-10 16:02:21 +0100" MODIFIED_BY="[Empty name]" ORDER="339" SD_1="1.0" SD_2="1.0" SE="0.31622776601683794" STUDY_ID="STD-Jarvela-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="17.110956183038486"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.1437664312140194" CI_END="7.427200337976506" CI_START="3.9780765049394233" DF="2" EFFECT_SIZE="5.702638421457965" ESTIMABLE="YES" I2="6.706254427755183" ID="CMP-003.14.03" MODIFIED="2015-06-10 16:02:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34236337536584416" P_Z="9.108860856688782E-11" STUDIES="3" TAU2="0.24901108075777495" TOTAL_1="76" TOTAL_2="74" WEIGHT="25.784830257951363" Z="6.4810464709063345">
<NAME>&gt; 5000 mL</NAME>
<CONT_DATA CI_END="16.25248844742248" CI_START="3.74751155257752" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="146.0" MEAN_2="136.0" MODIFIED="2015-06-10 16:02:23 +0100" MODIFIED_BY="[Empty name]" ORDER="341" SD_1="7.6" SD_2="15.2" SE="3.1901037451408856" STUDY_ID="STD-Shackford-1983" TOTAL_1="30" TOTAL_2="28" WEIGHT="4.083137571833272"/>
<CONT_DATA CI_END="9.9138926645475" CI_START="2.0861073354524997" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="139.0" MODIFIED="2015-06-10 16:02:23 +0100" MODIFIED_BY="[Empty name]" ORDER="342" SD_1="7.2" SD_2="7.2" SE="1.996920706410825" STUDY_ID="STD-Shackford-1987" TOTAL_1="26" TOTAL_2="26" WEIGHT="7.669727543429612"/>
<CONT_DATA CI_END="6.945358657929768" CI_START="3.4546413420702087" EFFECT_SIZE="5.199999999999989" ESTIMABLE="YES" MEAN_1="141.5" MEAN_2="136.3" MODIFIED="2015-06-10 16:02:23 +0100" MODIFIED_BY="[Empty name]" ORDER="242" SD_1="2.5" SD_2="3.1" SE="0.8905054744357275" STUDY_ID="STD-Shao-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.03196514268848"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-05-05 15:31:27 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-04-26 11:23:33 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfUAAAN0CAYAAACtO7FFAACAAElEQVR42uydAWRX3///v+Tj4yPJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-05-05 15:31:27 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-05-05 15:31:27 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each 'Risk of bias' item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWcAAANxCAIAAAC3yu91AAAsMUlEQVR42u3dv44lR93G8ZGQEMEG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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-04-27 15:34:48 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.04" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Hypertonic salt versus isotonic salt solution for peri-operative resuscitation, outcome: 1.4 Total volume of crystalloid administered (L).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAKo0lEQVR42u3dT2ybZx3A8Tfx6yR2UqdvFm9jCA6D8U9CII0xBkJM
GpdJ2wnENCEOFZddkbhw4IKEEBJoXLggYBe0cUECNGligNodOlAPk6ZJgxYmJnXVtib128Rt7MRx
je3Xzdqo/+K8dvL6/Xw0bOpSRXnz7fM87y8Om4oCSN+0S4CwEBb5Ft7p/zDu/idKnvr/JYijuH8+
6z7Gg9diBzb2GFYcDR6ia16Ir5Y2+M1IWaS+FUaxq8lwYUW7VrBuS9evUeJij1thFF/d8XYVBvs6
vO8+Y0EaW6E9jjEe3q+9DZywO8ILnUL8lUWBDKtQuuH61Gzuer3UfanZTafZV+r+uhQ0d/5pJr85
QXFVf9P6+7OVP86c/+l1L9d+ee/bRxY2dXNbUzdKIb6DYWcc3emLWdQqza91H8OLwfLC2jUvP/pa
rfHxy9PnlpQzqq3wRpOFyVmw7ip2c6qWSz++90SjXNtZr+bebJSWapda9wtnqK2wtw82S7f5k6U7
eimjtisbQatdPvv01s/LX/hhc/Dqfcfr/Wu2sLmtnP2EFTebV89UOVPbKgTTM8c/dSXulN/ZvDA4
aL25EVz4ZGczuDTdUc5+tsKoK3nImyf+GQRh/EhwLOhE310d7Hyt16fqndNbpVpdV/s/vOfz+8qL
jfeWpueaRzrvVILnH79nq/faqS93Fmu9c/2R84+eVM5+z1j52wZ7NueOr7Xu+dbJTmM2+H3l4bO9
116Ynms0C70T1i9+11LOMGH1hlZRkOewgtaP/tR+u9a5tD3bPWu91r8GVy5emZ26cvJnP7j4ar2g
nKHOWHk8Vu1ybPNKcD5c3W5Vin9LXllpBBt/KX1t6uvBYlE4Q52xdp+38vqXbnr63teD4HPvt670
fllcTxbvU4+0dbO/u8KcO/Jw+9x99y+strb6I9LS0Qv9lx+ac2msWPvy+PPLcXu50P5wvf9thnJl
Y+bMfx+a2bATDnl4332HmFfvzR97tTMfXp5OJu2t4uZnv/1C+X/PysaKNeQ9YVhcWV5YC+ul9Ur3
l9VPmFs5Y6Xg3VL56MKJZrl7H9h3+kXXxFaYwnr1h86ljcJzKz954HvFzdnuC994wfdwbIX71ykn
K9Xi5cKl+kebK9VCeFkptsJ9K748eO5Mf2x5u/5ScXu75qoIa3iD97mvfCb55ZnVc+fCB5vfmT7b
9s4+W+HwqqWVlx946ZnprV8fS85aH7nUfr93VxhUtppSEdawZ/Zyuff29lp1rvVe/z3tldb2eqsf
Vsv7ZGyFQwvD/o9NLC1sF5/8/nKtWmmsn38j+a26eYMVa2iFaDXZEWvtaGN7tTqzVgzrgxVrzved
rVjDWn03eT69GsSb7Wh7oxiUnxgsZrMuj7CG1Xufe89mdeel9VeXOtVaqzP7lstjKxxW733uyZm9
8cGLUePBf0zNlVeUIqyhzX/+jZkznSVvixFWyp57Znv10+tr13bVf3cDwkqbsBzeERbCAmGlzxFL
WAgLYeXcuksgLISFsEBYCCsbzLGEhbAQVs6ZYwkLYSEsEBbCyghzLGEhLISVc+ZYwkJYCAuEhbAy
whxLWAgLYeWcOZawEBbCAmEhrIwwxxIWwkJYOWeOJSwyEFbsyjCCsHTFKMLK+b/mhFGFpasd5lhD
Cm/1m/HVB6WRZliRbZF07woZMMcSFsIir2E5WGHFQliZY44lLISFsHLOHEtYt9aqFOLCoi+4sNJV
LW1FCyca5Zov+XhM3W5iNRnfK2yVy2vdp9qTb+7xrWbrbguFdQudUrP/vNjcFJatMD3hX5Pnf7f3
+Ad1JaxbrlhfSp5nV3zJbYUpKpz4anLWmmv7mlux0jP/2KlkS5zZ4x80x7Ji3bqs5vzp2SN3bTSK
Du/CStPS5XteX5555YuBsIR1CAjLGQthZYcFS1gIC2HlnDmWsBAWwgJhIayMMMcSFsJCWIdCa6EQ
hwfys1vmWJMcVrXcPtE5+pSf3cqQLLxtplWa7/3s1qlHKuP/vwn3tpkJDqtTbvSfF5/6lbBshekJ
55Pn4p99vYSVotV3k+cz/xr/x7ZgTfBWGB73s1tWrBGYfyy5HbxrxtdLWClaK1Yry6dalY1Xxv+x
zbEmeCsMgqVv/nalWlwvHkBYDlmTHNbBEdYEb4UIC4R1J+yEwkJYCCvnzLGEhbAQFggLYWWEOZaw
EBbCyjlzLGEhLIQFwkJYGWGOJSyEhbByzhxrSOENX42DIHJtSDus3s8Sxsoi7a1QU4xmK/xgR0we
lMYe3exH7Hd2Qlsi7go57GFZpxhFWLq6yhwrzcN7bJDFKMLSFA7vCAthkfB+LGEhLISVc+ZYwkJY
CAuEhbAywhxLWAgLYeWcOZawEBbCAmEhrIwwxxIWwkJYOWeOJSyEhbBAWAgrI8yxhIWwEFbOmWMJ
C2EhLBAWwsoIcyxhISyElXPmWMJCWAgLhIWwMsIcS1gIC2HlnDmWsBAWwgJhIayMMMcSFsJCWDln
jiUshIWwQFgIKyPMsYTF4Q8rjmOXZkxqC2EcLuYjrDiKImX1jXyOderudv0/9ebcqQm7cFPRTX4j
jq5/zmtYIz5k1e5euNh9apX6T8ISVkoW2o3kJmGrOVkXLrxJVkHUfxw85DuuUWrWS/3nC4+ezMVd
YXLG6h61ouSBEVl5I3muv+iMRZo7xmDFas2183BX6As+LvNHW0lgs3kYN0RxbKEaj7VCqVKttTqz
Z/OyFe7eEt0VjkjUaK0uz771IWEJi6HvCkFYCAth0eOIJSyEhbByzs8VCgthISwQFsLKCHMsYSEs
hJVz5ljCQlgIC4SFsDLCHEtYCAth5Zw5lrAQFsICYSGsjDDHEhbCQlg5Z44lLISFsEBYCCsjzLGE
hbAQVs6ZYwkLYSEsEBbCyghzLGEhLISVc+ZYwkJYCAuEhbAywhxLWAgLYeWcOZawEBbCAmEhrIww
x0o5rNilYQRh6Qpb4SiZYw0pvPGCFcU761bvIXKhSCOsgajfmItESluhmBjNGSuOHd9JfyuMLFpX
mWO5KyQLYVmwsGKNkDmWsBAWwgJhIayMMMcSFsJCWDlnjiUshIWwQFgIKyPMsYSFsBBWzpljCQth
ISwQFsLKCHMsYSEshJVz5ljCQlgIC4SFsDLCHEtYCAth5Zw5lrAQFsICYSGsjDDHEhbCQlg5Z44l
LISFsEBYCCsjzLGEhbAQVs6ZYwmLwyR0CRhC8i+j7z7GvedIWKRY1k5UcWQrZASiWFh7ZI5185Zu
sE4JC3eFCGvymGMJizEfsqLrbhF3MW5gf3o3hOZYpLVeXfPPHrbCuGv4fsf/N2biP2T2PmJ40yDp
McdK8/Ae64qRrFixNYv9mYpusmLtfJMR7vA4f9sVKxr+pDX+XfQA9u08fJL7/YgGpIzx8O66MIrD
e+TwzigO7zCSFWu/R77xLnhxMOb1dfzr+Zg/xTS+imHqF+CDacUB3eiO47KP+y5t3H9x9v9pTqdf
+uSPGyb7U0zno4WZ/Xt1gDvTZH+K6XykCXjbTDT5q1YGP8Uwi3+nrvugObitzeKnGGb5czcqObyy
/y2dHHybIIufYsoD0gOaY0Xj/jqPf441zo+YxlfR5B1bIcJCWCAshIWwQFgIC2GBsBAWwgJhISyE
BcLiEPs/8jqbl+gKcG4AAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-04-27 15:34:48 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-003.10" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 3 Subgroup analysis - hypertonic salt versus isotonic salt solution for peri-operative resuscitation, outcome: 3.10 Peak serum sodium (meq/L) by dose of HS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-04-08 13:54:09 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2016-04-08 17:14:27 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-04-08 17:13:51 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-04-08 17:13:51 +0100" MODIFIED_BY="[Empty name]">MEDLINE (Ovid SP) 1946 to April 2007.</TITLE>
<APPENDIX_BODY MODIFIED="2008-01-16 16:20:28 +0000" MODIFIED_BY="[Empty name]">
<P>#1 explode saline solution, hypertonic/ all subheadings<BR/>#2 explode hypertonic solutions/ all subheadings<BR/>#3 (hypertonic NaCl) or (hypertonic saline) or (hypertonic solution*)<BR/>#4 Ringer's solution/ all subheadings<BR/>#5 #1 or #2 or #3 or #4<BR/>#6 #5 not (explode glucose solution, hypertonic / all subheadings)<BR/>#7 #6 not colloid*<BR/>#8 explode surgical procedures, operative/ all subheadings<BR/>#9 explode specialties, surgical/ all subheadings<BR/>#10 explode surgery/ all subheadings<BR/>#11 (surg* near procedur*) or surger* or operat*<BR/>#12 #8 or #9 or #10 or #11<BR/>#13 #7 and #12<BR/>#14 RANDOMIZED-CONTROLLED-TRIAL in PT<BR/>#15 CONTROLLED-CLINICAL-TRIAL in PT<BR/>#16 explode RANDOMIZED-CONTROLLED-TRIALS/ all subheadings<BR/>#17 explode RANDOM-ALLOCATION/ all subheadings<BR/>#18 explode DOUBLE-BLIND-METHOD/ all subheadings<BR/>#19 explode SINGLE-BLIND-METHOD/ all subheadings<BR/>#20 #14 or #15 or #16 or #17 or #18 or #19<BR/>#21 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS))<BR/>#22 #20 not #21<BR/>#23 CLINICAL-TRIAL in PT<BR/>#24 explode CLINICAL-TRIALS / all subheadings<BR/>#25 (clin* near trial*) in TI<BR/>#26 (clin* near trial*) in AB<BR/>#27 (singl* or doubl* or trebl* or tripl*) near (blind* or mask*)<BR/>#28 (#27 in TI) or (#27 in AB)<BR/>#29 explode PLACEBOS/ all subheadings<BR/>#30 placebo* in TI<BR/>#31 placebo* in AB<BR/>#32 random* in TI<BR/>#33 random* in AB<BR/>#34 explode RESEARCH-DESIGN/ all subheadings<BR/>#35 #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33<BR/>or #34<BR/>#36 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS))<BR/>#37 #35 not #36<BR/>#38 #37 not #22<BR/>#39 TG=COMPARATIVE-STUDY<BR/>#40 explode EVALUATION-STUDIES/ all subheadings<BR/>#41 explode FOLLOW-UP-STUDIES/ all subheadings<BR/>#42 explode PROSPECTIVE-STUDIES/ all subheadings<BR/>#43 control* or prospectiv* or volunteer*<BR/>#44 (#43 in TI) or (#43 in AB)<BR/>#45 #39 or #40 or #41 or #42 or #43 or #44<BR/>#46 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS))<BR/>#47 #45 not #46<BR/>#48 #47 not (#22 or #38)<BR/>#49 #22 or #38 or #48<BR/>#50 #13 and #49<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-04-08 17:14:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-04-08 17:14:16 +0100" MODIFIED_BY="[Empty name]">EMBASE (Ovid SP) 1974 to April 2007.</TITLE>
<APPENDIX_BODY MODIFIED="2008-01-16 16:29:15 +0000" MODIFIED_BY="[Empty name]">
<P>#1 saline solution</P>
<P>#2 explode "hypertonic-solution" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
<P>#3 (hypertonic NaCl) or (hypertonic saline) or (hypertonic solution*)</P>
<P>#4 "Ringer-solution" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
<P>#5 sodium chloride in TI, AB</P>
<P>#6 #1 or #2 or #3 or #4 or #5</P>
<P>#7 #6 not (glucose or fructose)</P>
<P>#8 explode surgery/ all subheadings</P>
<P>#9 (surg* near procedur*) or surger* or operat*</P>
<P>#10 "surgical-technique" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
<P>#11 #8 or #9 or #10</P>
<P>#12 #7 and #11</P>
<P>#13 explode "randomized-controlled-trial" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
<P>#14 (randomi?ed controlled trial*) in TI, AB</P>
<P>#15 random*</P>
<P>#16 explode "randomization-" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
<P>#17 randomi?ation</P>
<P>#18 explode "clinical-trial" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
<P>#19 clinical near trial*</P>
<P>#20 explode multicenter-study / all subheadings</P>
<P>#21 multi?cent*</P>
<P>#22 explode phase-4-clinical-trial / all subheadings or explode double-blind-procedure / all subheadings or explode single-blind-procedure / all subheadings</P>
<P>#23 (RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*) in TI, AB, TW</P>
<P>#24 ((SINGL* or DOUBL* or TREBL* or TRIPL*) near (BLIND* or MASK*)) in TI,AB</P>
<P>#25 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24</P>
<P>#26 (human) in DER</P>
<P>#27 (animal or nonhuman) in DER</P>
<P>#28 #26 and #27</P>
<P>#29 #27 not #28</P>
<P>#30 #25 not #29</P>
<P>#31 #12 and #30</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-04-08 17:14:08 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-04-08 17:14:08 +0100" MODIFIED_BY="[Empty name]">CINAHL (1982 to April 2007)</TITLE>
<APPENDIX_BODY MODIFIED="2008-01-16 16:40:16 +0000" MODIFIED_BY="[Empty name]">
<P>#1 explode "Saline-Solution-Hypertonic" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#2 explode "Hypertonic-Solutions" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#3 (hypertonic NaCl) or (hypertonic saline) or (hypertonic solution*)</P>
<P>#4 explode "Lactated-Ringer's-Solution" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#5 explode "Sodium-Chloride" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#6 #1 or #2 or #3 or #4 or #5</P>
<P>#7 #6 not (glucose or fructose)</P>
<P>#8 explode "Surgery-Operative" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#9 (surg* near procedur*) or (surg* and procedur*)or surger* or operat*</P>
<P>#10 #8 or #9</P>
<P>#11 #7 and #10</P>
<P>#12 Randomized Clinical Trial*</P>
<P>#13 Controlled Clinical Trial*</P>
<P>#14 explode "Random-Assignment" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#15 "Double-Blind-Studies" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#16 "Single-Blind-Studies" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#17 explode "Clinical-Trials" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#18 (clin* near trial*) in TI</P>
<P>#19 (clin* near trial*) in AB</P>
<P>#20 (singl* or doubl* or trebl* or tripl*) near (blind* or mask*)</P>
<P>#21 (#20 in TI) or (#20 in AB)</P>
<P>#22 "Placebos-" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#23 placebo* in TI</P>
<P>#24 placebo* in AB</P>
<P>#25 random* in TI</P>
<P>#26 random* in AB</P>
<P>#27 "Study-Design" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#28 "Comparative-Studies" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#29 explode "Evaluation-Research" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#30 "Prospective-Studies" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE</P>
<P>#31 control* or prospectiv* or volunteer*</P>
<P>#32 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31</P>
<P>#33 sheep or dog* or cat* or guinea?pig* or mouse or experimental animal*</P>
<P>#34 explode animals/ all topical subheadings / all age subheadings</P>
<P>#35 #33 or #34</P>
<P>#36 human*</P>
<P>#37 #35 not (#34 and #35)</P>
<P>#38 #32 not #37</P>
<P>#39 #11 and #38<BR/>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-04-08 16:57:18 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-04-08 16:57:18 +0100" MODIFIED_BY="[Empty name]">LILACS (1982 to April 8, 2016)</TITLE>
<APPENDIX_BODY MODIFIED="2008-01-16 16:41:19 +0000" MODIFIED_BY="[Empty name]">
<P>"HYPERTONIC" or "HYPERTONIC SALINE SOLUTION/" or "HYPERTONIC SOLUTION, SALINE/" or "HYPERTONIC SOLUTIONS/" or "RINGER" or "SODIUM CHLORIDE" or "SODIUM CHLORIDE SOLUTION, HYPERTONIC/" [Words] and "SURGERY" or "SURGICAL" or "OPERATION" or "surg$" or "operat$" [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-04-08 17:14:27 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2016-04-08 17:14:27 +0100" MODIFIED_BY="[Empty name]">CENTRAL, (<I>The Cochrane Library, April 2007</I>)</TITLE>
<APPENDIX_BODY MODIFIED="2008-01-16 16:41:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>#1 MeSH descriptor Sodium Chloride explode all trees<BR/>#2 MeSH descriptor Saline Solution, Hypertonic explode all trees<BR/>#3 ( (hypertonic in All Text and NaCl in All Text) or (hypertonic in All Text and saline in All Text) or (hypertonic in All Text and solution* in All Text) )<BR/>#4 (Ringer's in All Text and solution in All Text)<BR/>#5 (#1 or #2 or #3 or #4)<BR/>#6 MeSH descriptor Glucose Solution, Hypertonic explode all trees<BR/>#7 (#5 and not #6)<BR/>#8 (#7 and not colloid* in All Text)<BR/>#9 MeSH descriptor surgical procedures, operative explode all trees<BR/>#10 MeSH descriptor Specialties, Surgical explode all trees<BR/>#11 MeSH descriptor Specialties, Dental explode all trees<BR/>#12 MeSH descriptor Surgery explode all trees<BR/>#13 (surg* in All Text near/6 procedur* in All Text)<BR/>#14 (surger* in All Text or operat* in All Text)<BR/>#15 (#9 or #10 or #11 or #12 or #13 or #14)<BR/>#16 (#8 and #15)<BR/>5 not #36<BR/>#38 #37 not #22<BR/>#39 TG=COMPARATIVE-STUDY<BR/>#40 explode EVALUATION-STUDIES/ all subheadings<BR/>#41 explode FOLLOW-UP-STUDIES/ all subheadings<BR/>#42 explode PROSPECTIVE-STUDIES/ all subheadings<BR/>#43 control* or prospectiv* or volunteer*<BR/>#44 (#43 in TI) or (#43 in AB)<BR/>#45 #39 or #40 or #41 or #42 or #43 or #44<BR/>#46 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS))<BR/>#47 #45 not #46<BR/>#48 #47 not (#22 or #38)<BR/>#49 #22 or #38 or #48<BR/>#50 #13 and #49</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-04-08 16:50:43 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2016-04-08 16:50:43 +0100" MODIFIED_BY="[Empty name]">Search update: April 2007 to April 8, 2016</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-09 17:51:39 +0000" MODIFIED_BY="Jane Cracknell">
<P>
<B>Search strategy for EMBASE (Ovid SP)</B>
<BR/>
<BR/>#1.     exp sodium chloride/ or Ringer solution/<BR/>#2.     exp hypertonic solution/<BR/>#3.     (hypertonic adj3 (NaCl or saline or solution*)).mp.<BR/>#4.     #1 or #2 or #3<BR/>#5.     (glucose or fructose).mp.<BR/>#6.     #4 not #5<BR/>#7.     surgery/ or ((surg* adj3 procedur*) or surger* or operat*).ti,ab.<BR/>#8.     (RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER* or ((SINGL* or DOUBL* or TREBL* or TRIPL*) adj3 (BLIND* or MASK*))).mp. not (animal not (human and animal)).sh.<BR/>#9.     #6 and #7 and #8<BR/>
<BR/>
<B>Search strategy for MEDLINE (Ovid SP)</B>
<BR/>
<BR/>#1.     saline solution, hypertonic/ or hypertonic solutions/<BR/>#2.     (hypertonic adj3 (NaCl or saline or solution*)).mp. or ringer.mp.<BR/>#3.     #1 or #2<BR/>#4.     exp glucose solution, hypertonic/ or colloid*.mp.<BR/>#5.     #3 not #4<BR/>#6.     exp surgical procedures, operative/ or exp specialties, surgical/ or exp surgery/<BR/>#7.     ((surg* adj3 procedur*) or surger* or operat*).mp.<BR/>#8.     #6 or #7<BR/>#9.     #8 and #5<BR/>#10.     ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.<BR/>#11.     #9 and #10<BR/>
<BR/>
<BR/>
<B>Search strategy for CINAHL (EBASCOhost)</B>
<BR/>
<BR/>S1. (MM "Saline Solution, Hypertonic") or (MM "Hypertonic Solutions") <BR/>S2. (MH "Lactated Ringer's Solution") <BR/>S3. TX (hypertonic and (NaCl or saline or solution*)) or Ringer <BR/>S4. (MH "Sodium Chloride") <BR/>S5. S1 or S2 or S3 or S4 <BR/>S6. TX glucose or fructose <BR/>S7. S5 not S6 <BR/>S8. (MH "Surgery, Operative") <BR/>S9. TX surger* or operat* <BR/>S10. S8 or S9 <BR/>S11. S7 and S10  <BR/>
<BR/>
<BR/>
<B>Search strategy for CENTRAL, <I>The Cochrane Library</I>
</B>
<BR/>
<BR/>#1    MeSH descriptor Saline Solution, Hypertonic explode all trees<BR/>#2    MeSH descriptor Hypertonic Solutions explode all trees<BR/>#3    (hypertonic NaCl) or (hypertonic saline) or (hypertonic solution*)<BR/>#4    Ringer* near solution*<BR/>#5    Sodium Chloride<BR/>#6    (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7    MeSH descriptor Glucose Solution, Hypertonic, this term only<BR/>#8    (#6 AND NOT #7)<BR/>#9    MeSH descriptor Surgical Procedures, Operative explode all trees<BR/>#10   MeSH descriptor Specialties, Surgical explode all trees<BR/>#11   MeSH descriptor Surgery explode all trees<BR/>#12   (surg* near procedur*) or surger* or operat*<BR/>#13   (#9 OR #10 OR #11 OR #12)<BR/>#14   (#8 AND #13)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;18 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;25 full-text articles assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;190 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;190 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;284 records identified through database searching:&lt;br&gt;PubMed 123&lt;br&gt;EMBASE 146&lt;br&gt;CINAHL 2&lt;br&gt;Cochrane library 12&lt;br&gt;LILACS 1&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;165 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;b&gt;7 full-text articles excluded:&lt;/b&gt;&lt;br&gt;2 - not randomized&lt;br&gt;3 - no outcomes of interest reported&lt;br&gt;2 - HS not compared to IS&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>